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Abstract 
Cation exchange chromatography (CEX) has risen as a promising alternative to Protein-A affinity 
chromatography for the capture of monoclonal antibody (mAb). mAb capture with CEX works on the 
basis of electrostatic interactions and is sensitive to buffer conditions, especially for weak CEX 
materials that present variable ionization according to buffer pH. While mAb capture with CEX is 
primarily based on strong CEX resins, CEX membranes are advantageous as they do not cause high 
pressure drop that is associated with resins. It is critical to investigate the role of buffer conditions on 
the performance of IgG/mAb binding with weak CEX membranes.  
The main objective of this PhD work was to investigate the role of buffer on IgG/mAb binding with 
weak CEX membranes and on IgG/mAb unfolding, based on which the design space was developed 
for mAb capture with CEX to assure process productivity and product quality. Buffer effects were 
investigated in terms of buffer pH, concentration of buffer cations (or counter-ions in CEX), 
concentation of buffer anions (or co-ions in CEX) and type of buffer anions. Two commonly used 
buffers in CEX, phosphate citrate buffer (contain multi-valent co-ions) and acetate buffer (contain 
monovalent co-ions), were employed. The model proteins include IgG for its cheap cost and availability 
in large quantity, as well as a humanized mAb, Bevacizumab and a chimeric mAb, Rituximab. The 
weak CEX membrane employed is Natrix C weak CEX membrane, as it possesses a high binding 
capacity at optimized buffer conditions. Methodologies employed in this work include, swelling 
experiment, Environmental Scanning Electron Microscopy (ESEM), static and dynamic protein 
binding, high-throughput intrinsic fluorescence measurement, size-exclusion liquid chromatography 
(SE-HPLC) and Design of Experiment (DoE), response surface model (RSM), two adsorption models, 
the Langmuir model and the steric-mass action (SMA) model. 
The first section of this work focuses on investigating the buffer effects on IgG/mAb binding with 
weak CEX membranes, which will facilitate the subsequent design space development for improved 
process productivity. The structure of the weak CEX hydrogel membrane employed in this work is 
sensitive to buffer conditions. The role of buffer pH, counter-ions, and co-ions on the membrane 
swelling behavior and its surface morphology was investigated through swelling experiment and 
ESEM. Buffer pH and counter-ions had a significant influence on membrane swelling and membrane 
pore size, while the effect of co-ion type was negligible. The role of buffer conditions, especially the 
co-ion type on static IgG/mAb binding with Natrix C weak CEX membrane was then quantified with 
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two adsorption models, the Langmuir model and the steric mass-action (SMA) model. The estimated 
model parameters of both adsorption models revealed the significant effect of co-ions on IgG binding. 
It was proposed that multi-valent co-ions may promote the binding affinity compared to monovalent 
co-ions by creating more binding patches on the IgG surface [1]. Co-ions may also affect the structure 
of IgG molecules thus changing the IgG binding capacity. When investigating the effect of co-ion type 
on static Bevacizumab binding with Natrix C weak CEX membrane, it was found that the co-ion effect 
was only significant at relatively high concentration.  
The second section of this work focuses on developing an efficient tool for investigating the structure 
of IgG/mAb and then applying the tool for investigations on buffer effects on IgG/mAb structure. A 
high-throughput intrinsic fluorescence microplate method was developed for fast detection of IgG/mAb 
structural changes. Comparison of the emission spectra of thermally stressed IgG samples collected 
from a cuvette spectrofluorometer and a fluorescence microplate reader demonstrated that the intrinsic 
fluorescence microplate method was as efficient in detecting IgG structural changes as its counterpart. 
The method was also shown to be effective in detecting structural changes of thermally stressed 
Bevacizumab and the effect of buffer conditions, especially the counter-ion concentration (Cs) and co-
ion type. Both Cs and co-ion type had significant effect on the structural changes of mechanically 
stressed IgG, where higher Cs induced protein unfolding, and co-ion type affected structural changes. 
The effect of co-ion type on the unfolding of Bevacizumab after binding with a weak CEX membranes 
was significant at a relatively high initial concentration (≥ 7 mg/mL). The structural changes of mAb 
were also related to the monomer percentage detected by SE-HPLC.  
Finally, a framework for design space development for mAb capture with weak CEX membranes 
was established. The first step was the identification of critical process parameters through risk 
assessment, where four critical parameters were identified as buffer pH, buffer molarity, Cs (Na+ 
concentration) and mAb concentration based on the literature. The second step was to study the 
characterization range of buffer pH, molarity and Cs (Na+ concentration) through static binding, to 
identify the range of conditions for high Rituximab binding capacity and low Rituximab structual 
changes. The third step was developing the design space with a response surface model (RSM). The 
construction of the RSM was based on a DoE study of the four critical parameters at three levels for 
static Rituximab binding with Natrix C weak CEX membrane.  The fourth step was to examine the 
RSM through performing static Rituximab binding and dynamic Rituximab binding with Natrix C weak 
CEX membrane at the optimal buffer conditions estimated with the RSM.  
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In conclusion, this study shows that co-ions have significant effect on the structural changes and the 
binding of IgG, Bevacizumab, and Rituximab with Natrix C weak CEX membranes, and should not be 
overlooked in optimizing the buffer conditions during mAb capture with CEX membranes. The intrinsic 
fluorescence microplate method was demonstrated to be an efficient tool in analyzing the structural 
changes of IgG/mAb. The SMA adsoprtion model could be used to investigate buffer effects on 
IgG/mAb binding and as an supplementary tool to investigate buffer effects on the structural changes 
of IgG/mAb. The framework for design space development established in this work can help 
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Chapter 1 Introduction 
1.1 Research motivation 
Monoclonal antibodies (mAbs) are antibodies produced by clones of a unique B cell that target one 
specific epitope for one antigen [2], which enable effective applications in cancer treatment, 
autoimmune disease treatment and Alzheimer's disease treatment. After the approval of the first 
therapeutic chimeric and humanized mAb in the late 1990s, there has been a constant increase in 
demand for mAb products, with a growing market estimated to be 70 mAb products associated with 
sales of £125 billion by 2020 [3]. Recent advances in cell culture technology have prompted cell lines 
with high-growth characteristics and led to high antibody titers up to 10 g/L [4, 5]. The improved 
productivity of mammalian cell culture processes has shifted the bottleneck of antibody production to 
the downstream section where downstream processes are estimated to take up to 50% ~ 80% of total 
manufacturing costs in 2011 [6]. 
The production of IgG/mAbs commonly takes place in mammalian cells, especially CHO cells [7]. 
After harvesting the cells, cell debris is removed by centrifugation or precipitation and cell culture 
supernatant is collected for the following downstream process. A conventional downstream process 
(Figure 1) starts with a capture step and several polishing steps to remove product contaminate, i.e. host 
cell proteins (HCPs), DNA, viruses, and high molecular weight aggregates [8]. Most of the capture step 
for commercial mAbs is realized with Protein-A affinity chromatography. The products recovered from 
Protein-A resins then go through several polishing steps including anion exchange chromatography 
(AEX), cation exchange chromatography (CEX), and hydrophobic interaction chromatography (HIC) 
to further remove HCP, DNA and aggregates. After a viral clearance step, the formulation step uses 
ultrafiltration/diafiltration (UF/DF) buffer exchange and product concentrating.  
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Figure 1 Flowchart of conventional antibody purification process. 
The capture step with Protein-A affinity chromatography provides a high specificity with over 99.5% 
reduction of product impurities in a single step [9]. However, the development of Protein-A affinity 
chromatography is hindered by the expensive resin material, low resin stability and low productivity 
[9]. The limitations of Protein-A chromatography call for more economic and efficient non-affinity 
chromatographic alternatives for the capture of mAbs. Cation exchange chromatography has been 
successfully employed as a polishing method during industrial antibody purification processes due to 
the relatively low material cost, simple methodology, and mild buffer conditions [10, 11]. There is a 
growing interest in applying CEX for mAb capture [12-22], while there are challenges in achieving 
high purity and binding capacity. 
CEX capture differs from Protein-A capture mainly in two ways. Protein-A capture is based on 
affinity while CEX capture is based on electrostatic interaction which is strongly influenced by buffer 
conditions. Therefore improving the performance, especially the productivity and product quality, of 
CEX capture would require understanding and the ability to control buffer effects. Based on the type 
of ligands, CEX materials can be categorized as strong or weak ion exchanger. For strong ion 
exchangers, the functional groups are completely ionized over a wide pH range, while for weak ion 
exchangers, the ionization of functional groups varies with pH. The variable ionization of weak ion 
exchangers with pH offers better flexibility during elution where pH can be adjusted so that only the 
target proteins are eluted. Weak CEX materials are very sensitive to buffer conditions compared to 
strong CEX materials, however, there has been very few work on investigating the buffer effects on 
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mAb capture with weak CEX materials. Protein-A ligands binds to the constant regions of mAbs [23] 
while several research groups have suggested that CEX ligands bind to the variable regions of mAbs 
that vary among different types of mAbs [24-26]. Differences in binding regions indicated process 
development for CEX capture requires more detailed mAb-specific information compared to Protein-
A capture, thus process development for CEX capture can be time-consuming. Therefore it is critical 
to establish a framework for high-throughput design space development for CEX capture. According 
to Quality by Design (QbD) principles [27], design space development is essential for process 
improvement by quantifying the effect of material and process parameters on the performance of the 
process [28, 29]. There have been several studies on design space development for mAb polishing with 
IEX resins [11, 30-32], while no work has been done on design space development for mAb capture 
with CEX materials. Design space development for mAb capture requires different parameters and 
goals from that for mAb polishing. 
In addition to the challenges listed above, the current CEX capture process is plagued by its reliance 
on column chromatography, where mass transport is dominated by pore diffusion and lowers the 
column efficiency. Membrane chromatography has risen as a promising alternative for column 
chromatography in CEX capture [33, 34]. The mass transport with CEX membrane is dominated by the 
convective transport of proteins, which allows for higher productivity and lower operational cost [35-
37]. However for membranes with non-uniform pore size distribution and uneven thickness, the inlet 
flow distribution may be distorted and lead to low utilization of binding sites on the membrane [36].Yet 
there has been very few work on mAb capture with CEX membranes [22, 38]. 
 
1.2 Research objectives and hypotheses 
The main objective of this PhD work was to investigate the effect of buffer co-ions on IgG/mAb binding 
with weak CEX membranes. The model proteins include IgG for its cheap cost and availability in large 
quantity, as well as a humanized mAb, Bevacizumab and a chimeric mAb, Rituximab. The weak CEX 
membrane employed is Natrix C weak CEX membrane, as it contains a high density of carboxylic acid 
binding groups and possesses a high binding capacity at optimized buffer conditions. The selected 
buffer solutions are two commonly used buffer type in CEX, phosphate citrate buffer and acetate buffer, 
that possess distinct ion characteristics.  
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Four specific objectives were pursued to build knowledge and develop tools for achieving the main 
objective. The first specific objective was to investigate the effect of pH, counter-ions and co-ions on 
the swelling behavior and pore structure of Natrix C weak CEX membranes. The pore structure 
visualization of the membrane was achieved with ESEM. The hypothesis and experimental approach 
for this section are listed below. 
Hypothesis: buffer pH, counter-ions and co-ions affect membrane properties, namely the membrane 
swelling behavior and its surface morphology of weak CEX membranes 
Experimental approach: membrane swelling experiment and Environmental Scanning Electron 
Microscopy (ESEM) analysis for Natrix C weak CEX membranes treated with two buffers with various 
pH, counter-ions and co-ions. 
The second specific objective was to examine the effect of buffer conditions, with an emphasis on 
co-ion type, on IgG/mAb binding with Natrix C weak CEX membranes, using two adsorption models. 
Proteins investigated were lysozyme, IgG and a humanized mAb, Bevacizumab. The hypothesis and 
experimental approach for this section are listed below. 
Hypothesis: Buffer co-ions affect the binding capacity of IgG/mAb with weak CEX membranes 
Experimental approach: Static binding of lysozyme, IgG and Bevacizumab with the Natrix C weak 
CEX membrane in phosphate citrate buffer and acetate buffer. The binding results were analyzed with 
the Langmuir and SMA adsorption models. 
The third specific objective was to investigate the buffer effects on IgG/ mAb structure, especially 
the effect of counter-ion concentration (Na+ concentration) and co-ion type (valence and chemistry), 
with a microplate intrinsic fluorescence method. Proteins of interest were mechanically stressed IgG 
and Bevacizumab after binding with Natrix C weak CEX membranes. The hypothesis and experimental 
approach for this section are listed below. 
Hypothesis: Buffer counter-ion concentration and co-ion type affect the structure of IgG/mAb.  
Experimental approach: IgG and Bevacizumab were mechanically stressed in phosphate citrate 
buffer and acetate buffer. The structure of the mechanically stressed IgG/mAb samples was observed 
with intrinsic fluorescence microplate method and analyzed with a response surface model and SMA 
adsorption model. 
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The fourth objective was to establish a framework for design space development for mAb capture 
with weak CEX membranes employing the experimental observations and tools developed in this work.  
Experimental approach: Rituximab, a chimeric mAb, was selected for binding and elution in static 
and dynamic conditions with Natrix C weak CEX membranes. The structure of Rituximab was analyzed 
with the intrinsic fluorescence microplate method. A response surface model (RSM) model with four 
critical process parameters at three levels (identified from risk assessment) was constructed to describe 
the relationships of the parameters and Rituximab binding capacity.  
 
1.3 Thesis structure 
This thesis consists of the literature review (Chapter 2), results and discussion (Chapter 3 to7), and 
conclusions and recommendations (Chapter 8) (Figure 2). Chapter 3 to Chapter 7 address one of the 
specific objectives formulated in the previous section.  
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Chapter 2 
This chapter summarizes the scientific literature and fundamental principles relevant to the 
development of this thesis: (1) IgG and mAb structure and characteristics; (2) IgG and mAb capture; 
(3) Ion exchange chromatography; (4) IgG and mAb capture with cation exchange chromatography; 
(5) IgG/mAb unfolding and buffer effects; (6) Quality by Design principles. 
Chapter 3 
This chapter investigates the effect of pH, counter-ions and co-ions on membrane swelling behavior 
and membrane surface pore structure of Natrix C weak CEX membrane. The pore structure 
visualization of the membrane was achieved with ESEM.  
Chapter 4 
This chapter investigates buffer effects on static IgG and Bevacizumab binding with a weak CEX 
membrane, Natrix C weak CEX membrane, where the effect of co-ion types is studied with phosphate 
citrate buffer and acetate buffer. The Langmuir model and SMA model were employed to gain a better 
understanding of buffer effects at a molecular level, and knowledge gained from which contributes to 
risk assessment and analysis of productivity in Chapter 7. 
Chapter 5 
A high-throughput intrinsic fluorescence method using microplates for the detection of IgG/ mAb 
unfolding is developed in this chapter through examining emission spectra collected from thermally 
stressed IgG in PBS buffer and phosphate citrate buffer with spectrofluorometers and plate readers, as 
well as emission spectra of thermally stressed Bevacizumab in phosphate citrate buffer and monomer 
analysis with SE-HPLC.  
Chapter 6 
The high-throughput method developed in Chapter 5 was applied to probe the buffer effects on 
IgG/mAb unfolding in this chapter, especially the effect of counter-ion concentration (Cs) and co-ion 
type, results from which shed light to buffer selection for maintaining product quality during design 
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Chapter 7 
This chapter presents the framework for high-throughput design space development for mAb capture 
with CEX membranes, where parameter effects on productivity and product quality are monitored by 
binding capacity and protein unfolding. Design space is developed for Rituximab capture with Natrix 
C weak CEX membrane in four steps: (1) identify key parameters with risk assessment; (2) study the 
characterization range; (3) establish design space with a RSM; (4) test optimal buffer conditions in 
static binding mode and dynamic binding mode. 
Chapter 8 
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Chapter 2 Literature review 
2.1 IgG/mAb structure and characteristics  
Human immunoglobulins are glycoproteins produced by plasma cells functioning as antibodies. Their 
general functions are antigen binding and effector binding. Immunoglobulins are divided into five 
classes, IgA, IgD, IgE, IgM, and IgG. Type G immunoglobulin (IgG) is the most abundant antibody, 
about 13.5 g/L in terms of serum concentration.  
IgGs are “Y” shaped tetramers with two heavy chains (H) of type γ and two light chains (L) of type 
κ or λ (Figure 3). IgGs can be cleaved into two Fab fragments and one Fc fragment by the proteinase 
papain, with the Fab fragment being the antigen-binding part while the Fc fragment binds to cell surfaces 
for interaction. IgG consists of variable regions (V) and constant regions (C), as shown in Figure 3. The 
Fc fragment consists of two constant regions, CH2 and CH3 for each heavy chain. The oligosaccharides 
are linked to the amide group of an asparagine residue in the Fc fragment through a N-glycosidic link. 
Disulfide bonds stabilize IgGs by linking the two heavy chains together and linking the heavy chains 
to the light chains, and also exist within the domains to stabilize the tertiary structure. IgGs are greatly 
mobile in the hinge region. The molecular weight of an IgG is approximately 150 kDa [39]. 
 
 
Figure 3 Schematic representation of IgG structure.  
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Depending on the differences in function and structure, antibodies can be divided into polyclonal 
antibodies and monoclonal antibodies. The difference between polyclonal antibodies and monoclonal 
antibodies is that polyclonal antibodies are produced by different B cells and can bind to different 
epitopes of one antigen, which means polyclonal antibodies contain antibodies with various variable 
regions. While monoclonal antibodies are clones of one unique B cell and bind with only one specific 
epitope for one antigen [2], they contain only one type of variable region. 
Polyclonal human IgG is the main component of intravenous immunoglobulin (IVIG) which is a 
blood product for treating patients with antibody deficiencies and was licensed in the USA in 1981 [40, 
41]. The isoelectric point (pI) of polyclonal human IgG ranges from 6.5 to 10 [42]. When pH is below 
the pI value of a protein, the surface basic residues will be ionized thus the protein molecule is positively 
charged.  
mAbs only target one specific epitope for one antigen [2] therefore enable their effective applications 
in cancer treatment, autoimmune disease treatment and Alzheimer's disease treatment [43]. To date 
there are over 80 FDA approved mAb drugs [44-46], and are named according to the sub-stems 
developed by the International Nonproprietary Names (INN) system in 1997 [47] (Table 1). mAbs can 
be categorized based on their origin. Humanized mAb and chimeric mAb are the two categories of 
interest in this work. 
Table 1 Name system for humanized and chimeric mAbs. 








According to the 2014 WHO’s definition of humanized mAb, it is “one for which both chain types 
are humanized as a result of antibody engineering. A humanized chain is typically a chain in which the 
complementarity determining regions (CDR) of the variable domains are foreign (originating from one 
species other than human, or synthetic) whereas the remainder of the chain is of human origin” [47]. 
The 2014 WHO’s definition of chimeric mAb is “one of which both chain types are chimeric as a result 
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of antibody engineering. A chimeric chain is a chain that contains a foreign variable domain (originating 
from one species other than human, or synthetic) linked to a constant region of human origin” [47]. The 
structure of humanized mAbs, chimeric mAbs and murine mAbs are illustrated in Figure 4. As 
humanized mAbs contain more human sequences, they are potentially less immunogenic than chimeric 
mAbs [48].  
 
Figure 4 Illustration of murine, chimeric and humanized mAbs. The murine sequences are shown in 
white and the human sequences are shown in gray. Copyright (2004), with permission from Springer 
[48]. 
Two therapeutic mAbs of interest in this work include a humanized mAb, Bevacizumab, and a 
chimeric mAb, Rituximab. Bevacizumab is a therapeutic mAb under the brand name Avastin from 
Genentech, Inc., which was first approved by FDA for metastatic colorectal cancer treatment in 2004 
[49]. Bevacizumab is a humanized IgG1 mAb that binds with high affinity to human vascular 
endothelial growth factor. Bevacizumab contains 93% of human sequences and 7% of murine 
sequences, that are complementarity-determining regions (Figure 5). Its molecular weight is 149 kDa 
[50] and the pI value is approximately 8.3 [51, 52]. The percentage of soluble aggregates of 
Bevacizumab drug products that were formulated into 25 mg/mL was determined to be around 3% by 
SEC [53, 54]. 
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Figure 5 Structure of Bevacizumab, consisting of six murine specificity sequences (green dots) 
grafted onto a backbone of disulfide linked heavy and light chains containing variable and constant 
regions [55]. 
Rituximab is a therapeutic mAb under the brand name Rituxan from Genentech, Inc., which was 
first approved by FDA for rheumatoid arthritis treatment in 2006 [56]. Rituximab is a chimeric 
murine/human mAb directed against the CD20 antigen found on the surface of normal and malignant 
B lymphocytes [57-59]. It is an IgG1 κ immunoglobulin containing murine light- and heavy-chain 
variable region sequences and human constant region sequences [60] (Figure 6). The molecular weight 
of Rituximab is approximately 144 kDa [61] and the isoelectric point is 8.68 [60]. The percentage of 
soluble aggregates of Rituximab drug products that were formulated into 10 mg/mL was determined to 
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Figure 6 Structure of Rituximab. Reprinted from Critical Reviews in Oncology/Hematology, 37/1, S. 
Sacchi et al., Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody 
Rituximab, 13-15, Copyright (2001), with permission from Elsevier [62]. 
 
2.2 IgG/mAb capture 
2.2.1 Traditional affinity chromatography 
The capture step is usually accomplished with Protein-A affinity chromatography. Affinity 
chromatography separates proteins on the basis of reversible noncovalent interactions between the 
target protein and immunoglobulin-binding ligands immobilized on chromatography resins. Protein-A 
is a natural immunoglobulin-binding protein derived from a strain of Staphylococcus aureus, and was 
the first identified immunoglobulin-binding protein. The intact native Protein-A molecule is anchored 
to the cell wall of Staphylococcus aureus and consists of three regions (1) the signal sequence that is 
cleaved off during secretion; (2) five highly homologous Ig-binding domains (designated E, D, A, B, 
and C) and (3) the C-terminal cell wall binding domain (designated X). Domain X is usually engineered 
to be deleted for Protein-As for IgG/mAb capture purpose. After the truncation, the molecular weight 
of Protein-A is reduced to 42 kDa [63].  Each of the Ig-binding domains can bind to the Fc part of 
human IgG1, IgG2, and IgG4 [64] and crystallographic studies indicated that it binds at the junction 
between the CH2 and CH3 domains of the Fc region of IgG [65] (Figure 7). The biospecific binding of 
Ig-binding domains results in a high specificity with over 99.5% reduction of product impurities in a 
single step [9, 24]. The unbound impurities from the mixture are washed off, and target proteins are 
eluted later by lowering pH or increasing ionic strength. 
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Figure 7 Molecular structures of antibody-binding domains of Protein-A. Ig-binding domain of 
Protein A (yellow) bound to the CH2−CH3 domain interface. Reprinted with permission from N. 
Kruljec, T. Bratkovic, Alternative Affinity Ligands for Immunoglobulins, Bioconjug Chem, 28 
(2017) 2009-2030. Copyright (2017) American Chemical Society. 
 
The development of Protein-A affinity chromatography is hindered by the expensive resin material, 
low resin stability and low productivity. The cost of Protein-A resins per liter (US$9,000–14,000) was 
almost 5 times more expensive than ion exchange resins (US$2,000–3,000) in 2014 [18, 66]. While the 
patent expiry of Protein-A in recent years has prompted new Protein-A vendors offering new Protein-
A resins at US$6,000–7,000, the price is still not as competitive as that of ion exchange resins [67]. 
Protein-A ligands may suffer from denature from the harsh sanitization solution of sodium hydroxide 
and may leach from the resin matrix. Ligand leaching contaminates the product and have to be removed 
from the final product as they may cause immunogenic responses in human body [68]. The product 
quality can also be compromised by the elution conditions of Protein-A chromatography, where the 
typical elution pH is between 3 and 4. Antibodies subject to such a low pH may go through 
conformational changes and form aggregates [23]. Traditional Protein-A resins generally have a 
dynamic binding capacity (DBC) less than 40 g/L which limits the productivity of the process [21]. 
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Considering the limitations of Protein-A affinity chromatography, there are mainly two ways to 
improve the IgG/mAb capture step. One is to enhance the stability and capacity of affinity 
chromatography, the other is to explore more economic, reliable and efficient non-affinity 
chromatographic alternatives. 
 
2.2.2 Enhanced Affinity chromatography  
The limitations of natural immunoglobulin-binding proteins, such as Protein-A, prompted development 
of enhanced affinity ligands with increased thermal stability or milder elution conditions. Natural 
immunoglobulin-binding proteins are generally sensitive to extreme pH conditions, while low pH is 
required for elution during the capture step and high pH is required for the removal of contaminants 
from chromatographic columns [69]. Therefore new affinity ligands have been engineered based on the 
structures of the natural counterparts, with some engineered ligands outperforming the natural 
counterparts in terms of chemical stability or binding specificity. 
 Nilsson et al. [70] engineered a Protein-A variant by mutating two amino acids in the B domain (one 
of the Ig-binding domain listed above) that are key to protein stability, and renamed it as the Z domain. 
The engineered variant can not only endure protease degradation but also has greater alkaline stability, 
which enables harsh elution or cleaning conditions. Linhult et al. [71] also worked on mutagenesis 
studies of Z domain and designed Protein-A variants with increased tolerance to alkaline conditions. 
Other groups [72-74] worked on designing ligands that enable milder elution conditions during protein 
capture. Pabst et al. [72] engineered a single-mutation Protein-A ligand ( Z(H18S)4) and a double-
mutation Protein-A ligand (Z(H18S, N28A)4) that supported elution pH at 0.5 unit higher than usual 
pH, and achieved comparable dynamic binding capacity and selectivity.  
However, the application of engineered affinity ligands in protein capture is plagued by its high 
production costs and unstable structure, which prompted the development of affinity ligands based on 
alternative scaffolds that are smaller and simpler than immunoglobulins. One of the commonly used 
alternative scaffolds is the Z domain [75]. A short peptide ligand is another affordable alternative with 
relatively high stability and moderate affinity to proteins, which enables mild elution conditions [76-
78]. Moreover, there have also been attempts on synthetizing small functional mimetics of natural Ig-
binding proteins [79].  
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2.2.3 Non-affinity chromatography 
The limitations of Protein-A chromatography may also be addressed by non-affinity chromatographic 
alternatives, where ion exchange chromatography (IEX) and multi-modal chromatography (MMC) 
have gained a lot of interest. The potential of IEX in mAb capture will be discussed in detail in the next 
section (2.3). 
MMC is a chromatographic method combining multiple types of interaction between the stationary 
phase and the mobile phase, where multimodal ligands comprising ion exchange, hydrogen bonding 
and hydrophobic interaction groups are commonly used [80]. The complex composition of multimodal 
ligands enables great flexibility in designing MMC material with high selectivity for protein capture. 
One family of multimodal ligands is the hydrocarbyl amine family, which consists of the hexyl amine 
(HEA HyperCel™), the propyl amine (PPA HyperCel™) and the 2-aminomethylpyridine sorbents that 
offer electrostatic and hydrophobic interactions [81, 82]. Protein binding with this type of ligands 
happens at physiological conditions through a combination of electrostatic interactions and 
hydrophobic interactions, while elution happens when the electrostatic interactions are disturbed [83]. 
The other family of multimodal ligands is the Capto™ family, where the N-benzyl-N-methyl 
ethanolamine (Capto™ adhere) and the 2-benzamido-4-mercaptobutanoic acid (Capto™ MMC) are 
most studied. These ligands were developed based on the finding that introducing hydrogen bonding 
groups near the charged groups led to high breakthrough capacities at high salt concentrations [84].  
Commercial MMC materials have gained great attention for their potential in mAb capture (Table 
2), with MEP Hypercel™ sorbent being the most extensively studied. MEP Hypercel™ offers similar 
binding capacities as Protein-A materials at only 25% of the cost and with better stability [85]. 
However, protein elution with MEP Hypercel™ requires a low pH condition at around 4. HEA 
Hypercel™ and PPA Hypercel™ offer milder elution conditions for similar binding capacity [86]. 
Capto™ MMC is a weak cation exchanger with a phenyl group as hydrophobic moiety, an amide group 
for hydrogen bonding, and a thioether group for thiophilic interaction, which has been patented for 
mAb capture in 2011 and 2012 [87]. Joucla et al. [88] compared the performance of mAb capture 
between Capto™ MMC and a strong cation exchanger, Capto™ S at optimal binding and elution 
conditions. When increasing the buffer conductivity, no significant change in mAb retention was 
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Table 2 MMC materials for mAb capture [89]. 
Product 
name 
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2.3 Ion exchange chromatography 
2.3.1 IEX materials 
IEX materials bind with proteins according to their distinct charge characteristics. This technique works 
on the basis of the reversible electrostatic interactions between the charged functional groups on the 
stationary phase and the protein molecules in the mobile phase with opposite charges [90]. Depending 
on the format of the stationary phase, IEX materials exist as IEX resin and IEX membrane. For both 
IEX resin and IEX membrane, their functionality comes from their ligands. Based on the type of ligands 
and the ionizing strength, IEX materials can be categorized as either a strong or weak ion exchanger. 
For a strong ion exchanger, the functional groups are completely ionized over a wide pH range, holding 
a high ion exchange capacity. Common strong ion exchange ligands (Table 3) are sulfo (S) group for 
strong cation exchanger and quaternary ammonium (Q) group for strong anion exchanger. For weak 
ion exchangers, the ionization of functional groups varies with pH, offering better flexibility. Common 
weak ion exchange ligands are carboxyl (C) group and for weak cation exchanger and 
diethylaminoethyl (DEAE) group for weak anion exchanger. The ligand type and density are critical to 
the performance of both IEX resin and membrane. 
Table 3 Selected ligands for ion exchange materials. 
Ligand type Ligand name Class Ligand structure 
Cation exchanger Sulpho (S) Strong -SO3 
Sulfopropyl (SP) Strong -CH2CH2CH2SO3 
Carboxymethyl (CM) Weak -CH2COO- 








Weak -CH2CH2N+ (C2H5)2 
Dimethylaminoethyl 
(DMAE) 
Weak -CH2CH2N+ (CH3)2 
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2.3.1.1 IEX resin 
IEX resins are the most commonly used IEX materials for protein purification, where porous resin 
beads are loaded in a glass or steel column. Other properties of the ligand, including the matrix material, 
particle size, pore size and porosity are crucial to the performance of IEX resin in protein purification. 
An inert matrix material with high physical stability and chemical stability eliminates non-specific 
interactions and ensures reproducibility of the process. The matrix of IEX resin is usually based on 
inorganic materials, synthetic resins or polysaccharides. The mean particle size of commercial IEX 
resins lies between 3 μm (MiniBeadsTM) to 200 μm (Sepharose Big Beads) [91]. The pore size of 
functionalized, hydrated IEX resins is approximately 1 to 2 nm, while macroporous resins have 
macropores with a size of about 20 to 100 nm [92]. Hart et al. [93] suggested that an intermediate 
apparent pore size is optimal for resin capacity for a mAb, with 17% increase of maximum dynamic 
binding capacity compared to resins with small pores or large pores. High porosity of IEX resins 
provides a large surface area, which usually lead to higher binding capacity. 
The use of IEX resins for protein purification suffers from a few problems. The mass transport in 
IEX resins is dominated by pore diffusion which prolongs the processing time and lowers the separation 
efficiency. The high pressure drop across the column limits the flow rate and can also result in resin 
deformation [94]. Channeling may occur with cracked resin beads and lead to poor bed utilization [95]. 
 
2.3.1.2 IEX membrane  
The recent development of IEX membranes has prompted membrane chromatography to be a promising 
alternative to column chromatography in protein purification [33, 34, 37, 96]. For IEX membranes, the 
pore size is significantly larger than that of IEX resins, thus the mass transport of protein molecules to 
ligands on the IEX membrane is dominated by bulk convection (Figure 8). With minimized pore 
diffusion, higher flow rates improve productivity. Considerable buffer consumption may also be 
reduced with shortened overall process time [35]. Compared to resins, IEX membranes also stand out 
for the operational and economic advantages. The flow-independent property enables the system to be 
easily scaled up. The lower pressure drop reduces expenses on pressure-resistant equipment. In 
addition, cheap IEX membranes are disposable, which eliminate the expenses on cleaning, regeneration 
and sanitization [36]. 
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Figure 8 Comparison of mass transport in (a) IEX resin and (b) IEX membrane. 
Despite the advantages of IEX membranes over resins, there remain several limitations to be 
addressed. For membranes with non-uniform pore size distribution and uneven thickness, the inlet flow 
distribution may be distorted since the feed flow will preferably go through larger pores or thinner 
areas. This leads to low utilization of binding sites on the membrane [36]. The conventional membrane 
modules with inlet and outlet at the center are problematic due to the high radial to axial aspect ratios. 
The large variability in flow path lengths and solute residence time distribution within the membrane 
will lead to broad elution peaks and early breakthrough of bound solutes. Madadkar et al. [97] proposed 
implementing a flow directing layer (FDL) within the membrane module and observed improved 
separation efficiency for the FDL module housing strong cation exchange membranes. Most IEX 
membranes have lower surface-to-bed volume ratio than IEX resins, which will result in lower binding 
capacity, therefore limiting its applications in the bind/elute mode where protein of interest is bound 
onto the membrane and impurities are eluted. In order to improve the binding capacity of IEX 
membranes, considerable work has been done on coating pores with porous polymer to create a three-
dimensional structure thus increasing the binding surface [95]. 
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Similar to IEX resins, the performance of IEX membranes in protein purification is largely dependent 
on the membrane properties, including matrix material, pore size and pore size distribution. Table 4 
lists a selection of commercial IEX membranes with their properties. The most extensively used matrix 
material for IEX membrane is regenerated cellulose (RC) for its low cost, while the short lifetime 
remains a problem. Compared to natural polymers, synthetic organic polymer supports have better 
chemical and physical stability that will increase their reusability. A variety of synthetic polymer 
materials are used for commercial IEX membranes, e.g. polyethersulfone (PES), polypropylene (PP), 
and polyvinylidene fluoride (PVDF). Some inorganic materials, e.g. alumina, glass fiber, and carbon 
nanofiber have also been investigated for their high uniformity [98].  
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Pore size Binding 
capacity 
Manufacturer 








(now part of 
Merck KGaA) 







 Mustang E Modified 
PES 
0.2μm n/a Pall 
Corporation 
 Sartobind Q RC > 3μm > 29mg/ml 
(Albumine) 
Sartorius 
 Sartobind D RC > 3μm > 29mg/ml 
(Albumine) 
Sartorius 
CEX Natrix S 
(Discontinued) 
Hydrogel 0.45μm n/a Natrix 
Separations 
(now part of 
Merck KGaA) 
 Natrix C weak 
CEX 
(Discontinued) 




(now part of 
Merck KGaA) 







 Sartobind S RC > 3μm >25 mg/ml 
(Lysozyme) 
Sartorius 
 Sartobind C 
(Discontinued) 
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The IEX membrane of interest in this work is the weak CEX membrane, Natrix C weak CEX. Natrix 
C weak CEX membrane consists of a functionalized hydrogel with three-dimensional porous structure, 
physically supported by a polyolefin backbone (Figure 9) [99]. Containing a high density of carboxylic 
acid binding groups, Natrix C weak CEX membranes possess a high binding capacity at optimized 
buffer conditions. A couple of groups have assessed its potential application in mAb capture [38, 99, 
100]. Kuczewski et al. [100] designed a single-use mAb purification process with Natrix C weak CEX 
membrane in a bind/elute mode for capture, followed with Chromasorb (AEX membrane) and 
Sartobind Phenyl (HIC membrane) at flow-through mode for polishing. The group reported an overall 
yield of 63%, with aggregate level < 0.5 % and HCP less than 50 ppm for a mAb produced in a PER.C6 
human cell line. Hou and the group [99] reported a higher yield of 90% with Natrix C weak CEX 
membrane, with binding capacities >60 mg/mL, HCP removal > 85% and DNA reduction >99% at an 
optimized bind/elute mAb capture process. The potential of applying Natrix C weak CEX membrane 
for mAb capture had been explored by Hassel and Moresoli [38], where membrane structure was 
characterized through swelling and Field Emission Scanning Electron Microscopy (FESEM) at various 
pH conditions. They reported that the membrane average pore size was lower at pH below 5.5, 
reflecting the nearly zero surface charge of the membrane material. Maximum IgG binding capacity 
was observed at pH 4.8 and 0 M KCl, whereas highest IgG elution was obtained at pH 7 and 0 M KCl.  
 
Figure 9 Illustration of the 3-dimensional hydrogel porous structure of Natrix C weak CEX 
membrane [101]. 
 
  24 
2.4 IgG/mAb capture with CEX 
2.4.1 Principles and application 
IEX has been successfully employed as a polishing step in industrial antibody purification processes 
due to the relatively low material cost, simple methodology, and mild operating conditions, while its 
application in the capture step has been limited [10, 11]. Recent development of CEX materials with 
improved ligand density and pore structure leads to better selectivity and enhanced binding capacity of 
over 100 mg/mL, which enables it to be a promising alternative to Protein-A chromatography for mAb 
capture [20, 21].  
mAb capture with CEX works on the basis of reversible electrostatic interactions. In the bind/elute 
mode, positively charged mAb molecules will be absorbed to negatively charged CEX material at 
selected pH of binding buffer. As the pI of HCP are generally lower than antibodies, Ng et al. [102] 
separated HCP from IgG1 in the Protein-A effluent using pH-induced chromatography with a CEX 
resin. It has been reported that mAb capture with CEX can achieve an overall yield of 76% to 88%, 
which is comparable to the overall yield of 85% with Protein-A chromatography [88].  
Application of CEX for mAb capture was reported as early as 1998 where a CEX resin with high 
charge density, CM-HyperD, demonstrated sufficient yield and resolution in capturing a mAb at an 
ionic strength equivalent to cell culture supernatant [12]. mAb capture with CEX has since gained great 
attention in the industry and numerous studies have worked on improving the HCP removal and yield 
for mAb capture with CEX. Follman and Fahrner [13] from Genentech evaluated a three-step 
chromatographic purification process with CEX capture for a mAb using SP-Sepharose Fast Flow resin, 
where the order of the process steps was found to have a significant effect on the HCP removal. HCP 
removal is critical to the purity of mAb products. Effective HCP removal (<2 ng/mg mAb) was 
achieved with processes in the sequence of CEX–AEX–hydrophobic interaction chromatography, 
CEX–AEX–mixed CEX, and CEX–mixed CEX–AEX. Arunakumari and colleagues in Medarex (now 
part of Bristol-Myers Squibb) proposed a two-step purification schemes potentially for large-scale 
mAbs manufacturing, with a capture step by a CEX resin of high dynamic binding capacity (100 g/L) 
and a polishing step with an AEX membrane with an equivalent loading of 2100 g/L [14, 15]. Ng and 
Snyder from Bio-Rad laboratories demonstrated the effectiveness of NuviaTM S in a capture step of a  
three-column process, with more than 99% HCP reduction and 95% ~ 99.4% DNA clearance [16]. A 
50-cycle study showed consistent chromatography performance of NuviaTM S. Recent researches 
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reported enhanced performance of CEX capture for IgG with  advance chromatin extraction, where the 
dynamic binding capacity increased to 173 g/L [17]. CEX for mAb capture has been realized with a 
series of commercialized monoclonal antibodies: Simulect (basiliximab) from Novartis, Synagis 
(palivizumab) from Medimmune, Soliris (eculizumab) from Alexion Pharmaceuticals, Inc. and 
Humira® (adalimumab) from Abbott Laboratory [18, 19]. 
 
2.4.2 Buffer effect on IgG/mAb binding with CEX 
mAbs bind to CEX materials based on electrostatic interactions, therefore the performance is strongly 
influenced by buffer conditions. For IgG/mAb binding with CEX, buffer conditions include buffer pH, 
type and concentration of buffer cation (counter-ion), and type and concentration of buffer anion (co-
ion), among which counter-ion concentration (Cs) is the most investigated factor [42, 103-105]. Ionic 
strength is defined as a measure of the concentration of charges in a solution [106], which has a linear 
relationship with conductivity. In most studies, changes in ionic strength or conductivity of a buffer are 
manipulated by adding salt to the buffer and thus changing the Cs. The concentration of co-ions is 
usually manipulated by changing the buffer molarity. 
Numerous groups investigated buffer effects on IgG/mAb binding with CEX resins [42, 103-105], 
while only a few investigated with CEX membranes [22]. Since CEX resins and CEX membranes 
possess the same ligand group, previous work with resins can still provide valuable information for 
understanding buffer effects with membranes. 
As opposed to strong CEX materials, weak CEX materials contain functional groups that present 
variable ionization according to buffer pH. The performance of weak CEX materials is more susceptible 
to buffer effects compared to strong cation exchangers. Yet buffer effects on IgG/mAb binding with 
weak CEX resins and membranes have rarely been studied.  
Buffer pH  
Buffer pH is a critical factor during IgG/mAb binding with CEX. mAb capture with CEX works on the 
basis of reversible electrostatic interactions. During the binding step, positively charged mAb molecules 
will be absorbed to negatively charged CEX material at selected buffer pH. While during the elution 
buffer, the electrostatic interactions can be disrupted by changing the buffer pH and the bounded mAb 
molecules can be eluted out. The investigation of pH effect was often correlated with the effect of buffer 
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ions. Faude et al. [107] reported a correlation between buffer pH and the maximum dynamic binding 
capacity of strong CEX resins with a human mAb. With increasing buffer molarity, maximum mAb 
dynamic binding capacity was observed at a lower pH. Gillespie [103] observed correlating effect of 
pH and counter-ions on the maximum mAb dynamic binding capacity of strong CEX resins with a 
mAb. At low pH, the maximum mAb dynamic binding capacity was insensitive to Cs, while at higher 
pH, an optimal Cs for the maximum mAb dynamic binding capacity was observed. 
Counter-ion 
The driving force for protein binding to CEX materials is the displacement of counter-ions by the target 
protein. Therefore, the type and concentration of counter-ions is critical to the binding performance of 
CEX materials. 
Sodium ion (Na+) is the most commonly used counter-ion in CEX for mAb capture. It was proposed 
that the smaller size of Na+ compared to K+ facilitates the water displacement process and thus a weaker 
competitor for protein binding [107]. Almodovar et al. [108] proposed that the effect of counter-ions is 
dependent on their molecular size, aqueous diffusivity, and charge. In a comprehensive investigation 
on the effect of the type of counter-ion on static mAb binding for three strong CEX resins of different 
structure, NuviaTM S, UNOsphereTM S and CaptoTM S, Almodovar et al. selected four counter-ions with 
distinct molecular size, aqueous diffusivity, and charge, including Na+, tetra-n-butylammonium 
(TBAH), arginine (Arg), and calcium (Ca2+). The rate of protein adsorption was observed to increase 
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Table 5 Properties of the counter-ions used in the work of Almodovar et al. [108]. 
Type Structure Charge 
at pH 5 
Aqueous 
diffusivity 










Calcium Ca2+ +2 0.79 × 10 -5 0.28 
Arginine 
 
+1 0.60 × 10 -5 0.36 
TBAH 
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A negative effect of Cs on the binding capacity due to competitive binding has been widely reported 
[104, 110-112]. Forrer et al. [110] reported a linear decrease of polyclonal IgG binding capacity with 
increasing ionic strength (70 to 170 mM) with a strong CEX resin, Fractogel EMD SE HiCap (M). 
Stone et al. [104] observed 50% decrease of the maximum binding capacity of a mAb when the ionic 
strength increased from 20 mM to 70 mM, with four agarose-based strong CEX resins. Bhambure et 
al. [112] also observed higher static binding capacity of a mAb in buffer solution with an ionic strength 
of 20 mM than that of 100 mM for two tentacular strong CEX resins. 
Co-ion 
During the process of IgG/mAb binding with CEX, co-ions are the ions that carry negative charges, 
and will be attracted to the surface of the positively charged IgG/mAb molecules. Therefore the type 
and concentration of co-ions also affect the movement of IgG/mAb molecules. The effect of co-ions on 
IgG/mAb binding with CEX has been probed by a few groups. Wrzosek et al. [113] reported a 50% 
decrease of mAb binding capacity for SP Sepharose Fast Flow, when switching buffer type from 
phosphate buffer to phosphate citrate buffer. At the same buffer molarity, phosphate citrate buffer 
contains more multi-valent anions than does phosphate buffer. It was proposed that multi-valent anions 
may compensate the global positive charges of the mAb, thus weakening the electrostatic interaction 
with cation exchangers [107]. However, the effect of co-ions on local protein charge characteristics was 
not addressed.  
 
2.5 IgG/mAb unfolding and buffer effects 
2.5.1 IgG/mAb unfolding 
Usually native proteins in solution are in equilibrium with a small number of unfolded intermediates. 
When exposed to thermal stress, mechanical stress or changes in the buffer composition, the 
equilibrium will be disturbed and lead to increased number of unfolded intermediates. These 
intermediates expose more hydrophobic patches and are more flexible compared to the folded state, 
which may lead to the formation of protein aggregates [114]. The unfolding of IgG/mAb can be detected 
with differential scanning calorimetry [115-119], circular dichroism spectroscopy [117, 120, 121], 
dynamic light scattering [122, 123] and fluorescence spectroscopy [124-130], among which intrinsic 
fluorescence spectroscopy has gained interest as a fast and non-invasive analytical method.  
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When a protein molecule partially or completely unfolds, the hydrophobic patches buried inside the 
molecule will be exposed thus increasing the hydrophobicity of the local environment [131]. IgG/mAb 
contains amino acids with intrinsic fluorescence, including tryptophan and tyrosine, that are very 
sensitive to changes in hydrophobicity and will exhibit an increase in the fluorescence intensity or 
maximum emission wavelength when excited at a certain wavelength. Maximum emission wavelength 
is the emission wavelength at which the maximum fluorescence intensity is observed. At an excitation 
wavelength of 280 nm, both tryptophan and tyrosine will be excited and show an increase in the 
fluorescence intensity when the degree of protein unfolding increases, while there may be an increase 
in the maximum emission wavelength for tryptophan depending on the type of the solvent used [132-
134]. Emission wavelength for tryptophan and tyrosine is usually set between 280 nm to 450nm 
(through the filter setting). When applying intrinsic fluorescence spectroscopy for the detection of 
protein unfolding, one can only detect the degree of unfolding through changes in hydrophobicity of 
the protein molecules, but cannot distinguish between partially unfolded proteins and completely 
unfolded proteins. 
 
2.5.2 Buffer effect on IgG/mAb unfolding 
During the IgG/mAb capture process, factors such as pH, ion type and ion concentration of buffer, 
especially counter-ion concentration (Cs) and co-ion type may have great impact on the structure of 
IgG/mAbs. 
pH and counter-ion 
Buffer pH is the most critical factor among all buffer factors, that may induce partial/complete protein 
unfolding and alters colloidal stability [114]. Buffer pH affects IgG/mAb structure by changing the 
charge distribution on the protein surface, thus changing the electrostatic interactions within and 
between protein molecules [135, 136]. One of the drawbacks of IgG/mAb capture with Protein-A 
chromatography is that low pH (around 3) is required to elute target IgG/mAbs off the chromatographic 
media, while the low pH disturbs the structure of IgG/mAbs, and induces unfolding and aggregation 
[137]. 
Investigations of pH effect on IgG/mAb unfolding were often correlated with the counter-ion 
concentration (Cs). Bickel et al. [115] investigated the effect of pH and NaCl concentration on the 
unfolding of a mAb, where the investigated pH ranged from 2 to 7 and NaCl concentration ranges from 
 
  30 
0 M to 1.5 M. It was concluded that the degree of unfolding was highest at low pH (pH 3.5) and high 
ionic strength (1.5 M). Herdberg et al. [138] mapped the degree of unfolding of mAb across pH from 
4 to 9 and NaCl concentration from 0 M to 1.0 M. After stressing the samples at 40 °C for 4 weeks, a 
higher degree of unfolding was found at pH < pH 5 for all NaCl concentration. A higher degree of 
unfolding was also found at pH 5 to pH 9 when NaCl concentration was less than 0.2 M. Sahin et al. 
[117] investigated the degree of unfolding of four types of human IgG1 under the effect of buffer pH 
and Cs, while the relatively small range of Cs investigated (54 mM and 100 mM) did not show any 
differences in unfolding when studied at the same pH. Increasing protein unfolding was observed when 
decreasing pH from 6.5 to 3.5 for both Cs conditions. These studies revealed the complexity of the 
effect of pH and Cs on mAb unfolding, and both indicated that low pH (2~3.5) and high Cs (1.5 M) may 
enhance protein unfolding. 
Co-ion 
The effect of buffer co-ion on IgG/mAb unfolding has been correlated with the Hofmeister effects. 
Hofmeister proposed that salts have different effects on the solubility of proteins and the stability of 
their secondary and tertiary structure [139]. The salt-out effects of anions were listed as citrate ion > 
phosphate ion > acetate ion > chloride ion. Most studies on IgG/mAb unfolding showed good agreement 
with the Hofmeister series. Rubin et al. [140] investigated the unfolding of a monoclonal human IgG1 
induced by various buffer type, including acetate, sulfate and formate. Acetate was found to be the most 
stabilizing anion, where no unfolding was observed at moderate concentration and slow unfolding at 
low concentration. Singla et al. [141] studied the unfolding of an IgG1-based mAb in buffer type 
commonly used in CEX, citrate, acetate and phosphate buffer, where citrate buffer was the only type 
that induced unfolding even without salt addition. Barnett et al. [142] explored the ion effect of acetate 
and citrate on an anti-streptavidin IgG1 and observed that citrate tended to accumulate around the 
surface of the anti-streptavidin IgG1 compared to acetate. The accumulation of citrate resulted in 
conformational changes, weaker electrostatic repulsion between proteins and thus increased unfolding 
rates.  
 
2.6 Quality by Design principles 
The US FDA and other health authorities have been actively promoting Quality by Design (QbD) for 
the manufacturing and development of pharmaceuticals since 2002 [27].The main objective of QbD is 
 
  31 
to ensure product quality throughout the manufacturing process, which renders more flexibility towards 
changes in process conditions. The key elements include the quality target product profile (QTPP), 
critical quality  attributes (CQAs), critical material parameters (CMPs), critical process parameters 
(CPPs), risk assessments, design space, control strategy and product life cycle management [143]. The 
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Figure 10 Quality by Design (QbD) roadmap [144]. 
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During the production of pharmaceutical products, variations within and between batches are very 
common and difficult to eliminate, while these variations can be minimized through the design space 
development. The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) has described design space in the ICH Q8 guidance [145] as, 
“the multidimensional combination and interaction of input variables that have been demonstrated to 
provide assurance of quality within an acceptable range”. The anticipation of issues and achievement 
of a better process control is possible when the design space is defined. It renders the manufacturing 
process flexibility, as stated by the guidance “working within the design space is not considered a 
change” [145]. The design space development has been achieved with small molecule pharmaceuticals 
[146-148], while there is also growing work in downstream processes of mAb manufacturing [30, 149-
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Table 6 Literature review of design space development for mAb downstream processes. 






• identified key operating parameters to be, protein 
loading, resin hydrophobicity, load conductivity, 
chase conductivity, and load sialic acid (SA level) 
• determined the design space that enabled a high step 
yield (≥ 40%) and high-molecular weight aggregate 











chromatography for viral 
clearance 
 
• established a multivariate approach used to evaluate 
process parameter impacts on viral clearance, based 
on the levels of retrovirus-like particles (RVLP) 











for viral clearance (model 
virus: X-MuLV, SV40, 
and 
MMV) 
• identified key parameters as, conductivity, load 
density, pH and flow rate 
• determined the design space that enabled a high 
virus reduction level, expressed in LRV, 5.6 to 6.1 














for removal of aggregates 
• identified equilibration buffer as the key parameter. 
Its operating range is set at 40 ± 5 mM acetate, pH 
5.0 ± 0.1 
• identified  elution buffer, load mass, and gradient 
elution volume are non-key parameters; their 
operating ranges are set at 250 ± 10 mM acetate, pH 
6.0±0.2, 45±10 g/L resin, and 10±20% CV 
respectively 
• purity of the sample was 99.8% or above and the 




The development of design space is important in quantifying the effect of material and process 
parameters on the performance of mAb manufacturing process, in terms of productivity and product 
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quality [28, 29]. During design space development, it is critical to first identify CMPs and CPPs through 
risk assessment. Design space development can be significantly expedited with tools such as Design of 
Experiment (DoE) and high-throughput process, which will be discussed in the next sections. 
 
2.6.1 Risk assessment  
A risk assessment of the process parameters is required to identify the CMPs and CPPs that have 
significant impact on CQAs and productivity. The assessment serves as a basis for minimizing the 
number of parameters required for the design space development. Failure mode and effects analysis 
(FMEA) is a numerical tool used to assess the criticality of process parameters [30, 151, 154]. Xu et al. 
applied the FMEA approach by creating a cause-and-effect diagram for all process parameters and then 
generating a Pareto plot to identify the parameters with greatest potential impact on the removal of 
aggregates with strong CEX resins [31]. 
Using FMEA, each parameter is assessed based on scientific experience and knowledge on 
equipment and process control capability and then ranked by the risk priority number (RPN) scores 
which is calculated by the severity (S), occurrence (O), and detection (D) of the risks (RPN=S×O×D). 
Severity means the severity of the potential effect of the failure. Occurrence is the likelihood that the 
failure will occur. Detection rates the likelihood that the problem will be detected before it reaches the 
end-user. Rating scales usually range from 1 to 5 or from 1 to 10, with the higher number representing 
the higher seriousness or risk. For example, on a ten-point scale, Severity of 1 means low risk to the 
end user, and a score of 10 means high risk to the end user; Occurrence of 1 means low probability of 
the risk happening, and a 10 means a very high probability of the risk happening; Detection of 1 means 
a process that will likely detect a failure, and a 10 means the process will likely not detect a failure. The 
specific rating descriptions and criteria is defined by the analysis team to fit processes being analyzed. 
An example of a five-point severity scale suggested by Stamatis’s reference book on FMEA [155] is 
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2.6.2 Design of Experiment (DoE) 
One-factor-at-a-time approach consumes significant amount of time and raw materials, and neglects 
interactions between process parameters. Therefore, the more advanced characterization approach such 
as DoE has drawn great attention. DoE maximizes the information of experimental data with statistical 
analysis [156]. DoE also enables investigations on parameter interactions and classification of 
parameters according to their influence on product quality and productivity, which is fundamental to 
design space development [151]. 
Lain et al. [18] designed the operating window with DoE for the capture of IgG1 (pI=8.1) from 
clarified harvest with GigaCap S-650M. The group examined the loading conditions and elution 
conditions separately to eliminate the complicity of the experimental design. For the loading DoE, 
loading pH at three levels (4.9, 5.2, and 5.5) and conductivity at two levels (4.0 and 5.0 mS/cm) were 
evaluated. For the elution DoE, pH (4.8, 5.3 and 5.8) and conductivity (90, 120 and 150 mS/cm) were 
evaluated at three levels. Interaction plot and contour plot for yield and HCP were constructed. The 
optimal loading conditions were found at pH 5.2 ± 0.2 and conductivity of 4.5 ± 0.5 mS/cm and optimal 
elution conditions were pH 5.3 ± 0.2 and NaCl concentration of 110 ± 15 mM, where >98% recovery, 
>98% purity, and >95% HCP removal were achieved. The robustness of the conditions was then 
confirmed at intermediate and large scale, where the intermediate scale-up used a 2.6×14.5 cm (77 mL) 
column, and large scale-up chromatography used a 5.05×14.3 cm (286 mL) column. 
Comparable operating space of loading buffer was reported by Miesegaes et al. [157], where load 
pH between 5.3 to 5.7 and conductivity < 5.0 mS/cm was defined as the optimal conditions to achieve 
highest yield and purity for IgG4 mAb capture with strong CEX resins. The group started by 
establishing an initial operating space, based on prior industry knowledge, information with other mAbs 
and observation from own database. Scouting studies with five commercial CEX resins for IgG4 mAb 
(pI = 7.5) determined an appropriate center-point condition of pH 5.3 and 5.0 mS/cm conductivity, 
based on which a five-point DoE was conducted to determine the optimal combination of loading pH 
and conductivity. Nevertheless, the group proposed that designs space development for mAb capture 
with CEX should be treated on a case-by-case basis.  
Tao et al. [66] looked into the process optimization for CEX capture with two mAbs (mAb A: pI=6.5 
and mAb B: pI= 8.7). Loading conditions were optimized by testing the effect of pH (4.5, 5 and 5.5) 
and conductivity (5, 11 and 17 mS/cm) on DBC and HCP removal. The approach was similar to that of 
Lain et al. [12], while the operating space of conductivity was much higher, because the conductivity 
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of harvested cell culture supernatant ranged from 12 mS/cm to15 mS/cm. Adding a dilution or UF step 
prior to CEX capture is not favorable for large-scale manufacturing, therefore performance 
optimization of CEX depends more on pH adjustment. No correlation was observed between HCP 
removal and pH or conductivity, while decreasing DBC with increasing loading pH was reported, 
especially for the more acidic mAb A. The operating space was determined to be loading pH 4.6±0.05 
for mAb A and 4.8± 0.2 for mAb B, with fixed conductivity at 14 mS/cm. Optimization of elution 
conditions was realized by a central composite face-centered design (CCFD) which consists of 13 
experimental points. Elution buffer pH and sodium ion concentration ([Na+]) were examined at two 
levels for their effect on yield, HCP reduction and elution volume. Contour plots showed elution pH to 
be the most influential factor on HCP removal. The statistical model predicted the optimal elution 
conditions for the two mAbs, which was pH 5/ pH5.1 with [Na+] of 210 mM with Fractogel SO3 /Poros 
XS for mAb A; pH5.5 with [Na+] of 300 mM/275 mM for Fractogel SO3 /Poros XS for mAb B. 
 
2.6.3 High-throughput processing 
High-throughput processi stands out as an efficient and economic approach for better process and 
product understanding during process development. It is the integration of miniaturization, automation 
and parallelization [158-161]. The workflow of high-throughput includes “planning an experimental 
setup using a systematic approach, carrying out experiments by testing various experimental conditions 
in a parallel manner, analyzing data using high-throughput analysis, and evaluating data and analyzing 
the results” [162, 163]. The implementation of high-throughput reduces the time frame of screening 
process from weeks to hours, with less sample consumption and larger experimental window.  
A couple of groups have worked on high-throughput mAb purification with IEX resins [20, 162, 
164-166]. Stein and Kiesewetter [20] conducted pH screening for optimal mAb binding and HCP 
removal with Fractogel® EMD SO3− (M) and Fractogel® EMD SE Hicap (M). Results of batch 
screening were comparable between the 100 mL scale and 200 µL scale with the 96-well plate format 
(manual liquid handling). Coffman et al. [164] evaluated the application of a 96-well filter plate (50/100 
µL) format for optimizing mAb purification conditions with IEX resins, incorporated with a robotic 
liquid-handling system, Tecan Genesis 150. The miniaturized batch-binding format reported the same 
trend of purity and recovery with process parameters as that with the regular column, which provided 
valuable information for process development. Grönberg [162] presented a case study of a high-
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throughput process combined with DoE to optimize mAb purification with 96-well filter plates and 
mini-columns assisted by TECAN Freedom Evo 150 robot.  
There has not been any high-throughput work with IEX membranes for mAb purification. Yoshimoto 
et al. [167] investigated the dynamic binding of BSA with IEX membranes in 96-well microplates. The 
dynamic BSA binding capacities obtained from the high-throughput process with IEX membrane (disks 
with 7 mm diameter and 2 mm thickness) was in good agreement with those from the regular sized IEX 
disk column (disks with 12 mm diameter and 3 mm thickness in a disk holder). 
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Chapter 3 Effect of buffer on the structure of weak CEX membranes 
3.1 Introduction 
Prior to probing buffer effects on the interaction of IgG/mAb and weak CEX membranes, it was critical 
to investigate the effect of buffer on the membrane structure, especially for the Natrix C weak CEX 
membrane employed in this work. The Natrix C weak CEX membrane presented a unique three-
dimensional macroporous hydrogel structure, and when interacting with a buffer solution, the 
membrane material swelled in response to the environment, namely pH and ionic strength. The swelling 
behavior of the membrane altered the pore size, which in turn affected the protein binding capacity and 
the protein transport within the pores.  
Ionic strength is a measure of the concentration of charges of all ions in a solution [106], which is 
influenced by both the concentration of counter-ions (buffer cations in the case of CEX) and co-ions 
(buffer anions in the case of CEX). The concentration of counter-ions is denoted as, Cs, and is often 
manipulated by adding NaCl or KCl to the buffer. The concentration of co-ions could be represented 
by buffer molarity.  
Hassel and Moresoli [38] investigated the swelling behavior of Natrix C weak CEX membrane 
equilibrated in phosphate citrate buffer with pH ranging from 4.5 to 7, and KCl additions ranging from 
0M to 1M. It was reported that the swelling factor of Natrix C weak CEX membrane was dependent on 
both pH and ionic strength of buffer. Hassel and Moresoli [38] also characterized the pore size of Natrix 
C weak CEX membrane equilibrated in phosphate citrate buffer with pH ranging from 4.5 to 7, and 
KCl additions of 0M and 1M, with Field Emission Scanning Electron Microscopy (FE-SEM). However, 
visualizations with SEM require the membrane samples to be coated with a layer of gold particles and 
then operating in high vacuum mode, which may damage the fragile structure of the hydrogel material. 
Therefore it was proposed to use the Field Emission Gun Environmental Scanning Electron Microscopy 
(FEG-ESEM) for the visualization of hydrogel membrane surface pore structure. ESEM offers high 
resolution secondary electron imaging in a gaseous environment, which eliminates the need for 
conductive coating and can operate at low vacuum mode, which helps protect the structure of fragile 
samples. 
It was hypothesized that buffer pH, counter-ions, and buffer type (represented by buffer co-ions) 
could affect membrane properties, namely the membrane swelling behavior and membrane surface pore 
structure of weak CEX membranes. The hypothesis was tested with Natrix C weak CEX membrane, 
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employing two most common buffer types for CEX, the phosphate citrate buffer and the acetate buffer. 
Buffer pH and ionic strength were selected based on Hassel and Moresoli [38]’s work and adjusted 
accordingly to meet the specific objectives in this work. Buffer effects on membrane swelling behavior 
were investigated with membrane swelling experiments, while buffer effects on membrane surface pore 
structure were investigated with Environmental Scanning Electron Microscopy (ESEM). 
 
3.2 Materials and methods 
3.2.1 Buffers 
All buffers and solutions were prepared with ultra-purified water. Stock sodium phosphate citrate buffer 
was prepared by mixing 100 mM citric acid (EMD Chemicals Inc., Gibbstown, USA) solution and 200 
mM sodium phosphate dibasic (Fisher Scientific, Fair Lawn, USA) solution. Stock sodium acetate 
buffer was prepared by mixing 200 mM acetic acid (EMD Chemicals Inc., Gibbstown, USA) solution 
and 200 mM sodium acetate (EMD Chemicals Inc., Gibbstown, USA) solution. All buffers were 
adjusted to the desired pH by adding approximately 1 drop of 0.1 M HCl or 0.1 M NaOH solution. This 
amount was considered negligible and was not accounted in the buffer composition. 
For the swelling experiment, stock sodium phosphate citrate buffer at pH 4.5 to 7 and stock sodium 
acetate buffer at pH 4.5 to 6 were used. Potassium chloride (EMD Chemicals Inc., Gibbstown, USA) 
was added into the stock phosphate citrate buffer and stock acetate buffer to achieve a KCl 
concentration of 0.1M, 0.3M, and 1M.  
For the microscopy experiment, the stock sodium phosphate citrate and acetate buffer at pH 5 were 
diluted to various concentrations and sodium concentration was adjusted with sodium chloride (BDH 
Inc., Toronto, Canada). See Appendix A for details of buffer preparation.  
 
3.2.2 Membranes 
Weak CEX membranes, Natrix C weak CEX membranes (disc diameter: 25 mm) were kindly provided 
by Natrix Separations Inc. (Burlington, Ontario, Canada). 
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3.2.3 Membrane swelling 
Each membrane disc (25 mm diameter) was cut into eight pieces and the dry weight of each piece was 
measured. Each membrane piece was immersed in 20 mL buffer with distinct pH and KCl concentration 
in a vial and then incubated on a shaker (Thermo Scientific 2309 lab rotator, Canada) for 4 hours. After 
the incubation, the membrane pieces were removed and hung for 10 min before the wet weight was 
measured. The procedure is illustrated in Figure 11. 
 
Figure 11 Illustration of the swelling experiment. 
The swelling factor qms was calculated as the ratio of the mass of swollen membrane (g) to the mass 




        Equation 3-1 
where mswollen is the mass of the wet membrane (g) and mdry is the mass of the dry membrane (g). 
 
3.2.4 Environmental scanning electron microscopy (ESEM) 
Membrane samples (5 mm × 5 mm) were equilibrated for 24 h in buffer solution with various molarity, 
and cation concentration at pH 5 to examine the effect of ion type and concentration ( 
Table 8). The stock 150 mM sodium phosphate citrate buffer has a sodium concentration of 206 mM 
(1), and was diluted four times to achieve a lower sodium concentration of 50 mM and buffer molarity 
of 37.5 mM (2). The sodium content of the 37.5 mM sodium phosphate citrate buffer (2) was adjusted 
by adding NaCl to achieve a sodium concentration of 206 mM (3), keeping the buffer molarity the same 
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as (2). The stock 75 mM sodium acetate buffer (4) has a sodium concentration of 50 mM, and it is 
equivalent to the diluted sodium phosphate citrate buffer (2).  
Table 8 Buffer solutions at pH 5 for the Environmental scanning electron microscopy (ESEM) 
experiment. 
 Buffer type Sodium concentration 
(mM) 
(1) 150 mM phosphate citrate buffer 206 
(2) 37.5 mM phosphate citrate buffer 50 
(3) 37.5 mM phosphate citrate buffer 
+ NaCl 
206 
(4) 75 mM acetate buffer 50 
   
 
Membrane samples were freeze-dried (Epsilon1-4, Martin Christ, Germany) for 22 hours before 
visualization with Field Emission Gun Environmental Scanning Electron Microscopy (ESEM, Quanta 
250, FEI company, Netherlands) at the low vacuum mode. The magnification was 5000 ×. The average 
pore diameter was estimated with the Pore Image Processor (2016) in MATLAB (R2015b). Method 
for pore size analysis employed in this work is based on the methodology reported previously [38] for 
SEM and Natrix C weak CEX membranes, where light-colored regions of the image were defined as 
pores, as illustrated in Figure 12. The black/white contrast of the ESEM images was corrected with the 
Background Correction Function, and binary operations were used to improve pores recognized by the 
program. Correction and threshold values were adjusted by visually verifying pores defined by the 
software.  
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Figure 12 (A) Original SEM image of Natrix C weak CEX membrane and (B) Pores defined by the 
Pore Image Processor over the original SEM image [38]. 
3.2.5 Statistical analysis 
Analysis of variance (ANOVA) and paired sample t-test were employed for statistical analysis at a 
confidence interval of 95%. 
 
3.2.6 Summary of experimental conditions 
The effect of pH, counter-ions and co-ions on membrane swelling behavior and membrane surface pore 
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3.3 Results and discussion 
3.3.1 Effect of buffer conditions on membrane swelling 
The swelling behavior of Natrix C weak CEX membrane was investigated in phosphate citrate buffer 
with a pH range of 4.5 to 7 and KCl concentrations ranging from 0 M to 1 M, and in acetate buffer with 
a pH range of 4.5 to 6 and KCl concentrations ranging from 0 M to 1 M (Figure 13).  
 
 
Figure 13 Swelling factor of Natrix C weak CEX membrane in (A) phosphate citrate buffer and (B) 
acetate buffer at various pH and KCl concentration. Error bars represent standard error (n=3).  
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The membrane swelling in phosphate citrate buffer was affected by pH, and the pH effect was 
statistically significant (ANOVA, 95% confidence). At a given KCl concentration, the swelling factor 
initially increased significantly with pH, and then leveled off at pH 6.0. When pH was increased from 
4.5 to 7, the swelling factor increased significantly by 104% at 0 M KCl and increased significantly by 
43% at 1M KCl (Paired t-test; 95%). The swelling behavior reflects the composition of the membrane, 
which contains porous polyacrylate hydrogel with pendant carboxylic acid ligands that exhibit variable 
ionization according to pH condition. The effect of pH on membrane swelling could result from 
electrostatic repulsion. With a pKa of 5.3 [38], the carboxylic acid ligands of the membrane will be 
ionized and negatively charged at pH>5.3. The increasing negative surface charge of the material with 
pH will lead to strong repulsion within the polymer network, thus the polymer chain tends to uncoil 
and allows more water molecules to be attracted to the hydrophilic carboxylic group [38]. While at pH 
6.0, it is proposed that the pores of hydrogel almost reached their maximum size, thus further pH 
increase did not influence the swelling factor. 
The membrane swelling in phosphate citrate buffer was affected by KCl concentration, and the KCl 
concentration effect was statistically significant (ANOVA, 95% confidence). In general, the swelling 
factor decreased with KCl concentration at a given pH. The most pronounced effect of KCl 
concentration on swelling factor was observed at pH 5, with a reduction of 25%. However, significant 
decrease of swelling factor with increasing KCl concentration was not observed (Paired t-test; 95%), 
and indicated that this method was not capable of distinguishing the KCl concentration effect on 
swelling factor. 
The membrane swelling in phosphate citrate buffer confirmed that both the pH and the KCl 
concentration of buffer have a significant influence on membrane swelling (ANOVA, 95% confidence). 
The swelling factor was found to increase with pH significantly. The swelling factor qms  in phosphate 
citrate buffer ranged from 1.9 ± 0.1 (pH 4.5; 0 M) to 3.8 ± 0.1 (pH 7; 0 M), smaller than values reported 
previously by Hassel and Moresoli [38] for the same Natrix C weak CEX membrane in phosphate 
citrate buffer where qms was 3.4 (pH 4.5; 0 M) and 4.53 ± 0.03 (pH 7; 0 M). The ratio of qms (pH 7) / 
qms (pH 4.5) in this work was 2.0 and the ratio was 1.3 in Hassel and Moresoli’s work. The difference 
in results may come from differences in humidity and temperature at the time of experiment. The 
standard error in this work was higher than that from Hassel’s work, which suggested that the 
methodology is difficult to control, such as small sample size and material heterogeneity. Membrane 
swelling may not be the best method to assess small contributions of pH. 
 
  48 
The membrane swelling in acetate buffer was affected by pH and KCl concentration, and the two 
effects were statistically significant (ANOVA, 95% confidence), as same for the phosphate citrate 
buffer. Paired t-test (95% confidence, P = .35) were performed and concluded that there was no 
significant difference of swelling factors between the two types of buffer.  
 
3.3.2 Effects of buffer conditions on membrane surface pore size  
The effect of buffer type, molarity and counter-ion concentration on the membrane morphology was 
explored by conducting microscopy imaging. Environmental scanning electron microscopy (ESEM) 
offers high resolution secondary electron imaging in a gaseous environment, which eliminates the need 
for a conductive coating and can preserve the fragile structure of hydrogel membrane. The average pore 
diameter of Natrix C weak CEX membrane freeze-dried after equilibration in different buffer 
conditions (Table 10) revealed the effects of counter-ion/co-ion concentration and co-ion type on pore 
structure. 
Table 10 Estimated pore diameter of freeze-dried Natrix C weak CEX membrane according to 
equilibration buffer conditions. 




(average ± SD, 
n=3, µm) 
Phosphate citrate buffer 150  206  0.62±0.05 
Phosphate citrate buffer 37.5  50  0.65±0.05 
Acetate buffer 75  50  0.64±0.05 
Phosphate citrate buffer + NaCl 37.5 206  0.54±0.04 
No equilibration   0.64±0.07 
 
The ESEM images of Natrix C weak CEX membrane equilibrated in phosphate citrate buffer and 
acetate buffer with different Na+ concentration was collected and analyzed (Figure 14, Figure 15, Figure 
16 and Figure 17). The effect of ion type on the pore diameter of Natrix C weak CEX membrane was 
found to be insignificant (Paired t-test; 95%), as the average pore diameters of membranes equilibrated 
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in phosphate citrate buffer and acetate buffer with the same sodium concentration were similar. The 
observation corresponded with the similar membrane swelling factors between the two buffer types. At 
equivalent sodium concentration, buffer molarity had an effect on the pore diameter, where the pore 
diameter of Natrix C weak CEX membrane equilibrated in 150 mM phosphate citrate buffer was larger 
than that in 37.5 mM phosphate citrate buffer with the same Na+ concentration. However, the effect of 
buffer molarity on the pore diameter was insignificant (Paired t-test; 95%). Na+ concentration also had 
an effect on the pore diameter of Natrix C weak CEX membrane, as the pore diameter of membrane 
equilibrated in 37.5 mM phosphate citrate buffer with increased Cs was smaller than that equilibrated 
in 37.5 mM phosphate citrate buffer. However, the effect of Na+ concentration on the pore diameter 
was also insignificant (Paired t-test; 95%). It was suggested that ESEM was not sufficient in revealing 
the effect of buffer molarity and Na+ concentration on the pore diameter of membranes. 
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Figure 14 (A) Original ESEM image of Natrix C weak CEX membrane after equilibrating in 150 
mM phosphate citrate buffer with a Na+ concentration of 206 mM and (B) ESEM images processed 
with the Pore Image Processor. Images were taken at a magnification of 5000 x. 
 
Figure 15 (A) Original ESEM image of Natrix C weak CEX membrane after equilibrating in 37.5 
mM phosphate citrate buffer with a Na+ concentration of 50 mM and (B) ESEM images processed 
with the Pore Image Processor. Images were taken at a magnification of 5000 x. 
 
  51 
 
Figure 16 (A) Original ESEM image of Natrix C weak CEX membrane after equilibrating in 75 mM 
acetate buffer with a Na+ concentration of 50 mM and (B) ESEM images processed with the Pore 
Image Processor. Images were taken at a magnification of 5000 x. 
 
Figure 17 (A) Original ESEM image of Natrix C weak CEX membrane after equilibrating in 37.5 
mM phosphate citrate buffer with a Na+ concentration of 206 mM and (B) ESEM images processed 
with the Pore Image Processor. Images were taken at a magnification of 5000 x. 
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The applicability of ESEM for quantitatively characterizing the pore size of Natrix C weak CEX 
membrane remains limited because of the heterogeneity of the membrane material. This heterogeneity 
is visible in the ESEM image of both the native membrane and the freeze-dried membrane previously 
equilibrated in buffer where irregular porous hydrogel, physically supported by interlaced thin fibers 
was observed (Figure 18).  
 
Figure 18 ESEM images of (A) the surface of native dry Natrix C weak CEX membrane and (B) the 
surface of freeze-dried Natrix C weak CEX membrane equilibrated in pH 7 phosphate citrate buffer 
and subsequently freeze-dried. Images were taken at a magnification of 1000 x. 
 
3.4  Conclusion 
In this chapter, the role of buffer pH, counter-ion concentration, and buffer type on membrane 
properties, namely the membrane swelling behavior with K+ as counter-ion and its surface morphology 
with Na+ as counter-ion, were investigated through the swelling experiment and ESEM, for the weak 
cation exchange hydrogel membrane, Natrix C weak CEX membrane. 
The swelling factors of Natrix C weak CEX membrane in both phosphate citrate buffer and acetate 
buffer indicated that both the pH and the K+ concentration of buffer had a significant influence on 
membrane swelling (ANOVA, 95%). The swelling factor increased with increasing pH significantly 
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(Paired t-test; 95%). However, there were no significant difference of swelling factors between the two 
types of buffer for all pH and K+ concentration investigated in this study (Paired t-test, 95% confidence, 
P = .35). The reliability of the methodology for assessing swelling should be further investigated. 
Surface pore size of Natrix C weak CEX membrane freeze-dried after equilibration in different buffer 
conditions was visualized by ESEM. It was proposed that both sodium concentration and buffer 
molarity had an effect on the pore diameter of Natrix C weak CEX membrane, but the effect were 
insignificant (Paired t-test; 95%). The effect of buffer type on the pore diameter of Natrix C weak CEX 
membrane was found to be insignificant (Paired t-test; 95%), which corresponded with the similar 
membrane swelling factors between the two buffer types. However, as observed in ESEM image of 
both the native membrane and the freeze-dried membrane previously equilibrated in buffer, the 
applicability of ESEM for quantitatively characterizing the pore size of Natrix C weak CEX membrane 
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Chapter 4 Effect of co-ion and counter-ion on IgG/mAb binding with 
Natrix C weak CEX membranes 
4.1 Introduction 
IgG/mAb binding with CEX is based on the electrostatic interactions between positively charged 
proteins and the negatively charged porous chromatography absorbent. The binding capacity of proteins 
with CEX not only depends on the characteristics of the protein and the membrane, but also largely on 
the buffer conditions.  
Numerous studies have investigated the IgG/mAb binding with strong CEX resins [1, 104, 107, 108, 
110-113, 168], while limited studies were conducted with weak CEX resins. As opposed to strong CEX 
materials, weak CEX materials contain functional groups that present absorbent variable ionization 
according to buffer pH, which makes weak CEX materials more susceptible to buffer conditions. 
Nonetheless, the buffer conditions in IgG/mAb binding with weak CEX materials has not been 
thoroughly investigated. In terms of the format of the chromatography, resins are the most commonly 
used stationary phase for IgG/mAb binding, while membranes have risen as a cheaper and more 
efficient alternative to resin [33, 34, 37]. However, buffer effects on strong or weak CEX membranes 
for IgG/mAb binding have rarely been studied [22, 38]. 
Buffer conditions of importance in the binding of IgG/mAb with CEX materials comes from its pH, 
cation (counter-ion), and anion (co-ion) content. The effect of buffer ions has been confounded with 
the effect of pH in the literature [107, 168]. Given their confounding effect, in this chapter buffer pH 
was kept constant to focus on the effect of the ion content of the buffer. During binding with CEX 
materials, counter-ions compete with positively charged protein molecules for the negatively charged 
binding sites on the material surface, while co-ions will form a layer around the positively charged 
protein molecules and shield the protein surface. The concentration of counter-ion (Cs) is the most 
critical factors in IgG/mAb binding with CEX, as protein molecules displace counter-ions on the CEX 
material during the binding process. A negative effect of Cs on the binding capacity due to competitive 
binding has been widely reported [104, 110-112]. The effect of co-ions on IgG/mAb binding with CEX 
has been probed by a few groups [107, 113], however, its effect on local protein characteristics was not 
addressed. Wrzosek et al. [113] reported a 50% decrease of mAb binding capacity for SP Sepharose 
Fast Flow, when switching buffer type from phosphate buffer to phosphate citrate buffer. At the same 
buffer molarity, sodium phosphate citrate buffer contains more multi-valent anions than sodium 
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phosphate buffer. It was proposed that multi-valent anions may compensate the global positive charges 
of the mAb, thus weakening the electrostatic interaction with cation exchangers [107].  
In this chapter, it was hypothesized that buffer co-ions will affect the binding capacity of proteins 
with weak CEX membranes. Co-ions are buffer anions in the context of CEX. The hypothesis was 
tested with Natrix C weak CEX membrane, employing two most common buffers with different co-ion 
type, valence and chemistry, where phosphate citrate buffer contains multi-valent co-ions and acetate 
buffer contains monovalent co-ions. Counter-ion concentration was also investigated with NaCl 
addition, since in chapter 3 membrane swelling was impacted by NaCl addition.  
The selection of co-ion and counter-ion concentration was based on Hassel’s work [38] for IgG 
binding with Natrix C weak CEX membrane. Natrix C weak CEX membrane was reported to show 
high salt tolerance at pH 5 [22] for mAb binding, thus pH of all buffers was fixed at 5 in this chapter. 
Three proteins with different size and pI were selected, lysozyme with its relatively small molecular 
size and relatively high pI, IgG with its relatively large size and low pI, and Bevacizumab as a 
humanized mAb for investigating co-ion effect on mAb binding. Static protein binding was analyzed 
from the equilibrium isotherms and with the Langmuir model and the SMA model to better understand 
the role of ions at a molecular level. A 96-well plate platform was developed for protein binding with 
membranes to facilitate the investigation to be performed in an efficient and cost-effective manner. 
Throughout this document, high-throughput binding refers to binding taking place in 96-well 
microplates. 
 
4.2 Materials and methods 
4.2.1 Buffers and chemicals 
All buffers and solutions were prepared with ultra-purified water (with Resistivity ≥ 16 MΩ • cm). 
Sodium phosphate citrate buffer was prepared by mixing citric acid (EMD Chemicals Inc., Gibbstown, 
USA) solution and sodium phosphate dibasic (Fisher Scientific, Fair Lawn, USA) solution. Sodium 
acetate buffer was prepared by mixing acetic acid (EMD Chemicals Inc., Gibbstown, USA) solution 
and sodium acetate (EMD Chemicals Inc., Gibbstown, USA) solution. All buffers were adjusted to the 
desired pH by adding approximately 1 drop of 0.1 M HCl or 0.1 M NaOH solution. This amount was 
considered negligible and was not accounted in the buffer composition. Desired counter-ion 
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concentration, sodium, was achieved with the sodium content of the buffer and sodium chloride (BDH 
Inc., Toronto, Canada) addition. Sodium chloride addition was obtained with a stock 5 M NaCl solution. 
See Appendix A for details of buffer preparation. The major ionic species present in the buffers are 
given in Table 11. 
Polysorbate 20 (Alfa Aesar, Heysham, England) and Nile Red (Sigma-Aldrich, Oakville, Ontario, 
Canada) were used for the quantification of surfactant in mAb samples. 
Table 11 Major ionic species in 150 mM sodium phosphate citrate buffer and 200mM sodium acetate 
buffer at pH 5. 
 150 mM Sodium phosphate citrate buffer 
200 mM Sodium acetate 
buffer 
Counter-ions Na
+ (206 mM) 
H+ 











4.2.2 Proteins  
Lysozyme was purchased from Neova Technologies (Abbotsford, British Columbia, Canada). Human 
polyclonal IgG was purchased from Equitech-Bio, Inc. (Kerrville, Texas, USA), which is referred to as 
“IgG” in this work, unless indicated otherwise. The mAb samples (in vials), Bevacizumab, were 
generously provided by Apotex Inc. (North York, Ontario, Canada). Bevacizumab is supplied at a 
concentration of 25 mg/mL, with 0.4 mg/mL (0.04% w/v) polysorbate 20, at pH 6.2. Properties of the 
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Table 12 Properties of lysozyme, IgG and Bevacizumab. 
Properties Lysozyme [169] IgG [170] Bevacizumab [51, 52] 
Molecular weight 
(Mw; kDa) 
Around 14 Around 150 Around 149 
Isoelectric point (pI) 
11 
Range from 4 to 9, 







11 16 16 
Lysine 
(pKa=10.5) 
6 45 45 
Histidine 
(pKa=6) 
1 14 14 
 
4.2.3 Membranes  
Weak CEX membrane, Natrix C weak CEX membranes (disc diameter: 47 mm) were kindly provided 
by Natrix Separations Inc. (Burlington, Ontario, Canada).  
 
4.2.4 Bevacizumab dialysis and Polysorbate 20 quantification 
Bevacizumab dialysis served two purposes in this work: (1) formulate Bevacizumab sample to the pH, 
conductivity, and Bevacizumab concentration of the binding solution; (2) remove the surfactant 
Polysorbate 20 to avoid potential interferences with the binding. The following procedure for mAb 
dialysis was developed from the work of Torres et al. [171], where conductivity was used to identify 
when the binding solution had reached the target conditions. The procedure for Polysorbate 20  
quantification was developed from the work of Arora et al. [172].  
The dialysis was done with the a 10 kDa molecular weight cutoff (MWCO) membrane with a 
diameter of 25 mm, Ultracel regenerated cellulose membrane (EMD Millipore Corporation, 
Massachusetts, USA), to ensure the retention of Bevacizumab. The dialysis was performed with a 10 
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mL Amicon stirred cell (EMD Millipore, Darmstadt, Germany), where nitrogen gas was used for 
pressurizing the cell at 45 psi. A volume of 8 mL of Bevacizumab samples was filled in the stirred cell 
and concentrated to 4 mL at first, and 4 mL of the binding buffer (phosphate citrate buffer or acetate 
buffer at pH 5 and conductivity) was then added to the stirred cell. The mixture was then concentrated 
to 4 mL and a second volume of binding buffer (4 mL) was added. This procedure was repeated for 3 
times. 
To confirm that the Bevacizumab samples were formulated to pH 5 and conductivity of the target 
binding solution, pH and conductivity were measured with SevenMulti™ pH meter (METTLER 
TOLEDO, Ontario, Canada). To verify that the Bevacizumab samples were retained, the UV 
absorbance of Bevacizumab samples was measured before and after dialysis with the Synergy 4 multi-
detection microplate reader (BioTek Instruments, Winooski VT, US) for UV at 280 nm. mAb loss was 
less than 1%. 
The effectiveness of polysorbate 20 removal by dialysis was evaluated by quantifying the polysorbate 
content with Nile Red through fluorescence intensity (Sigma-Aldrich, Oakville, Ontario, Canada). First 
step was to generate the calibration curve of Polysorbate 20 solution (without Nile Red) in binding 
buffer with a Polysorbate 20 concentration of 0.01, 0.02, 0.03, 0.04, 0.05, 0.08, 0.1, 0.2, 0.5, 0.8 and 
1mg/ml. A volume of 4.1 µL Nile Red stock solution (100 µM in ethanol) was then added to 200µl 
Polysorbate 20 solution in a 96-well non-binding black microplate (Greiner Bio-One, North Carolina, 
USA). After equilibrating for 30 minutes on a shaker at 125 rpm, the fluorescence spectra (Excitation: 
550 nm/Emission: 570 to 700 nm) for each Polysorbate 20 concentration were collected with the 
Synergy 4 microplate reader, at sensitivity of 95 and emission step of 1 nm. The calibration curve 
indicated that the maximum fluorescence intensity was linearly proportional to Polysorbate 20 
concentration, with an R2 of 0.99. The next step was to add Nile Red to the Bevacizumab sample after 
dialysis and fluorescence spectra was collected at the same conditions (Excitation: 550 nm/Emission: 
570 to 700 nm) with the Synergy 4 microplate reader. The Polysorbate 20 concentration was then 
calculated from the maximum fluorescence intensity using the calibration curve, which showed that 
91% of Polysorbate 20 was removed. See Appendix A for calibration curves and concentration 
calculation of Polysorbate 20.  
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4.2.5 Milliliter-scale static protein binding with Natrix C weak CEX membranes 
Milliliter-scale static protein binding was conducted in 10 mL vials at room temperature, adapted from 
Hassel and Moresoli [38] for two types of protein, lysozyme and IgG. Buffer conditions are summarized 
in Table 13. The membrane sample was prepared by cutting one-eighth of a circular membrane piece 
(Diameter: 47 mm), with a membrane volume of 0.06 ± 0.002 mL. The membrane volume was 
calculated from the total mass of the membrane (measured in duplicates) and membrane density 
(0.42275g/ml). The total sample mass was measured with a Mettler AE 100 balance (readability 0.1 
mg). The membrane density was calculated by measuring the mass of the 47 mm circular membranes 
(measurements in triplicate; 0.17g) piece with a known volume of 0.399 mL[38]. 
Experiments for each protein concentration were conducted in triplicate. The membrane sample was 
first incubated in 5 mL of the desired binding buffer on a shaker (Thermo Scientific 2309 lab rotator, 
Canada) at 120 rpm for 2 h. The equilibrated membrane samples were then transferred to 10 mL protein 
solutions in the binding buffer, with initial concentration ranging from 0.1 mg/mL to 4 mg/mL. 
Incubation time was 72 h for lysozyme and 24 h for IgG to achieve equilibrium adsorption. 
Equilibration time was chosen from the work of Hassel and Moresoli [38]. At the end of the incubation, 
the solution was recovered and filtered through a 0.45 μm PES syringe filter (Thermo Scientific, 
Ottawa, Canada) before further analysis. 
 
4.2.6 High-throughput static protein binding with Natrix C weak CEX membranes with 
microplates  
The high-throughput static protein binding was performed in 96-well microplates at room temperature 
for two types of proteins, IgG and Bevacizumab. Buffer conditions are presented in Table 13.  
There were two considerations when investigating the membrane volume and the solution volume, 
(1) the ratio of Vsolution /Vmembrane (Equation 4-1) between the milliliter-scale (ratio = 167) and the high-
throughput binding should be kept relatively constant, and (2) the solution volume should be within the 
maximum working volume of 96-well microplates. Under these constraints, the appropriate membrane 
volume was determined to be 0.0013 mL, while the solution volume was 0.25 mL for high-throughput 
binding in this work. 
Circular membrane samples (Diameter: 2.6 mm) were prepared from full size membranes (Diameter: 
47 mm) and with a cork borer. The membrane volume was calculated from the total sample mass 
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(measured in duplicates with Mettler AE 100 balance, readability 0.1 mg) and membrane density 
(0.42275g/ml), which was 0.0013 mL. Initial IgG concentration ranging 0.1 mg/mL to 4 mg/mL, or 
initial Bevacizumab concentration ranging from 0.5 mg/mL to 10 mg/mL were prepared through 
dilution from the stock IgG solution (4 mg/mL) or stock Bevacizumab solution (10 mg/mL). Binding 
experiments for each protein concentration were conducted in triplicate. 
High-throughput binding was performed with 96-well non-binding clear microplates (Greiner Bio-
One, North Carolina, USA) on the shaker at 200 rpm. The equilibration time of membrane in buffer 
without protein was 1 h and the binding time was determined from time course experiments. Time 
course experiment for high-throughput binding was performed with IgG (C0= 3 mg/mL) in 150 mM 
phosphate citrate buffer and 200 mM acetate buffer at pH 5, in triplicates. 
A different set of high-throughput binding experiments was performed to evaluate if filtration was 
required in order to remove potential protein aggregates formed during the binding experiment. 
MultiScreen HTS 96-well filter plates with 0.45 μm PVDF membranes (EMD Millipore Corporation, 
Massachusetts, USA) were used. In this set of experiment, after equilibration with the buffer for 1h, 
Natrix C weak CEX membrane samples were recovered from the buffer by centrifugation 60 g for 2 
minutes, with Eppendorf centrifuge 5804R (Hamburg, Germany). A volume of 200 μL IgG solutions 
with various concentration were then added to each well with equilibrated membrane pieces. After 
binding, IgG solutions were filtered out at 60 g for 2 minutes and the filtrates were collected for further 
analysis. 
 
4.2.7 Protein Quantification 
Quantification of lysozyme, IgG and Bevacizumab was obtained by UV absorbance at 280 nm. 
Calibration curve for each protein was constructed for protein concentrations ranging from 0.1 mg/mL 
to 2 mg/mL. For lysozyme and IgG, the calibration curve was linear for concentration up to 1 mg/mL. 
For Bevacizumab samples, the calibration curve was linear for concentration up to 2 mg/mL. 
Calibration curves were prepared for each set of experiments for each protein. 
For milliliter-scale binding, the absorbance at 280 nm was determined with a UV-vis 
spectrophotometer (Spectronic GENESYS 5, Thermo Scientific, Waltham, USA). At the end of a 
binding experiment, a 2 mL volume of the solution was transferred to quartz cuvettes (Fisher Scientific, 
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Fair Lawn, USA), and the UV absorbance was measured at 280 nm. Protein concentration was 
calculated based on the calibration curve. 
For high-throughput binding, the protein concentration was determined with a Synergy 4 multi-
detection microplate reader (BioTek Instruments, Winooski VT, US). A volume of 150 µL of the 
binding solution was transferred to 96-well UV transparent plates (EMD Millipore, Darmstadt, 
Germany) and the UV absorbance was measured at 280 nm. Protein concentration was calculated based 
on the calibration curve. 
 
4.2.8 Determination of static protein binding capacity 
The static protein binding capacity was calculated from Equation 4-1,  
 
qe = (C0 − Ce) (
Vsolution
Vmembrane
) Equation 4-1 
 
where qe is the static protein binding capacity at equilibrium (mg/mL); C0 is the initial protein 
concentration (mg/mL); Ce is the equilibrium protein concentration (mg/mL); Vsolution is the total volume 
of binding buffer (mL); and Vmembrane is the volume of the membrane piece (mL). See Appendix F for 
calculation example. 
Note that the membrane volume used for calculating protein binding capacity in this work is the dry 
membrane volume, same as other work using the same membrane material [22, 173]. Protein binding 
capacity is largely dependent on the ion exchange capacity of the membrane, which is the number of 
active binding sites on the ion exchanger and was determined to be 204 mM for Natrix C weak CEX 
membrane based on the dry membrane volume [173]. Static binding capacity is the maximum amount 
of protein bound to the ion exchanger at given buffer conditions and protein concentration conditions, 
where protein is overloaded and should be able to bind to the surface of the ion exchanger as well as 
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4.2.9 Statistical analysis 
Analysis of variance (ANOVA) was employed for statistical analysis at a confidence interval of 95%. 
Paired two-sample t-test was employed for statistical analysis at a confidence interval of 95%. 
 
4.2.10 Summary of experimental conditions 
Table 13 Buffer conditions, model proteins and experimental conditions for static protein binding at 
pH 5 with Natrix C weak CEX membranes presented in Chapter 4. 
 
Section 
 Buffer Model 






150  206 Langmuir  IgG, 
lysozyme 
Milliliter-scale  
acetate 200  140 Langmuir  
4.4.2 phosphate 
citrate 
150  206 N/A IgG  Milliliter-scale 
and high-
throughput  acetate 200  140 
4.4.3 phosphate 
citrate 








acetate 200  206*, 256*, 
306* 
SMA 







100 140 N/A Bevacizumab High-
throughput  
acetate 200 140 
* with NaCl addition 
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4.3 Theory 
4.3.1 Protein adsorption model 
The representation of protein binding at an ion exchange (IEX) surface is most commonly described 
by the Langmuir model (Equation 4-2) [174]. 
qe =
qmax K Ce




The model is based on the assumptions of monolayer coverage and independent binding sites, with 
two model parameters representing the maximum adsorption capacity (qmax) and the equilibrium 
constant (K).   
The model can be modified by introducing the counter-ion concentration (Cs) to better interpret 
protein binding with ion exchange materials [175]. Brooks and Cramer [176] developed the steric mass-












which accounts for the multipoint binding characteristic of protein molecules and the steric hindrance 
of counter-ions with the protein characteristic charge (ν) and the steric factor (σ), respectively. The 
characteristic charge (ν) is the number of charged residues on the protein that interacts with the ion 
exchanger. Upon adsorption, an equivalent number of monovalent counter-ions on the ion exchanger 
will be displaced. The steric factor (σ) is the number of counter-ions on the ion exchanger shielded by 
the adsorbed protein thus prevented from exchanging with proteins in the mobile phase. The 
equilibrium constant (Ka) of the SMA model has a similar physical meaning as the K in the Langmuir 
model, describing the adsorption affinity. The ion exchange capacity (Λ) is an indication of the number 
of active binding sites on the ion exchanger. The SMA model assumes negligible co-ion effect and 
independent equilibrium parameters of solute or salt concentration. 
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4.3.2 Model parameter estimation and parameter sensitivity analysis 
Experimental static protein adsorption data (High-throughput binding) were fitted with two adsorption 
models, the Langmuir model (Equation 4-2) and the SMA model (Equation 4-3).  
The Langmuir model parameters, the maximum adsorption capacity (qmax) and the equilibrium constant 
(K), were estimated with the least squares approach (MATLAB, R2016b). 
The SMA model parameters, protein characteristic charge (ν), steric factor (σ), and equilibrium 
constant (Ka) were estimated with fzero and nlinfit (MATLAB, R2016b) (See Appendix C). The ion 
exchange capacity (Λ) was determined to be 204 mM [38, 173] for Natrix C weak CEX membrane. 
The coefficient of determination R2 was used as an indication of goodness of fit of the model. Parameter 
sensitivity analysis for the SMA model was conducted for IgG adsorption with Natrix C weak CEX 
membrane in phosphate citrate buffer at low Na+ concentration (206 mM) and high Na+ concentration 
(306 mM). The protein binding capacity at equilibrium (qe) was estimated by varying each parameter 
(ν, Ka or σ) by ±20% based on the estimated value, while keeping other parameters constant. 
 
4.4 Results and discussion 
The effect of buffer co-ions obtaiend by selecting two different buffers and counter-ions obtained by 
sodium concentration was evaluated for IgG/mAb binding with Natrix C weak CEX membrane. 
Binding experiments were performed according to the experimental conditions presented in Table 13. 
The effect of protein size and pI and buffer conditions on adsorption with Natrix C weak CEX 
membrane will be first investigated with IgG and lysozyme. After validating the high-throughput 
format for IgG binding with CEX membrane, investigations on the effect of buffer on IgG binding will 
be performed with the assistance of the Langmuir model and SMA model and a binding mechanism 
will be proposed. Lastly, the effect of buffer type (co-ion) on the binding capacity of Bevacizumab with 
Natrix C weak CEX membrane will be investigated and compared with IgG. 
 
 
4.4.1 Effect of buffer conditions on static protein binding for lysozyme and IgG 
The first step was to investigate the effect of protein size and pI and buffer conditions on adsorption 
with Natrix C weak CEX membrane. Lysozyme is selected as a model protein for its relatively small 
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molecular size (14 kDa) [169] and relatively high pI (11) [169], which makes it ideal for investigating 
protein capture with cation exchange chromatography. Lysozyme is one of the earliest characterized 
and most extensively studied globular proteins. The cost of lysozyme is low as it can be easily purified 
from egg white [177]. In contrast to lysozyme, IgG has a larger molecular size (150 kDa) [170] and 
lower pI (median of 6) [170] (Table 12). The binding buffer conditions and incubation period were 
selected based on Hassel’s work [38]. 
The equilibrium adsorption isotherms of lysozyme and IgG with Natrix C weak CEX membrane in 
phosphate citrate buffer and acetate buffer were estimated with the Langmuir model (Table 14.  The 
Langmuir model was appropriate in describing the adsorption of IgG with Natrix C weak CEX 
membrane in the present work. The predictability of the model was very good for a wide range of 
protein concentration, with an R2 value range from 0.96 to 0.99. The simple mathematical expression 
and model assumptions enable its application in various scenarios. The isotherms of lysozyme are 
relatively similar between buffers (Figure 19A) and exhibit nearly rectangular shape which represents 
high adsorption affinity. Similar rectangular adsorption isotherm profile of lysozyme was observed 
previously by Wang et al. [178] for different types of membrane chromatography materials,  Sartobind 
C and Sartobind S, in 10 mM potassium phosphate buffer at pH 7.  
Table 14 Fitted Langmuir model parameters for lysozyme and IgG with Natrix C weak CEX 
membrane. 
Protein Buffer K (mL/mg) qmax (mg/mL) R2 
Lysozyme Phosphate citrate 121 257 0.99 
 Acetate 255 27.5 0.96 
IgG Phosphate citrate 119 2.23 0.96 





  66 
 
Figure 19 Adsorption isotherms for (A) lysozyme and (B) IgG with Natrix C weak CEX membrane 
in 150 mM phosphate citrate buffer and 200 mM acetate buffer at pH 5. The curves represent 
estimates with the Langmuir model. Error bars represent standard error (n=3). 
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The profile of the adsorption isotherms for IgG with Natrix C weak CEX membrane in 150 mM 
phosphate citrate buffer and 200 mM acetate buffer at pH 5 (Figure 19B) are distinct from that of 
lysozyme, with lower saturation level and smaller slope, demonstrated by the lower estimated qmax and 
K value. The lower saturation level of IgG is due to its large size which induce stronger steric hindrance 
effect [179] during binding. Small proteins such as lysozyme also have a higher accessibility of active 
binding sites on the membrane [180]. The smaller slope reflects lower adsorption affinity, which may 
come from their differences in pI and amino acid composition (Table 12). Lysozyme has a higher pI 
(pI=11) therefore it is more positively charged than IgG (pI: 4~9) at pH 5. The higher content of arginine 
residues in lysozyme may also contribute to the strong affinity, since arginine is the major contributor 
for binding with cation exchangers [181].  
The nature of the buffer did not translate in differences of the adsorption process for lysozyme, 
possibly due to its strong binding affinity, where significant differences were observed for adsorption 
curves for IgG.  Lysozyme is not ideal for investigating co-ion effect, which is present when 
investigating IgG binding. Further investigation of the buffer effects of protein adsorption with Natrix 
C weak CEX membranes was pursued only for IgG as it is a better representation of mAb than 
lysozyme. A high-throughput platform for IgG binding with membranes was developed to ensure the 
investigation performed in an efficient and cost effective manner and will be discussed in the next 
section. 
 
4.4.2 Validation of high-throughput IgG binding with CEX membrane 
Down-scaling the IgG binding process from milliliter-scale to microscale will enable the rapid 
investigation of buffer effects but should not compromise the quality of the experimentation. The 
equilibrium binding time, the membrane volume, the solution volume and filtration methods were 
investigated. 
The equilibrium binding time for the microscale format was determined with phosphate citrate buffer 
(150 mM) and acetate buffer (200 mM) at pH 5. The equilibrium binding time determined from a time 
course experiment was 6 h for high-throughput IgG binding in both buffer types (Figure 20), compared 
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Figure 20 Time course experiment for high-throughput IgG binding (C0= 3 mg/mL) with 150 mM 
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High-throughput IgG binding was validated by comparing the IgG static binding capacity for the 
high-throughput system (without filtration) to the milliliter-scale system in both buffer types (Figure 
21). The trend of IgG binding capacities changing with equilibrium IgG concentrations in high-
throughput system appears to match that in milliliter-scale system in both buffer types, which indicated 
that high-throughput system was appropriate in investigating IgG binding with Natrix C weak CEX 
membrane [164, 182].  
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Figure 21 IgG static binding at milliliter-scale and high-throughput (without filtration) in 150 mM 
phosphate citrate buffer (A) and 200 mM acetate buffer (B) for initial IgG concentration ranging from 
0.25 mg/mL to 4 mg/mL. Error bars represent standard deviation (n=3). 
IgG static binding capacity was compared for high-throughput IgG binding without filtration and 
with filtration in 150 mM phosphate citrate buffer at pH 5, the trend of IgG binding capacities changing 
with equilibrium IgG concentrations for IgG binding without filtration appears to match that for IgG 
binding with filtration, with less than 20% difference on average. Therefore high-throughput binding 
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Figure 22 IgG high-throughput binding without and with filtration were compared in terms of 
binding capacities in 150 mM phosphate citrate buffer at pH 5 with initial concentrations of 0.5, 1 and 
3 mg/mL. Error bars represent standard deviation (n=3). 
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4.4.3 Effect of buffer type and sodium content on IgG binding capacity and 
mechanism 
High-throughput IgG binding with Natrix C weak CEX membrane was performed in 150 mM 
phosphate citrate buffer and 200 mM acetate buffer at pH 5, with Cs ranging from 140 mM to 306 mM 
by the sodium content of the buffer and NaCl addition. Investigations on the effect of buffer on IgG 
binding was performed with the assistance of the Langmuir model and SMA model. 
 
4.4.3.1 Type of buffer 
The Langmuir model (Equation 4-2) was employed for probing the effect of phosphate citrate buffer 
compared to acetate buffer on IgG binding capacity at pH 5. The counter-ion concentration (Cs) has 
been reported to negatively affect the binding capacity of strong ion exchangers, due to competitive 
binding between the sodium ions and protein molecules [183, 184]. 150 mM phosphate citrate buffer 
has a Cs of 206 mM and 200 mM acetate buffer has a Cs of 140 mM. Since the two types of buffer have 
different Cs, it was decided to adjust the Cs of acetate buffer with NaCl addition to match the Cs of the 
phosphate citrate buffer. The effect of the buffer type was investigated with the Langmuir model (Table 
15). The estimated K for the phosphate citrate buffer was twice the value for the acetate buffer, 
indicating a stronger adsorption affinity, which may have an adverse effect on the subsequent elution 
step. The estimated qmax in phosphate citrate buffer was 27% lower than acetate buffer, which suggested 
that the co-ions in the acetate buffer increased the amount of IgG adsorbed on the membrane. 
Table 15 Fitted Langmuir model parameters for IgG binding with Natrix C weak CEX membrane in 
150 mM phosphate citrate buffer and 200 mM acetate buffer at pH 5 with same Cs (206 mM). 
Buffer K (mL/mg) qmax (mg/mL) R2 
Phosphate citrate 0.79 147.4 0.90 
Acetate 0.30 187 0.95 
 
When interpreting protein adsorption with IEX membranes, however, the Langmuir model does not 
explicitly incorporate the Cs effect. The effect of Cs was obtained by developing a modified Langmuir 
model based on parameter estimates from binding experiments at three different Cs by NaCl addition, 
206 mM, 256 mM and 306 mM for phosphate citrate buffer and 140 mM, 190 mM and 240 mM for 
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acetate buffer. We have adopted the approach developed by Shekhawat et.al [185], where the Langmuir 
kinetic model was modified by representing the adsorption rate constant as a non-linear function of Cs. 
Their modified model gave a better prediction of mAbs adsorption with IEX membranes than the SMA 
model. In the current work, a linear relationship was found between model parameters and Cs for a 
given buffer type, phosphate citrate buffer (Equation 4-4) and acetate buffer (Equation 4-5). 
 
Phosphate citrate buffer  �
𝑞𝑞𝑚𝑚𝑚𝑚𝑚𝑚 = −0.87 𝐶𝐶𝑠𝑠 + 305.4  (𝑅𝑅2 = 0.98) 
  






Acetate buffer                      �
𝑞𝑞𝑚𝑚𝑚𝑚𝑚𝑚 = −1.55 𝐶𝐶𝑠𝑠 + 474.5 (𝑅𝑅2 = 0.99) 
 




For both buffers, the estimated qmax decreased linearly with Cs, which agreed with the role of the 
counter-ions as competitive binding and causing membrane pore shrinkage for CEX materials. The 
estimated K decreased with Cs (206 mM to 306 mM) for phosphate citrate buffer, while increased with 
Cs (140 mM to 240 mM) for the acetate buffer, which indicated that moderate Cs may improve protein 
transport by compressing the electrical double layer of Natrix C weak CEX membrane [186].  
Substituting Equation 4-4 and Equation 4-5 into the original Langmuir model gives the modified 
Langmuir model for phosphate citrate buffer and acetate buffer, respectively. The estimated adsorption 
isotherms of IgG and Natrix C weak CEX membrane from the modified model and the original 
Langmuir model was illustrated in Figure 23. Deviation at high Cs in phosphate citrate buffer implied 
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Figure 23 Adsorption isotherms of IgG with Natrix C weak CEX membrane in (A) pH 5 phosphate 
citrate buffer and (B) pH 5 acetate buffer in high-throughput system, according to different Na+ 
concentration. The curves represent estimates with the Langmuir model and the modified Langmuir 
model. Error bars represent standard error (n=3). 
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4.4.3.2 SMA model and electrostatic interactions 
The SMA model (Equation 4-3) was used to understand electrostatic interactions during protein 
adsorption with IEX membranes, through the characteristic charge (ν) and steric factor (σ) parameters.  
The SMA parameters were estimated from the adsorption isotherms (Figure 24) of IgG with Natrix 
C weak CEX membrane in two buffer types at pH 5, which are 150 mM phosphate citrate buffer and 
200 mM acetate buffer at pH 5 with Na+ of 206, 256 and 306 mM. The estimated SMA parameters for 
IgG with Natrix C weak CEX membrane are summarized in Table 16. The protein binding capacity 
results from the interaction between the charged protein, the number of native binding sites on the 
membrane, and the number of binding sites on the membrane shielded by bound proteins. In this work, 
the estimated ν of IgG in acetate buffer was around half of that in phosphate citrate buffer. The lower 
ν may explain the higher binding capacity observed in acetate buffer. The different ν between the two 
buffers may be explained by two hypotheses. One hypothesis is that multivalent co-ions in phosphate 
citrate buffer increased the protonation of histidine residues thus creating more binding patches on the 
protein surface [1]. Histidine has a lower side chain pKa [1] than lysine and arginine, therefore its 
protonation could be important in the strengthening of protein-membrane interactions at pH 5. The 
potential importance of histidine protonation in IgG binding with strong CEX resins has been reported 
previously by Luo et al. [187]. The second hypothesis is that the co-ions in the phosphate citrate buffer 
may induce a less compact IgG structure, which may lead to more arginine and lysine residues exposed 
on the IgG surface and potentially bind with the membrane. This hypothesis is supported by the higher 
estimated steric factor (σ) in phosphate citrate buffer than acetate buffer. Higher σ suggests that more 
binding sites were blocked by the adsorbed IgG molecules. The ν and σ estimates expanded knowledge 
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Figure 24 Adsorption isotherms of IgG with Natrix C weak CEX membrane in 150 mM phosphate 
citrate buffer and 200 mM acetate buffer at pH 5 with three Na+ conditions (from top to bottom curve 
for each buffer type: 206, 256 and 306 mM) in high-throughput system. The curves represent estimates 
with the SMA model. Error bars represent standard error (n=3). 
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Table 16 Fitted SMA model parameters for IgG and Natrix C weak CEX membrane in 150 mM 
phosphate citrate buffer and 0.2M acetate buffer at pH 5 with matching Na+. Confidence interval of 
estimated parameters in the bracket. 
Buffer  Ka ν σ R2 
Phosphate 
citrate  265.3 (±34%) 4.5 (±14%) 105.2 (±11%) 0.92 
Acetate  58.3 (±10%) 2.1 (±10%) 87.1 (±11%) 0.96 
 
The parameter sensitivity analysis of the SMA model was performed to reveal the contribution of 
each parameter to the binding capacity estimates and identify the most critical parameter. The 
sensitivity analysis was conducted using data from IgG binding with Natrix C weak CEX membrane in 
phosphate citrate buffer at pH 5 with Na+ of 206 mM and 306 mM. Each parameter was varied by ±20% 
based on the previously estimated values (ν0, σ0 and Ka0) while keeping the other two parameters 
constant. Estimated adsorption isotherms (Figure 25A) showed that model estimates were most 
sensitive to ν, where estimated equilibrium binding capacity decreased with increasing ν by 20% at 
high Na+ and 40% at low Na+. Protein adsorption with IEX membranes is based on electrostatic 
interactions, therefore changes in the charge characteristics of the protein or membrane should be most 
influential. Moderate sensitivity of Ka was observed (Figure 25B), where model estimates increased 
with increasing Ka by 10% at high Na+ and 20% at low Na+. The SMA model protein binding estimates 
were least sensitive to σ (Figure 25C), and remained nearly unchanged with varied σ at high Na+.  
The above parameter sensitivity analysis indicates that ν is the most influential parameter of the SMA 
model, which agrees with the electrostatic interactions as being the most influential to ion-exchange 
protein binding process. The relative importance of the adsorption constant Ka relates to its strong 
relationship with ν since more amino acid residues interact with binding sites on the membrane will 
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Figure 25 Parameter sensitivity analysis for SMA model parameters in high-throughput system: (A) 
characteristic charge (ν); (B) equilibrium constant (Ka); and (C) steric factor (σ) with pH 5 phosphate 
citrate buffer at low and high Cs. Error bars represent standard error (n=3). 
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4.4.3.3 Binding mechanism of IgG binding 
Based on the analysis of IgG binding with Natrix C weak CEX membrane at pH 5 and two different 
buffers, phoshphate citrate buffer with multi-valent co-ions and acetate buffer with monovalent co-ions, 
a schematic diagram of binding mechanism is proposed to represent the effect of counter-ions (Figure 
26) and the effect of co-ions and (Figure 27). It was proposed that buffer counter-ions compete with 
the protein molecules for the available sites on the membrane surface, which may result in decreased 
binding capacity, which was supported by estimated parameters of the Langmuir model and the SMA 
model (Figure 26). It was hypothesized that multivalent co-ions of the buffer may facilitate the binding 
process by strengthening the electrostatic interactions between the protein and the membrane (Figure 
27), compared to monovalent co-ions. In this work, it was proposed that buffer ions could potentially 
affect the number of charged residues on variable regions of IgG and the conformation of bounded IgG 
when interacting with CEX membranes, based on the estimated parameters of the SMA model (Figure 
27). In the diagram we are representing the binding take place between the variable region of IgG and 
the membrane surface, as proposed by a few groups [25, 26, 188]. Through peptide mapping, a few 
groups have predicted that IgG/mAb binds to CEX materials through the variable regions [25, 26, 188].  
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Figure 26 Illustration of the IgG binding mechanism with weak cation exchange membranes in the 
context of counter-ion effect. 
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Figure 27 Illustration of the IgG binding mechanism with weak cation exchange membranes in the 
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4.4.4 Effect of buffer type on Bevacizumab binding capacity 
The humanized mAb, Bevacizumab, is a therapeutic mAb for metastatic colorectal cancer treatment 
[49]. Investigations on buffer effects on Bevacizumab binding with Natrix C weak CEX membrane will 
help with buffer selections for improved binding capacity. Recent advances in cell culture technology 
have prompted cell lines with high-growth characteristics, high cell specific productivity and high cell 
stability. which leads to high antibody titers up to 10 mg/mL [4, 5]. In this work, preliminary work was 
conducted with 0.5 mg/mL to 3 mg/mL and subsequent work was conducted with Bevacizumab with 
initial concentration between 0.5 mg/mL to 10 mg/mL. 
High-throughput Bevacizumab static binding with Natrix C weak CEX membrane was performed 
with 96-well microplates to investigate differences in binding capacity between the phosphate citrate 
and acetate buffer. The binding buffer conditions employed were 100 mM phosphate citrate buffer and 
200mM acetate buffer at pH 5. The Na+ concentration of the two buffer solutions was adjusted to 140 
mM through NaCl addition. The equilibrium binding time for Bevacizumab with Natrix C weak CEX 
membrane was determined from a time course experiment in high-throughput format, where 
Bevacizumab samples with an initial concentration of 0.5 mg/mL and 3 mg/mL (Figure 28). For 
Bevacizumab samples with an initial concentration of 0.5 mg/mL, the equilibrium binding capacity did 
not change with time for both buffer types, which showed that the equilibrium binding time for 
Bevacizumab samples with very low concentration is 1 hour. For samples with an initial concentration 
of 3 mg/mL, the binding capacity started to level off after 6 hours in both buffer types, which showed 
that the equilibrium binding time for Bevacizumab samples with higher concentration is 6 hours. In the 
following sections, binding time of 6 hours were employed for Bevacizumab binding with Natrix C 
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Figure 28 Time course experiment for high-throughput Bevacizumab binding (C0= 0.5 and 3 mg/mL) 
with 100 mM phosphate citrate buffer and 200mM acetate buffer, both at pH 5 and Cs 140 mM. Error 
bars represent standard deviation (n=3). 
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The binding of Natrix C weak CEX membrane and Bevacizumab with initial concentration between 
0.5 mg/mL to 10 mg/mL was investigated (Figure 29). The equilibrium binding capacity of 
Bevacizumab were comparable for the two buffer types when the initial Bevacizumab concentration 
was no higher than 7 mg/mL (t-test, 95%, P = .18).  At initial Bevacizumab concentration of 7 mg/mL, 
the equilibrium binding capacity of Bevacizumab in phosphate citrate buffer was 156 mg/mL, and 151 
mg/mL in acetate buffer. When the initial Bevacizumab concentration was higher than 7 mg/mL, 
however, the equilibrium binding capacity was significantly higher in acetate buffer compared to the 
phosphate citrate buffer (t-test, 95%, P = .01). At initial Bevacizumab concentration of 10 mg/mL, the 
equilibrium binding capacity of Bevacizumab in phosphate citrate buffer was 253 mg/mL, and 340 
mg/mL in acetate buffer.  
The equilibrium binding capacity of Bevacizumab in 200 mM acetate buffer at pH 5 were 
significantly lower than IgG (t-test, 95%, P = .01). The differences in binding capacity may come from 
their differences in structure. Polyclonal antibodies contain antibodies with various variable regions 
while mAbs contain only one type of variable region. Several research groups have suggested that CEX 
material binds with the basic amino acid residues on the variable region of heavy chain (VH) of 
IgG/mAb [25, 26]. It may be speculated that the higher binding capacity of IgG than Bevacizumab may 
result from the larger number of basic amino acid residues on the various variable regions of IgG. 
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Figure 29 Static binding capacity of Bevacizumab with Natrix C weak CEX membrane in 100 mM 
phosphate citrate buffer and 200mM acetate buffer, both at pH 5 and with a Cs of 140 mM, in high-
throughput system. Error bars represent standard deviation (n=3). 
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4.5 Conclusion 
In this chapter, CEX membranes were employed as an alternative to Protein-A for mAb capture. 
Furthermore, weak cation exchange membranes were selected for their ability to display different 
charges to different buffer pH and ion conditions. Specifically, the role of buffer co-ion (chemistry and 
valence) on the static binding of IgG and Bevacizumab with a weak CEX membrane, Natrix C weak 
CEX membrane was probed in a high-throughput system. In contrast to Protein-A materials, protein 
binding with CEX materials is proposed to take place on the variable regions of antibodies [25, 26] 
through electrostatic interactions, therefore it was critical to investigate buffer effects on CEX binding 
with IgG/mAb. IgG was employed as the model protein for its cheap cost and availability in large 
quantity, and Bevacizumab was employed because it’s an humanized mAb with only one type of 
variable region. The two buffers of interest were phosphate citrate buffer and acetate buffer, that were 
commonly used in CEX for the polishing step of mAb purification in the industry, as well as for mAb 
capture in the literature [12, 13, 16, 18]. The Natrix C weak CEX membrane was reported to show high 
salt tolerance at pH 5 [22], thus pH of all buffer solutions was fixed at 5 in this chapter. Phosphate 
citrate buffer contains various multivalent co-ions, including C6H6O72- and HPO42-, whereas acetate 
buffer contains only monovalent co-ions.  
 The equilibrium adsorption isotherms estimated with the Langmuir model for IgG with Natrix C 
weak CEX membrane in phosphate citrate buffer and acetate buffer showed a significant effect of buffer 
type on the adsorption behaviors for IgG with Natrix C weak CEX membranes. In order to carry on 
extensive investigations on buffer effects in an efficient and economical way, a high-throughput 
microscale platform using 96 well microplates for IgG binding with membranes was developed. The 
high-throughput format was successfully validated against the milliliter-scale format. 
Two adsorption models, the Langmuir model and the SMA model, were employed for probing the 
buffer effects on the binding capacity of IgG with Natrix C weak CEX. The Langmuir model indicated 
higher binding capacity in acetate buffer, while stronger adsorption affinity in phosphate citrate buffer. 
To incorporate the effect of salt for protein adsorption with ion exchange membranes, a modified 
Langmuir model was developed by correlating model parameters with salt concentrations. The SMA 
model was employed to help understand the protein adsorption with ion exchange membranes at a 
molecular level. The estimated ν of IgG in acetate buffer was around half of that in phosphate citrate 
buffer, which indicated higher binding capacity in acetate buffer. It was proposed that the higher ν in 
phosphate citrate buffer was a result of improved protonation of histidine residues, due to the higher 
 
  87 
valence of co-ions in phosphate citrate buffer. It was also proposed that co-ions in phosphate citrate 
buffer induced less compact IgG structure, as the higher σ in phosphate citrate buffer would mean more 
hindered binding sites of the membrane. 
The investigation of buffer type was then conducted with the Bevacizumab. The equilibrium binding 
capacities were comparable between the two buffer types when the initial Bevacizumab concentration 
was below 7 mg/mL, while it was significantly higher in acetate buffer when the initial concentration 
was above 7 mg/mL.  
In conclusion, to achieve a higher binding capacity of polyclonal IgG or humanized mAb with weak 
cation exchange membranes, acetate buffer is preferred over phosphate citrate buffer, especially for 
samples with high concentration. 
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Chapter 5 Developing a high-throughput intrinsic fluorescence 
microplate method for the detection of IgG/mAb unfolding 
5.1 Introduction 
The effect of buffer on the static binding of IgG and Bevacizumab with a weak CEX membrane was 
examined in the previous chapter. In this chapter we have pursued the investigation of the effect of 
buffer on IgG/mAb, where our attention focused on the thermal treatment and the associated potential 
unfolding. We have used the experimental conditions, IgG in 10 mM PBS buffer, pH7, and the 
corresponding intrinsic fluorescence observations reported by Ohadi et al. [125] for a cuvette 
spectrofluorometer. These experimental conditions were used to develop a microplate reader method 
to monitor the unfolding of IgG and Bevacizumab when heated at 60°C in 100 mM phosphate citrate 
buffer, pH 5, representing a common buffer in weak CEX chromatography. Size-exclusion liquid 
chromatography (SE-HPLC) was also used as it is the standard method for characterizing protein 
aggregates, which allows the separation and quantification of protein dimers, trimers and oligomers. 
One of the major pathways of protein aggregation is through partial unfolding proteins whose 
interactions lead to the formation of protein aggregates, therefore characterizing the degree of protein 
unfolding can be indicative of the degree of protein aggregation [114]. Intrinsic fluorescence 
spectroscopy has gained interest as a fast and non-invasive analytical method for the detection of 
IgG/mAb unfolding [115, 124-128].  
Different laboratory fluorescence systems exist that differ primarily according to the type of light 
source and the path of the light source in addition to the volume of the sample required for analysis. 
These characteristics will be summarized in the following sections followed by a discussion on these 
systems for the detection of IgG/mAb unfolding. Two fluorescence systems will be discussed, the 
cuvette fluorescence spectrometer which offers high sensitivity and accuracy, but is more time-
consuming and material-consuming and the fluorescence microplate reader. The equipment used in this 
work, Cary Eclipse spectrofluorometer and Synergy 4 multi-mode microplate reader, were used as 
examples for comparison here. 
(1) Light source and position 
The light source of the Cary Eclipse cuvette spectrofluorometer is a xenon lamp, while the Synergy 
4 multi-mode fluorescence microplate reader offers the options of a xenon lamp and a tungsten lamp 
[189, 190]. The tungsten lamp is a less sensitive but cheaper alternative for the xenon lamp. For a Cary 
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Eclipse spectrofluorometer, the light goes through the sample horizontally from the side while in the 
Synergy 4 multi-mode microplate reader the light goes through the sample vertically from the top. 
(2) Detection modes 
Cary Eclipse spectrofluorometer employs a monochromator-based mode that uses multiple 
diffraction gratings to create the desired excitation and emission wavelengths, based on the wavelengths 
selected, while the Synergy 4 multi-mode microplate reader gives the options of a monochromator-
based mode or a filter-based mode that uses filter sets to select the wavelength; one filter for selecting 
the excitation wavelength and the other for emission wavelength [189, 190]. Monochromator-based 
mode provides better flexibility, while filter-based mode is cheaper and provides better sensitivity. 
(3) Sensitivity 
The sensitivity of detection is dependent on a few factors, including the photomultiplier tube (PMT) 
and bandpass. The Cary Eclipse spectrofluorometer allows increasing PMT up to 900 V [191], which 
will increase the sensitivity but will amplify any noise. For the Synergy 4 multi-mode microplate reader, 
the PMT is 700 V when using the filter-based mode and 800V when using the monochromator-based 
mode  [190], which means lower sensitivity compared to the Cary Eclipse spectrofluorometer at high 
PMT settings. The sensitivity settings can be altered through the software to lower the intensity in case 
of signal overflow. 
The bandpass is 5 nm for the Cary Eclipse spectrofluorometer and around 12 nm for the Synergy 4 
multi-mode microplate reader with monochromator-based mode. Wider bandpass gives higher 
fluorescence intensity, but worse wavelength resolution. 
(4) Sample holder 
The Cary Eclipse spectrofluorometer can be equipped with multi-cell holders that accommodate up 
to 6 cuvettes while the Synergy 4 multi-mode microplate reader can accommodate 1-well to 1536-well 
microplates. The working volume of a cuvette ranges from 500 µL to 2 mL, while the working volume 
can be as low as 100 µL for 96-well microplates. 
When applying intrinsic fluorescence spectroscopy to IgG/mAb unfolding detection, most studies 
have successfully employed a fluorescence spectrophotometer with cuvette for detecting IgG/mAb 
unfolding that underwent thermal stress or surfactant addition [124-128], while very few studies have 
explored a microplate reader for the detection of IgG/mAb unfolding [115] (Table 17).  In these studies, 
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all fluorescence spectra of the stressed samples were analyzed for potential changes in intrinsic 
fluorescence intensity and the corresponding maximum emission wavelength. In terms of experimental 
conditions for work with fluorescence spectrophotometers, all published studies reported in Table 17 
used stressed IgG/mAb samples with concentrations ranging from 0.05 mg/mL to 0.5 mg/mL and used 
quartz cuvettes with path length of 10 mm except for Zhang et al. [128]. Excitation wavelength was set 
at either 280 nm [115, 124] or 295 nm [126-128], except for  Ohadi et al. [125] where excitation 
wavelengths ranging  from 260 nm  to 350 nm were investigated to establish an excitation emission 
matrix for partial least squares regression analysis. Emission wavelength investigated in the literature 
ranged from 280 nm to 450 nm, except for Wang et al. [126] where a much wider range (250~820 nm) 
was examined.  
The only reported work with the fluorescence microplate reader, Bickel et al. [115] used a 
SpectraMax microplate reader for the detection of NaCl-induced unfolding of a humanized mAb. 
Excitation wavelength was set at 280 nm and emission wavelength was 300 ~ 450 nm for 0.1 mg/mL 
mAb samples. Bickel et al. observed a slight red-shift for samples with increasing pH (from 2 to 6) at 
1.5 M NaCl addition, which showed that the fluorescence microplate reader was capable of capturing 
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The main objective of this chapter was to develop a high-throughput intrinsic fluorescence method 
using microplates for detection of IgG and Bevacizumab unfolding, which will be used for the fast and 
low-cost investigations of buffer effects on unfolding, as well as design space development for 
IgG/mAb. In this work, high-throughput intrinsic fluorescence microplate method refers to method 
employing a plate reader and microplates for measuring the intrinsic fluorescence of stressed samples. 
Thermal stress was employed for inducing IgG/mAb unfolding, and the stress conditions were the same 
as Ohadi et al.’s work [125]. IgG and a humanized mAb, Bevacizumab, were examined at a 
concentration of 0.5 mg/mL, same as that in Ohadi et al.’s work [125]. Two types of buffer were 
examined through the method development, 10 mM PBS at pH 7, the buffer used previously with 
spectrofluorometer [125] and with microplate reader [115], and 100 mM phosphate citrate buffer at pH 
5 selected to reflect fluorescence observations to IgG/mAb binding with Natrix C weak CEX (Chapter 
4). The degree of Bevacizumab unfolding was obtained from the fluorescence measurements and the 
relative monomer content obtained with size-exclusion high performance liquid chromatography (SE-
HPLC). 
 
5.2 Materials and methods 
5.2.1 Buffers 
All buffers and solutions were prepared with ultra-purified water. Phosphate buffered saline (PBS), pH 
7, 10 mM, was prepared by mixing potassium phosphate monobasic (EMD Chemicals Inc., New Jersey, 
USA), sodium phosphate dibasic heptahydrate (VWR International, Ohio, USA), sodium chloride and 
potassium chloride (Fisher Scientific, Fair Lawn, USA). Phosphate citrate buffer, pH 5, 100 mM, was 
prepared by mixing citric acid (EMD Chemicals Inc., Gibbstown, USA) solution and sodium phosphate 
dibasic (Fisher Scientific, Fair Lawn, USA) solution.  
The running buffer for HPLC, 100 mM sodium phosphate buffer at pH 7 was prepared by mixing 
sodium phosphate dibasic heptahydrate (VWR International, Ohio, USA) and sodium phosphate 
monobasic (VWR International, Ohio, USA). See Appendix A for details of buffer preparation. 
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5.2.2 IgG and Bevacizumab 
IgG was purchased from Equitech-Bio, Inc. (Kerrville, Texas, USA). The mAb samples (in vials), 
Bevacizumab, were generously provided by Apotex Inc. (North York, Ontario, Canada). Bevacizumab 
is supplied at a concentration of 25mg/ml, with 0.4mg/ml (0.04%) polysorbate 20 at pH 6.2. All 
Bevacizumab samples were dialyzed as described previously in 4.2.4. 
 
5.2.3 IgG and Bevacizumab thermal stress 
A 10mL IgG or Bevacizumab sample was placed in centrifuge tubes were thermally stressed at 60 °C 
in a water bath (VWR® General Purpose Water Baths, Ohio, US) for 20, 40 and 60 min. The thermal-
treated samples were cooled on a lab bench to room temperature and then centrifuged with Eppendorf 
5804R (Hamburg, Germany) at 400g for 5 min to remove large insoluble aggregates. The supernatant 
was used for intrinsic fluorescence measurements and SE-HPLC analysis. 
 
5.2.4 Intrinsic fluorescence measurement with a spectrofluorometer 
The intrinsic fluorescence of IgG and Bevacizumab samples was measured with a Cary Eclipse 
spectrofluorometer (Palo Alto, CA) equipped with a Peltier multi-cell holder with quartz cuvettes with 
path length of 10 mm (Mandel Scientific, ON). Sample or buffer, 3 mL, were placed into each quartz 
cuvette. Each sample was measured in triplicates. Emission spectra were collected at an excitation 
wavelength of 280 nm and emission wavelength from 300 nm to 450 nm with 1 nm increments. The 
PMT voltage was set at 600 V and bandpass at 5 nm, and the scanning rate was 600 nm/min. The 
fluorescence intensity of samples were calculated by subtracting the fluorescence intensity of buffers. 
The experimental conditions were selected based on previous studies that employed a fluorescence 
spectrophotometer with cuvette for detecting unfolding of IgG and Bevacizumab samples that 
underwent thermal stress [124, 125, 128]. 
 
5.2.5 High-throughput intrinsic fluorescence microplate method 
The intrinsic fluorescence of IgG and Bevacizumab samples was measured with Synergy 4 microplate 
reader, where samples and blank buffers were prepared on 96-well non-binding black microplates 
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(Greiner Bio-One, North Carolina, USA). A volume of 200 µL sample or buffer were placed into each 
well and all samples were measured in triplicate. 
 Sensitivity for each sample set was investigated first to avoid measurement overflowing (signal 
saturation) for that given set which represented either IgG or Bevacizumab in a given buffer for the 
three incubation times at 60 °C. The highest sensitivity, 100, was assigned to the longest incubation 
time. If measurement overflowing occurred, a lower sensitivity would be selected and the measurement 
would be repeated until no measurement overflowing would occur. Sensitivity was set to 98 for IgG 
samples in PBS, while 93 for IgG and Bevacizumab samples in pH 5, 100 mM phosphate citrate buffer.  
Emission spectra were collected at an excitation wavelength of 280 nm and emission wavelength 
from 300 nm to 450 nm with a step size of 1 nm, which corresponded with the conditions used for the 
spectrofluorometer. The fluorescence intensity of samples were calculated by subtracting the 
fluorescence intensity of buffers. The average of the maximum fluorescence intensity and maximum 
emission wavelength of emission spectra were calculated with Excel from the triplicates. The standard 
deviation was less than 1% and will not be reported. The maximum emission wavelength represents 
the emission wavelength at which the maximum fluorescence intensity was observed.  
 
5.2.6 Size-exclusion high performance liquid chromatography (SE-HPLC) 
SE-HPLC was performed on Waters 2690 separations module (Waters, MA, USA) with the Sepax 
Zenix-C SEC-300 (Sepax Technologies, Newark, DE) column. Prior to SE-HPLC tests, all samples 
were filtered with a 0.45 μm PES syringe filter (Thermo Scientific, Ontario, Canada). A volume of 100 
µL of sample was loaded onto the SEC column. The flow rate of the mobile phase was increased from 
0 mL/min to 1 mL/min within 1 min, and the duration of elution was set to 20 min. The mobile phase 
consisted of 100 mM sodium phosphate buffer at pH 7. A calibration curve was prepared with various 
concentrations of Bevacizumab ranging from 0.0625 to 1 mg/mL, and UV absorbance was collected at 
280 nm to detect protein content. The monomer content was estimated from the area under the curve 
of the peak corresponding to the monomeric form of Bevacizumab. The relative monomer content was 
calculated as the ratio of the area of the monomer peak of a given thermal stress to the area of the 
monomer peak with no thermal treatment, by the Empower 3 software (See Appendix E). All 
measurements were carried out in duplicates. 
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5.2.7 Summary of experimental conditions 
Table 18 lists buffer conditions, model proteins and experimental conditions used in this chapter. 
Table 18 Buffer conditions, model proteins and experimental conditions for Chapter 5. 
Section 
Buffer 









100  phosphate 
citrate 
140 5 
5.3.2 100  phosphate 
citrate 




100  sodium 
phosphate 
/ 7 SE-HPLC 
 
 
5.3 Results and discussion 
5.3.1 Development of intrinsic fluorescence microplate method vs. 
spectrofluorometer method for thermally stressed IgG 
In this section, the high-throughput intrinsic fluorescence microplate method was developed by 
comparing to results from a spectrofluorometer. The next step was to apply the high-throughput 
intrinsic fluorescence microplate method to investigate thermally stressed IgG samples formulated in 
two buffer types, phosphate buffered saline (10 mM PBS at pH 7) and 100 mM phosphate citrate buffer 
at pH 5. 
 
5.3.1.1 Preliminary results with a cuvette spectrofluorometer  
The emission spectra of 0.5 mg/mL IgG samples in 10 mM PBS at pH 7 stressed at 60 °C for 20 min, 
40 min and 60 min were collected with a spectrofluorometer, using the same buffer conditions, IgG 
concentration, thermal treatment and measurement parameters as that in Ohadi et al.’s work [125]. The 
maximum fluorescence intensity of the stressed samples against incubation time were compared 
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between this work and the literature (Figure 30). Note that the maximum fluorescence intensities of 
Ohadi et al. [125] were visually extracted from their emission spectra at excitation wavelength of 280. 
The results obtained in this work showed a similar linear increase of the maximum fluorescence 
intensity with increasing incubation time, with a R2 of 0.97 and 0.98 for the published values. However, 
the magnitude of the fluorescence intensity was approximately 50% higher in this study compared to 
those reported by Ohadi et al. [125].  The only differences between the two studies are the source of 
IgG and their sensitivity settings that were not specified. The variable of the maximum fluorescence 
intensity with incubation time was similar in both studies, the spectrofluorometer cuvette methodology 
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Figure 30 Maximum fluorescence intensity vs. incubation time at 60 °C for 0.5 mg/mL IgG samples 
in 10 mM PBS at pH 7. Excitation wavelength at 280 nm and emission wavelength from 300 nm to 
450 nm with 1 nm increments. Comparison between Ohadi et al.’s work [189] and results from this 
work. Average values of triplicates for results in this work. 
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5.3.1.2 Detecting IgG unfolding in PBS by intrinsic fluorescence method with a fluorescence 
microplate reader 
The next step was to develop the fluorescence microplate reader method for the analysis of IgG 
unfolding in 10 mM PBS at pH 7 by collecting the emission spectra of 0.5 mg/mL IgG samples stressed 
at 60 °C for 20 min, 40 min and 60 min. The maximum fluorescence intensity of the stressed samples 
against incubation time at 60 °C were compared between results from the spectrofluorometer and the 
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Figure 31 Maximum fluorescence intensity vs. incubation time for 0.5 mg/mL IgG samples in 10 
mM PBS at pH 7 stressed at 60 °C. Excitation wavelength was 280 nm and emission wavelength was 
from 300 nm to 450 nm with a step size of 1 nm. The maximum fluorescence intensity for the cuvette 
spectrofluorometer is given by the left y-axis and is given by the right y-axis for the microplate 
reader. Average values of triplicates. 
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The maximum fluorescence intensity obtained with the cuvette spectrofluorometer and the 
microplate reader exhibited a linear increase with incubation time at 60 °C between 20 min to 60 min, 
with R2 of 0.97 for the cuvette spectrofluorometer and 0.99 for the microplate reader. The similar results 
suggest that microplate reader can be used as a potential alternative to cuvette spectrofluorometer, even 
though the value of the maximum fluorescence intensity was significantly different. The linear increase 
suggests increasing degree of protein unfolding. 
The maximum fluorescence intensity and the maximum emission wavelength of stressed and native 
IgG samples measured by the plate reader are summarized in Table 19. Maximum emission wavelength 
is the emission wavelength at which the maximum fluorescence intensity was observed. For all 
thermally stressed IgG samples, the maximum fluorescence intensity was significantly higher than that 
of the native IgG sample which suggested increased degree of unfolding, while no shift in maximum 
emission wavelength was observed. 
 
Table 19 Maximum fluorescence intensity and maximum emission wavelength of emission spectra of 
0.5 mg/mL IgG samples in 10 mM PBS at pH 7 after incubating at 60 °C for 0, 20, 40, and 60 
minutes, measured by the plate reader. The excitation wavelength was 280 nm and the sensitivity was 






0 10148 314 
20 20148 314 
40 21463 314 
60 22368 314 
 
 
5.3.1.3 Detecting IgG unfolding in phosphate citrate buffer with high-throughput intrinsic 
fluorescence method 
As buffer conditions may affect the intrinsic fluorescence of tryptophan, the high-throughput intrinsic 
fluorescence of 0.5 mg/mL IgG samples was assessed in a different buffer, 100 mM phosphate citrate 
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buffer at pH 5. The IgG samples were stressed at 60 °C for 20 min, 40 min and 60 min. The fluorescence 
emission spectra of stressed IgG samples obtained with the plate reader were compared to the spectra 
of native IgG (0 min) (Figure 32). The degree of unfolding of IgG samples was suggested by the 
maximum fluorescence intensity and the maximum emission wavelength, summarized in Table 20.  
  
 




Figure 32 Fluorescence emission spectra of 0.5 mg/mL IgG samples in 100 mM phosphate citrate 
buffer at pH 5. Samples according to incubation time at 60 °C. The excitation wavelength was 280 
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Table 20 Maximum fluorescence intensity and maximum emission wavelength of emission spectra of 
0.5 mg/mL IgG samples in 100 mM phosphate citrate buffer at pH 5 after incubating at 60 °C for 0, 
20, 40, and 60 minutes, measured with microplate reader. The excitation wavelength was 280 nm and 






0 8750 314 
20 11728 314 
40 16400 318 
60 18141 320 
 
 
The maximum fluorescence intensity increased with incubation time for thermally stressed IgG 
samples and was significantly higher than the native IgG sample, which may indicate conformational 
changes in all stressed samples. The maximum fluorescence intensity of IgG samples incubated for 20 
min was 34% higher than that of the native sample. The maximum fluorescence intensity of IgG 
samples incubated for 60 min was 11% higher than that of the samples incubated for 40 min, while it 
was 55% higher than the samples incubated for 20 min. The increase of the maximum fluorescence 
intensity of IgG samples according to incubation time was higher in the 100 mM phosphate citrate 
buffer at pH 5 than that in 10 mM PBS buffer at pH 7. It suggests that the increase in the degree of 
unfolding of IgG samples according to stress time was more pronounced in the phosphate citrate buffer 
than in the PBS buffer. Note that the sensitivity setting was different and set at 98 for IgG samples in 
PBS buffer, while the sensitivity was 93 for all samples formulated in phosphate citrate buffer to avoid 
signal overflow at higher sensitivity. 
A red-shift in the maximum emission wavelength was observed for IgG samples in phosphate citrate 
buffer, when stressed for at least 40 min. Maximum emission wavelength increased from 314 nm for 
native IgG samples to 320 nm for IgG samples stressed for 60 min, which suggested higher degree of 
unfolding with increased incubation time. No shift in maximum emission wavelength was observed for 
stressed IgG samples in PBS, which may reflect differences in the response of tryptophan to the buffer 
conditions. The citrate ions in phosphate citrate buffer have been reported to be more chaotropic than 
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phosphate ions in PBS [192, 193], which may relate to the response of tryptophan to hydrophobic 
environment. Further discussion of the effect of buffer type on IgG/mAb unfolding will be presented 
in the next chapter. 
 
5.3.2 Detection of thermally induced Bevacizumab unfolding and aggregation with 
high-throughput intrinsic fluorescence microplate method and SE-HPLC 
In the previous section, the intrinsic fluorescence microplate method was developed with thermally 
stressed IgG samples formulated in two buffer types. The increase in the maximum fluorescence 
intensity and red-shift in the maximum emission wavelength were observed which could reflect an 
increasing degree of IgG unfolding. As the structure of IgG is representative of mAb, the results 
obtained from IgG in the previous section were used to set the experimental conditions for the analysis 
for the Bevacizumab, which will be presented in this section. As the degree of protein unfolding may 
be indicative of the degree of protein aggregation, SE-HPLC will be applied for characterizing the 
degree of aggregation for Bevacizumab. In this section, we have limited the investigation to one buffer, 
100 mM phosphate citrate buffer at pH 5 which is representative of CEX binding conditions. 
 
5.3.2.1 Detection of Bevacizumab unfolding with high-throughput intrinsic fluorescence 
method 
The emission spectra of 0.5 mg/mL Bevacizumab samples in 100 mM phosphate citrate buffer at pH 5 
stressed at 60 °C for 20 min, 40 min and 60 min were collected with a plate reader and compared to 
those of native Bevacizumab (Figure 33). The maximum fluorescence intensity and the maximum 
emission wavelength are summarized in Table 21.  
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Figure 33 Fluorescence emission spectra of 0.5 mg/mL Bevacizumab samples in 100 mM phosphate 
citrate buffer at pH 5, according to incubation time at 60 °C. The excitation wavelength was 280 nm 
and the sensitivity was set at 93. Average values of triplicates. 
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Table 21 Maximum fluorescence intensity and maximum emission wavelength of emission spectra of 
0.5 mg/mL Bevacizumab samples in 100 mM phosphate citrate buffer at pH 5 after incubating at 60 
°C for 0, 20, 40, and 60 minutes, measured with microplate reader. The excitation wavelength was 






0 12487 314 
20 13276 314 
40 16182 320 
60 22258 320 
 
For all thermally stressed Bevacizumab samples, the maximum fluorescence intensity was 
significantly higher than the native Bevacizumab sample, which may reflect conformational changes 
in all stressed samples. The maximum fluorescence intensity of stressed Bevacizumab samples 
increased with increasing incubation time. The maximum fluorescence intensity of Bevacizumab 
samples incubated for 20 min was 6% higher than that of the native sample. The maximum fluorescence 
intensity of Bevacizumab samples incubated for 60 min was 38 % higher than that of the samples 
incubated for 40 min, and it was 68% higher than that of the samples incubated for 20 min. The increase 
of the maximum fluorescence intensity of Bevacizumab samples stressed for 20 min was lower than 
that of stressed IgG samples in the same phosphate citrate buffer (34%), which may suggest that 
Bevacizumab was more stable than IgG when thermally stressed for a relatively short time. The increase 
of the maximum fluorescence intensity of Bevacizumab samples with different incubation time was 
higher than IgG samples in the same buffer, which may indicate that the degree of unfolding of 
Bevacizumab increased more than IgG samples throughout the thermal incubation (Figure 34). 
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Figure 34 Maximum fluorescence intensity according to incubation time at 60 °C for 0.5 mg/mL IgG 
and Bevacizumab samples in 100 mM phosphate citrate buffer at pH 5. Average values of triplicates. 
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A red-shift in the maximum emission wavelength was observed for Bevacizumab samples incubated 
for at least 40 min, and was also observed for IgG (Table 20). When incubated for 40 min, the maximum 
emission wavelength increased from 314 nm to 318 nm for native IgG samples while it increased from 
314 nm to 320 nm for Bevacizumab samples. The red-shift suggested greater exposure of tryptophan 
residues in Bevacizumab samples, thus higher degree of unfolding with increased incubation time.  
Increase in the unfolding of 0.1 mg/mL Bevacizumab in 20 mM citrate buffer after incubating at 70 
°C for 10 min was also reported by Zhang et al. [128], where a significant increase in  fluorescence 
intensity and a red-shift of the maximum emission wavelength were observed. 
 
5.3.2.2 Detection of Bevacizumab aggregation with SE-HPLC 
The degree of protein unfolding detected by intrinsic fluorescence spectroscopy could be indicative of 
the degree of protein aggregation, while protein aggregation can also be measured directly with SE-
HPLC. The thermally stressed Bevacizumab samples were analyzed with SE-HPLC for monomer 
percentage (See Appendix E for chromatograms of Bevacizumab samples). Monomer amount was 
calculated based on the area under the curve pertinent to the peak of the monomeric form of 
Bevacizumab (Figure 35) according to the calibration curve, and the percentage of monomer was 
calculated by the Empower 3 software ( 
 
Table 22). Note that the peaks appeared after the main peak could be fragment peaks.  
 
  109 
 
Figure 35  SE-HPLC chromatogram of 0.5 mg/mL Bevacizumab samples in 100 mM phosphate 
citrate buffer at pH 5, after incubating at 60 °C for 20 min. 
 
Table 22 Peak characteristics and percentage calculated by Empower 3 software for 0.5 mg/mL 
Bevacizumab samples in 100 mM phosphate citrate buffer at pH 5, with 20 min incubation in 60 °C 
water bath. The % Area is calculated from the area of a given peak versus the area of all peaks.  
Peak Retention Time (min) Area (AU*sec) %Area Amount (mg/L) 
1 10.985 30979 0.62 - 
2-BEVA 12.585 4763186 95.38 456.411 
3 14.760 18506 0.37 - 
4 17.206 134957 2.70 - 
5 17.646 46466 0.93 - 
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SE-HPLC chromatogram of 0.5 mg/mL Bevacizumab samples in 100 mM phosphate citrate buffer 
at pH 5, with 0 min, 20 min, 40 min and 60 min incubation in 60 °C water bath are presented as below. 
 
 
Figure 36 SE-HPLC chromatogram of 0.5 mg/mL Bevacizumab samples in 100 mM phosphate 
citrate buffer at pH 5, with 0 min, 20 min, 40 min and 60 min incubation in 60 °C water bath.  
Monomer percentage was plotted versus the relative increase of maximum fluorescence intensity of 
stressed Bevacizumab compared to the native one (Figure 37). A decrease in monomer percentage may 
indicate an increase in aggregate formation. 
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Figure 37 Monomer percentage and relative increase of maximum fluorescence intensity according 
to incubation time at 60 °C for 0.5 mg/mL Bevacizumab samples in 100 mM phosphate citrate buffer 
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For Bevacizumab samples incubated for 20 min and 40 min, the monomer percentage decreased from 
95.4% to 91.3%, while the increase of maximum fluorescence intensity increased from 6% to 30%. For 
Bevacizumab samples incubated for 60 min, the monomer percentage slightly increased to 92% 
(insignificant increase based on paired t-test) while the relative increase of maximum fluorescence 
intensity further increased to 78%. It suggested that increasing incubation time from 40 min to 60 min 
may induce more unfolding of the monomers, but did not induce more aggregates formation. It 
indicated that the intrinsic fluorescence microplate method could be a measure of the monomer 
percentage, while require further investigation, such as buffer type and pH values. 
 
5.4 Conclusion 
The application of intrinsic fluorescence spectroscopy for IgG/mAb unfolding has relied heavily on the 
use of cuvette spectrofluorometers in the literature, while the potential of fluorescence plate readers has 
been overlooked. In this chapter, a high-throughput intrinsic fluorescence microplate method for the 
detection of IgG and Bevacizumab unfolding was developed with thermally stressed IgG and 
Bevacizumab for two different buffer conditions, 10 mM PBS at pH 7 and 100 mM phosphate citrate 
at pH 5. 
By comparing the intrinsic fluorescence emission spectra of thermally stressed IgG in PBS obtained 
with a cuvette spectrofluorometer and a fluorescence plate reader, a linear increase of the degree of 
protein unfolding with incubation time was observed for both systems, demonstrated by the linear 
increase of maximum fluorescence intensity with increasing incubation time. It indicated that the 
intrinsic fluorescence microplate method could be applied for detecting unfolding of stressed IgG 
samples in PBS.  
As phosphate citrate buffer is the buffer type used for IgG and Bevacizumab binding with Natrix C 
weak CEX membrane in this work, it was essential to examine protein unfolding of IgG and 
Bevacizumab samples in the phosphate citrate buffer at pH 5. The intrinsic fluorescence emission 
spectra of thermally stressed IgG samples in phosphate citrate buffer analyzed with the microplate 
method showed increasing maximum intrinsic fluorescence intensity with incubation time as observed 
in the PBS buffer. In addition, a red-shift of maximum emission wavelength was observed for the 
stressed IgG in phosphate citrate buffer. 
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The intrinsic fluorescence microplate method was applied to detect the unfolding of thermally 
stressed Bevacizumab samples in 100 mM phosphate citrate buffer at pH 5. Increasing maximum 
intrinsic fluorescence emission intensity with incubation time was observed as with IgG. When 
incubated for 20 min, the increase of the maximum fluorescence intensity of Bevacizumab samples was 
lower than that of IgG samples in the same phosphate citrate buffer, potentially indicating that 
Bevacizumab is more stable than IgG in this stress condition. While the increase of the maximum 
fluorescence intensity of Bevacizumab samples with different incubation time was higher than IgG 
samples in the same buffer, which could suggest that the degree of unfolding of Bevacizumab was 
higher than for IgG samples throughout the thermal incubation. The thermally stressed Bevacizumab 
samples were analyzed with SE-HPLC. It indicated that the unfolding of Bevacizumab detected by the 
intrinsic fluorescence microplate method could be related to the monomer percentage detected by SE-
HPLC. 
In summary, the high-throughput intrinsic fluorescence microplate method developed in this work 
could be applied for the detection of IgG/ mAb unfolding in an economic and efficient way. 
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Chapter 6 Effect of buffer on IgG/mAb unfolding 
6.1 Introduction 
During IgG/mAb separation with weak CEX chromatography, solution factors such as pH, type and 
concentration of buffer, especially counter-ion concentration (Cs) and co-ion type are critical to the 
productivity of the process and quality of the product, as they can affect the binding capacity and protein 
unfolding.  
The pH of the buffer may vary from 4 to 6 during the binding process of IgG/mAb with weak CEX 
materials, which affects binding and unfolding of the protein by changing the charge distribution on 
the protein surface [114, 135, 136]. For CEX chromatography, counter-ions will be buffer cations, 
usually sodium ions, where Cs is manipulated by NaCl addition, with typical concentration ranging 
from 20 mM to 150 mM. The driving force of protein binding to CEX materials will be the displacement 
of counter-ions on the CEX material by the target protein, and Cs may also affect protein unfolding. 
The effect of buffer pH on mAb unfolding is generally investigated together with the counter-ion 
concentration (Cs) [115, 117]. Bickel et al. [115] investigated the effect of pH and NaCl concentration 
on the non-specified mAb unfolding for mAb samples in buffer solutions with pH ranging 2 to 7 and 
NaCl concentration ranging from 0 mM to 150 mM. mAb unfolding was measured with Differential 
Scanning Fluorimetry (DSF), intrinsic and extrinsic fluorescence spectroscopy. Higher degree of 
unfolding was observed for mAb solutions in buffer contained 150 mM NaCl compared to 0 mM NaCl 
at pH 5, however, lower degree of unfolding was observed for mAb solutions in buffer containing 150 
mM NaCl compared to 0 mM NaCl when pH dropped to 2. Sahin et al. [117] reported on the degree of 
unfolding of four types of human IgG1 according to buffer pH and Cs. Unfolding was characterized by 
differential scanning calorimetry. The relatively small range of Cs investigated (54 mM and 100 mM) 
did not result in any differences of unfolding when studied at the same pH. Increasing protein unfolding 
was observed for pH 6.5 compared to 3.5 for both Cs conditions. These studies reveal the complexity 
of the effect of pH and Cs on mAb unfolding. Both studies indicate that low pH (2~3.5) and high Cs 
(1.5 M) may increase protein unfolding. Thus it is expected that choosing buffer with higher pH and 
lower Cs will minimize unfolding during the separation of mAb with weak CEX materials. 
Phosphate, citrate and acetate ions are among the most common co-ion type used in CEX 
chromatography, and their contribution to protein unfolding has been related to the Hofmeister series. 
Namely, according to the Hofmeister series, anions were ranked as sulphate > citrate > phosphate > 
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formate >acetate, where higher rank indicates a stronger ability of the anion to change tertiary structure 
of proteins [139, 194]. Note that the Hofmeister series may not be applicable when the ion concentration 
is low. Published studies show good agreement with the Hofmeister series [140-142, 195], where mAb 
prepared in buffer solutions containing anions of higher rank in the Hofmeister series demonstrated a 
higher degree of protein unfolding. Rubin et al. [140] investigated the unfolding of a IgG1-based mAb 
induced by co-ions, including acetate, sulfate and formate, where lowest protein unfolding was 
observed for protein sample with 25 mM acetate buffer, which is the lowest ranked anion in the 
Hofmeister series. Singla et al. [141] studied the effect of citrate (20 mM and 100 mM), acetate (25 
mM and 100 mM) and phosphate ions (15 mM) on the unfolding of a IgG1-based mAb and observed 
higher unfolding for protein samples with citrate ions, which was ranked higher than acetate and 
phosphate ions in the Hofmeister series. Barnett et al. [142] reported increased unfolding of an anti-
streptavidin IgG1 in 5 mM citrate buffer compared to 10 mM acetate buffer, explained by the 
accumulation of citrate ions around the surface of the anti-streptavidin IgG1. Based on the above 
studies, the Hofmeister series can serve as a reliable guidance for the selection of the co-ion type that 
minimize unfolding thus improving the quality of mAb during separation process with weak CEX 
materials. 
Buffer effects on binding capacity was discussed in Chapter 4, and their effects on protein unfolding 
would be investigated in detail in this chapter. It was hypothesized that buffer counter-ion concentration 
(Cs) and co-ion type (chemistry and valence) have an impact on IgG/mAb unfolding. A high-throughput 
intrinsic fluorescence microplate method developed in Chapter 5 is suitable for the detection of IgG/ 
mAb unfolding in an economic and efficient way and will be employed in this chapter. The hypothesis 
was tested with polyclonal human IgG, which is cheap and can be representative of the structure of 
mAb, and Bevacizumab, a humanized mAb. IgG and Bevacizumab samples were formulated with 
buffers at pH 5, with various Na+ concentration and co-ion type prior to mechanical stress (Table 24). 
Mechanical stress was used in this study to represent the shaking taking place during static binding, 
while the stress conditions were amplified for IgG to reveal the buffer effects. IgG samples were 
stressed by shaking for 24 hours while Bevacizumab samples were stressed by shaking for 1 hour 
without a membrane and then for 6 hours with a membrane (namely static binding). After being 
mechanically stressed, the IgG samples and Bevacizumab samples were analyzed with the intrinsic 
fluorescence microplate method developed in the previous chapter. Response surface model (RSM) 
used for analyzing the collected fluorescence intensities of IgG samples for buffer effects.  
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Through analyzing the buffer effects on IgG/mAb binding in chapter 4, the steric factor of IgG 
binding with Natrix C weak CEX membrane in phosphate citrate buffer was estimated to be 105 from 
the SMA model, which was 21% larger than the steric factor in acetate buffer. The steric factor 
represents the number of ion sites on the IEX material hindered by one bounded protein molecule, 
which could be an indicator of the size and conformational structure of protein molecules. Therefore 
the larger steric factor estimated for the phosphate citrate buffer may suggest that the IgG structure is 
less compact than that in acetate buffer which could result from the effect of buffer co-ions. In this 
chapter, the SMA model was used to understand the structure of Bevacizumab samples during binding 
with Natrix C weak CEX membranes. 
 
6.2 Materials and methods 
6.2.1 Buffers 
All buffers and solutions were prepared with ultra-purified water. Phosphate citrate buffer was prepared 
by mixing citric acid (EMD Chemicals Inc., Gibbstown, USA) solution and sodium phosphate dibasic 
(Fisher Scientific, Fair Lawn, USA) solution. Sodium acetate buffer was prepared by mixing acetic acid 
(EMD Chemicals Inc., Gibbstown, USA) solution and sodium acetate (EMD Chemicals Inc., 
Gibbstown, USA) solution. See appendix A for details. Na+ concentration was adjusted with sodium 
chloride (BDH Inc., Toronto, Canada). See Appendix A for details of buffer preparation. 
 
6.2.2 Proteins 
IgG was purchased from Equitech-Bio, Inc. (Kerrville, Texas, USA). Bevacizumab samples (in vials) 
were generously provided by Apotex Inc. (North York, Ontario, Canada). Bevacizumab is supplied at 
a concentration of 25mg/ml, with 0.4mg/ml (0.04%) polysorbate 20, at pH 6.2. All Bevacizumab 
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6.2.3 Membranes 
Weak CEX membrane, Natrix C weak CEX membranes (disc diameter: 47 mm) were kindly provided 
by Natrix Separations Inc. (Burlington, Ontario, Canada). Circular Natrix C weak CEX membrane 
samples (Diameter: 2.6 mm) were prepared with a cork borer for use in the static binding experiments. 
 
6.2.4 IgG subjected to shaking as mechanical stress 
IgG unfolding was investigated by Design of Experiment (DoE) involving 3 factors (Table 23). 37.5 
mM phosphate citrate buffer and 75 mM acetate buffer at pH 5 were used and the Na+ concentration of 
the buffer was adjusted accordingly with NaCl. The stress condition was identified by preliminary 
experiments and adapted from the literature work [196-198] , such that changes in intrinsic fluorescence 
intensity can be captured. In one study, Telikepalli et al. [196] stressed a IgG1 mAb sample at  300 rpm 
for 1 to 3 days for structural analysis, and in another study the group [197] investigated the physical 
stability of the lyophilized IgG1 mAb sample under shipping-like stress where samples were shaken 
from 5 min to 24 h at 3200 rpm. Uchino et al. [198] generate protein aggregates through stressing 
diluted commercialized mAb formulation at 250 rpm for 5min. In this work, samples were stressed by 
shaking at 200 rpm on a shaker (Thermo Scientific 2309 lab rotator, Canada) for 24 hours before the 
intrinsic fluorescence analysis.  
Table 23 DoE for investigating IgG unfolding for 37.5 mM phosphate citrate and 75 mM acetate 
buffer, at pH 5. 
Factor Level 
Na+ concentration (mM) 50 100 150 200 250 
IgG concentration (mg/mL) 0.5 1 2 3 4 
 
6.2.5 High-throughput Bevacizumab static binding 
The high-throughput static protein binding was performed in 96-well non-binding clear microplates 
(Greiner Bio-One, North Carolina, USA) at room temperature placed on a shaker at 200 rpm. Circular 
Natrix C weak CEX membrane samples (Diameter: 2.6 mm) were prepared with a cork borer. The 
membrane volume was calculated as indicated in 4.2.6. Bevacizumab samples with initial concentration 
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of 5 and 10 mg/mL in pH 5 100 mM phosphate citrate buffer or 200 mM acetate buffer were used. The 
equilibration time was 1 h and binding time was 6 h. Four replicates were performed for each 
concentration. The buffer conditions selected aligned with that used in chapter 4. 
For the analysis of the SMA model, static binding experiments of Bevacizumab with Natrix C weak 
CEX membrane were performed in 25 mM phosphate citrate buffer and 50 mM acetate buffer at pH 5 
with three different Na+ concentration, 50mM, 100 mM and 200 mM.  
 
 
6.2.6 High-throughput intrinsic fluorescence microplate measurement 
In order to minimized the disruption of the protein structure, mechanically stressed IgG samples and 
Bevacizumab samples were not centrifuged or filtered prior to intrinsic fluorescence measurements. 
After mechanically stressed, the stressed IgG samples or Bevacizumab samples (referred to as the after-
binding solution) were transferred to 96-well non-binding black microplates (Greiner Bio-One, North 
Carolina, USA). The emission spectra were collected with the Synergy 4 microplate reader, excitation 
at 280 nm and emission collected for 300~450 nm, at sensitivity of 80 and emission step of 1 nm in 
duplicates. Sensitivity was selected by testing the sample potentially with the highest fluorescence 
intensity until no signal overflowing was observed. The maximum fluorescence intensity was extracted 
from the emission spectra for each experimental condition. The degree of unfolding was determined as 
the maximum fluorescence intensity.  
 
6.2.7 Size-exclusion high performance liquid chromatography (SE-HPLC) 
SE-HPLC was performed on Waters 2690 separations module (Waters, MA, USA) with the Sepax 
Zenix-C SEC-300 (Sepax Technologies, Newark, DE) column. Prior to SE-HPLC tests, all samples 
were filtered with a 0.45 μm PES syringe filter (Thermo Scientific, Ontario, Canada). A volume of 100 
µL of sample was loaded onto the SEC column. The flow rate of the mobile phase was increased from 
0 mL/min to 1 mL/min within 1 min, and the duration of elution was set to 20 min. The mobile phase 
consisted of 100 mM sodium phosphate buffer at pH 7. A calibration curve was prepared with various 
concentrations of Bevacizumab ranging from 0.125 to 2 mg/mL, and UV absorbance was collected at 
280 nm to detect protein content. The monomer content was estimated from the area under the curve 
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of the peak corresponding to the monomeric form of Bevacizumab. The relative monomer content was 
calculated as the ratio of the area of the monomer peak of a given thermal stress to the area of the 
monomer peak with no thermal treatment, by the Empower 3 software (See Appendix E). All 
measurements were carried out in duplicates.  
 
6.2.8 Response surface model (RSM) 
RSM was used to represent and analyze the effect of Na+ concentration (50 mM ~ 250 mM) and protein 
concentration (0.5 mg/mL ~ 4 mg/mL) on intrinsic fluorescence representing IgG unfolding in each of 
the two buffers. After various trials with first-order linear, second-order linear (with various term 
combination) and non-linear regression (inversed), the experimental data for a given buffer was found 
to be best fitted into the following second-order polynomial equation (Equation 6-1), with a R2 of 0.7, 




where F is the intrinsic fluorescence emission intensity, which is the maximum intrinsic fluorescence 
intensity of emission spectra. Cp is the IgG concentration (mg/mL) and Cs (Na+ concentration) is the 
counter-ion concentration (mM) and β1, β2, β3, β4, and β5 represent the regression coefficients.  
The RSM was constructed with Jacobian method (MATLAB, R2016b) with 50 data points for IgG 
samples in phosphate citrate buffer and acetate buffer. Response surface, 2D contour plots, analysis of 
variance (ANOVA) and confidence interval of estimated regression coefficients were subsequently 
generated. See Appendix B for the ANOVA table. See Appendix C for MATLAB code. 
 
6.2.9 SMA model 
The SMA model and parameter estimation method used was the same as described previously in section 
4.3.1 for IgG.  
 
6.2.10 Summary of experimental conditions 
Table 27 lists buffer conditions, model proteins and experimental conditions used in this chapter. 
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Table 24 Buffer conditions, model proteins and experimental conditions for Chapter 6. 
Section 
Buffer 





6.3.1 37.5 phosphate 
citrate 
50, 100, 150, 
200, 250 





75 acetate 50, 100, 150, 
200, 250 
5 
6.3.2 100 phosphate 
citrate  









200 acetate 140 5 
25 phosphate 
citrate  
50, 100, 200 5 Bevacizumab  High-throughput 
static 
Bevacizumab 
binding – for 
SMA analysis 
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6.3 Results and discussion 
6.3.1 Effect of buffer on the maximum fluorescence intensity of IgG 
In this chapter, the intrinsic fluorescence emission spectra of IgG samples formulated in 37.5 mM 
phosphate citrate buffer and 50 mM acetate buffer for different Cs (Na+ concentration) and IgG 
concentration were collected after mechanical stress. The maximum fluorescence intensity was 
extracted from the emission spectra and summarized in Table 25 and Table 26. 
Table 25 Maximum fluorescence intensity of IgG in 37.5 mM phosphate citrate buffer at pH 5 after 
mechanical stress, measured with microplate reader. The excitation wavelength was 280 nm and the 
sensitivity was set at 80. Average values of triplicates. 
Cs (Na+ concentration) (mM) 
IgG concentration (mg/mL) 
0.5 1 2 3 4 
50 6931 16811 47791 35476 20230 
100 18487 22647 24319 40823 47927 
150 26255 20734 24104 39588 70859 
200 18334 29254 35476 53354 78214 
250 3714 33641 33460 53105 79505 
 
Table 26 Maximum fluorescence intensity of IgG in 50 mM acetate buffer at pH 5 after mechanical 
stress, measured with microplate reader. The excitation wavelength was 280 nm and the sensitivity 
was set at 80. Average values of triplicates. 
Cs (Na+ concentration) (mM) 
IgG concentration (mg/mL) 
0.5 1 2 3 4 
50 4500 17969 19002 15755 6536 
100 5917 13954 20967 37786 7239 
150 20622 16780 38079 37601 33516 
200 18334 16565 34860 37825 39847 
250 7271 10086 40968 45594 62880 
 
The maximum fluorescence intensity was fitted with second-order RSMs for stressed IgG samples 
in phosphate citrate buffer (Equation 6-2) and acetate buffer (Equation 6-3), respectively. The goodness 
of fit of the model was confirmed by R2, which was 0.82 for phosphate citrate buffer and 0.85 for 
acetate buffer. The effect of IgG concentration, Cs (Na+ concentration) and their interactions on the 
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degree of IgG unfolding were statistically significant for both buffer types, confirmed by analysis of 
variance (ANOVA) at 95% confidence level. As suggested in the following equations, the coefficients 
of first-order and second-order terms of protein concentration (Cp) were larger than that of Cs (Na+ 
concentration), indicating that Cp had a stronger influence on the fluorescence intensity of stressed IgG 
than Cs (Na+ concentration) in both buffer types.  
F = 2 × 104 + (−378) ∗ cp + (−30) ∗ cs + 771 ∗ cp2 + (−0.097) ∗ cs2 + 58 ∗
cpcs    
Equation 
6-2 
F = (−70) + (1 × 104) ∗ cp + 60 ∗ cs + (−3828) ∗ cp2 + (−0.4) ∗ cs2 + 76 ∗ cpcs 
Equation 
6-3 
Contour plots developed from Equation 6-2 and Equation 6-3 are presented in Figure 38. The 
mechanically stressed IgG samples in phosphate citrate buffer show no significant change in the 
maximum fluorescence intensity for Cs (Na+ concentration) ranging from 50 mM to 250 mM, which 
demonstrated negligible effect of Cs (Na+ concentration) on IgG unfolding. At higher IgG concentration 
(4 mg/mL) the maximum fluorescence intensity doubled when Cs (Na+ concentration) increased from 
50 mM to 250 mM, which demonstrated more significant effect of Cs (Na+ concentration) on IgG 
unfolding. The mechanically stressed IgG samples at 4 mg/mL in acetate buffer showed lower 
maximum fluorescence intensities than in phosphate citrate buffer at all Cs (Na+ concentration) 
conditions and was 26% lower at Cs (Na+ concentration) 250 mM, which may indicate lower degree of 
IgG unfolding in acetate buffer compared to phosphate citrate buffer. 
The effect of counter-ion concentration (Cs, Na+ concentration) and co-ion type (chemistry and 
valence) on the maximum fluorescence intensity of IgG observed in this study is in good agreement 
with the literature work with mAbs. Bickel et al. [115] observed higher degree of non-specified mAb 
unfolding for phosphate citrate buffer at Cs (Na+ concentration) 150 mM compared to Cs (Na+ 
concentration) 0 mM at pH 5 and proposed that higher salt concentration enhanced hydrophobic 
interactions of protein molecules and induced non-native conformation. Unfolding was measured with 
Differential Scanning Fluorimetry (DSF), intrinsic and extrinsic fluorescence spectroscopy. The lower 
degree of IgG/mAb unfolding in acetate buffer compared to phosphate citrate buffer observed in this 
study was also was observed by other groups [140-142]. Thus, proteins in solutions containing acetate 
ions should be more stable than those in solutions containing phosphate ions and citrate ions.  
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Formaneck et al. [199] investigated the effect of Na+ concentration on the structural stability of a 
non-mAb simpler protein, the human Lymphotactin, using extensive molecular dynamics (MD) 
simulations and reported that the structure of Lymphotactin with higher surface charge is more sensitive 
to the ionic environment compared to proteins with lower surface charge. Thus it is proposed that IgGs 
in phosphate citrate buffer potentially exhibiting higher surface charge may be more sensitive to Cs 
(Na+ concentration) compared to IgGs in acetate buffer in this study. This may explain the higher 
fluorescence intensity of IgGs in phosphate citrate buffer at high Cs (Na+ concentration) compared to 
IgGs in acetate buffer. The acetate buffer is recommended over phosphate citrate buffer for IgG to 
maintain a low degree of unfolding in various Cs (Na+ concentration) and protein concentration 
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Figure 38 3D and 2D contour plot of the fitted maximum fluorescence intensity  (RSM) for 
mechanically stressed IgG samples in (A) 37.5 mM phosphate citrate buffer; and (B) 50 mM acetate 
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6.3.2 Effect of buffer on Bevacizumab unfolding 
Investigations of the effect of Cs (Na+ concentration) and co-ion type on IgG maximum fluorescence 
intensity in the previous section was used to define the conditions for the investigation of buffer 
conditions with Bevacizumab. In this section, the effect of co-ion type (chemistry and valence) on 
Bevacizumab maximum fluorescence intensity will be discussed by comparing the intrinsic 
fluorescence emission spectra of Bevacizumab samples in 100 mM phosphate citrate buffer and 200 
mM acetate buffer at pH 5 and with the same Cs (Na+ concentration) after binding with weak CEX 
membranes. As protein unfolding could be indicative of protein aggregation, SE-HPLC will be applied 
for the analysis of the monomer content as an indication of potential aggregation. The Bevacizumab 
binding with weak CEX membranes was also analyzed with the SMA model to examine the effect of 
co-ion type on potential Bevacizumab unfolding. 
Since the static protein binding experiment with Natrix C weak CEX membrane was performed by 
shaking protein samples with the membranes, the binding process was viewed as a mechanical 
treatment. Phosphate citrate buffer, 100 mM, and acetate buffer, 200mM, both at pH 5 and Cs (Na+ 
concentration) 140 mM, were selected in accordance with the buffer conditions used in the previous 
binding experiment (section 4.4.4). The pH and Cs (Na+ concentration) of the two buffer types were 
kept the same so that the investigation can focus on the effect of co-ion type on mAb unfolding.  
 
6.3.2.1 Intrinsic fluorescence of Bevacizumab solutions under mechanical stress 
The effects of co-ion type (chemistry and valence) on the static binding capacity of Bevacizumab with 
Natrix C weak CEX membrane presented previously in section 4.4.4 showed comparable equilibrium 
binding capacities for the two buffer types when the initial Bevacizumab concentration was lower than 
10 mg/mL. The equilibrium Bevacizumab binding capacity in 200 mM acetate buffer was significantly 
(Paired t-test, 95%) higher than in 100 mM phosphate citrate buffer when the initial Bevacizumab 
concentration reached 10 mg/mL. It indicated that the effect of co-ion type on binding capacity was 
only prominent at high Bevacizumab concentration. In this section, the effect of co-ion type (chemistry 
and valence) on Bevacizumab maximum fluorescence intensity was investigated for initial 
concentrations of 5 and 10 mg/mL, representing low and high concentration conditions. 
The intrinsic fluorescence emission spectra of after-binding Bevacizumab samples in 100 mM 
phosphate citrate buffer and 200 mM acetate buffer, were collected and compared (Figure 39). The 
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intrinsic fluorescence intensity of the after-binding Bevacizumab samples appears to be comparable 
between the 100 mM phosphate citrate buffer and 200 mM acetate buffer when the initial Bevacizumab 
concentration was 5 mg/mL. In contrast, when the initial Bevacizumab concentration was 10 mg/mL, 
the intrinsic fluorescence intensity of Bevacizumab samples in 100 mM phosphate citrate buffer were 
significantly higher than that in 200 mM acetate buffer, which could suggest a higher degree of 
Bevacizumab unfolding. The observation corresponded to the ones in section 4.4.4 that the effect of 
co-ion type on Bevacizumab binding capacity tend to be more evident at higher Bevacizumab 
concentration.  
The equilibrium binding capacity of Bevacizumab were comparable for the two buffer types when 
the initial Bevacizumab concentration was less than or equal to 7 mg/mL. However, the equilibrium 
binding capacity was significantly higher in acetate buffer compared to the phosphate citrate buffer 
when the initial Bevacizumab concentration was 10 mg/mL. Based on these observations, the acetate 
buffer is recommended over phosphate citrate buffer for Bevacizumab binding with Natrix C weak 
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Figure 39 Intrinsic fluorescence emission spectra of the after-binding Bevacizumab samples with an 
initial concentration of 5 and 10 mg/mL, in 100 mM phosphate citrate buffer and 200 mM acetate 
buffer (both at pH 5 and Cs (Na+ concentration) 140 mM), respectively. Average values of duplicates. 
 
6.3.2.2 SE-HPLC analysis of Bevacizumab solutions after high-throughput binding 
Based on the previous section, it is proposed that 100 mM phosphate citrate buffer, pH 5 could result 
in higher degree of unfolding for after-binding Bevacizumab samples with an initial concentration of 
10 mg/mL compared to acetate buffer. As the degree of protein unfolding could be indicative of protein 
aggregation, SE-HPLC analysis was performed for the after-binding Bevacizumab samples in 100 mM 
phosphate citrate buffer and 200 mM acetate buffer (both at pH 5 and Cs (Na+ concentration) 140 mM), 
with an initial concentration of 10 mg/mL. The monomer percentage of the before-binding and after-
binding Bevacizumab samples in each buffer was 96%, which indicates negligible aggregation. The 
SE-HPLC analysis showed that the co-ion type did not have significant effect on the aggregation of 
Bevacizumab under mechanical stress (binding). 
 
  128 
 
6.3.2.3 SMA model of Bevacizumab binding with Natrix C weak CEX 
The static binding experiments for IgG analyzed with the SMA model in the previous section (4.4.3.2) 
indicates that the steric factor parameter could potentially be used to probe the effect of buffer on IgG 
unfolding. The steric factor of IgG binding with Natrix C weak CEX membrane in 150 mM phosphate 
citrate buffer was estimated to be 21% larger than in 200 mM acetate buffer, which suggest that the 
IgG structure was less compact in phosphate citrate buffer than in acetate buffer. The hypothesis of the 
structural change of IgG was confirmed by comparing the intrinsic fluorescence emission spectra of 
mechanically stressed IgG samples in phosphate citrate buffer and in acetate buffer (6.3.1). The higher 
maximum intrinsic fluorescence intensity was observed in phosphate citrate buffer compared to acetate 
buffer, which indicates that the distinct co-ion type in phosphate citrate buffer promoted unfolding of 
IgGs. Since similar intrinsic fluorescence differences were also observed with Bevacizumab samples 
after binding with Natrix C weak CEX membrane (section 6.3.2.1), the steric factor parameter of the 
SMA model will be discussed in this section for the binding of Bevacizumab with Natrix C weak CEX 
membrane. 
In this section, the results of the static binding experiments of Bevacizumab with Natrix C weak CEX 
membrane performed in 25 mM phosphate citrate buffer and 50 mM acetate buffer at pH 5 with three 
different counter-ion conditions, Cs (Na+ concentration) 50mM, 100 mM and 200 mM, were fitted into 
the SMA model for parameter estimation. The estimated steric factor (σ) in phosphate citrate buffer 
was 68% larger than in acetate buffer (Table 27), which indicates higher number of binding sites 
blocked by the adsorbed Bevacizumab molecules. This may be associated with potential structural 
changes undergone by Bevacizumab in phosphate citrate buffer, such as unfolding. Thus, the higher 
estimated σ in phosphate citrate buffer agrees with the observations of higher Bevacizumab unfolding 
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Table 27 Fitted SMA model parameters for Bevacizumab and Natrix C weak CEX membrane in 25 
mM phosphate citrate buffer and 50 mM acetate buffer at pH 5 with 50mM, 100 mM and 200 mM Cs 
(Na+ concentration). 
Buffer Type K ν σ R2 
Phosphate citrate 46.8 1.1 129 0.78 
Acetate 20.1 1.1 77.5 0.86 
 
6.4 Conclusion 
In this chapter, the effect of counter-ion concentration Cs (Na+ concentration) and co-ion type 
(chemistry and valence) of the buffer, on IgG and Bevacizumab, as representative mAb, was 
investigated with a high-throughput intrinsic fluorescence microplate method, SE-HPLC and static 
equilibrium binding.  
The intrinsic fluorescence emission spectra of mechanically treated IgG samples collected with the 
microplate method indicated pronounced effect of Cs (Na+ concentration) and co-ion type on IgG 
unfolding for initial IgG concentration of 4 mg/mL. The effect of Cs (Na+ concentration) on IgG 
unfolding observed in this work corresponds with that observed by Bickel et al. [115], that high Cs (Na+ 
concentration) may induce higher IgG/mAb fluorescence intensity at pH 5. The results shed light on 
buffer selection for maintaining the structural quality of IgG. Based on the results of this study, low Cs 
(Na+ concentration) is recommended for IgG to minimize potential unfolding in phosphate citrate buffer 
or acetate buffer; while acetate buffer is recommended for IgG formulation in cases when higher Cs 
(Na+ concentration) is required.  
The role of buffer composition on the mAb structure during binding was investigated from the 
emission spectra of Bevacizumab samples after-binding with Natrix C weak CEX membranes. It was 
proposed that co-ion type could have an impact on Bevacizumab unfolding for samples at higher 
concentration (10 mg/mL), where higher maximum fluorescence intensity was observed in phosphate 
citrate buffer compare to the acetate buffer. In this work, SMA model was found to be an effective 
supplementary tool for evaluating protein unfolding. Previously, the SMA model has been used 
primarily for evaluating the electrostatic interactions between proteins and IEX materials. While protein 
unfolding is governed by noncovalent interactions including hydrogen-bonding, van der Waal’s, 
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hydrophobic interactions, and electrostatic interactions [200], weak CEX materials exhibiting variable 
ionization according to pH may influence protein structure through electrostatic interactions. The 
higher maximum fluorescence intensity of Bevacizumab in phosphate citrate buffer was supported by 
the higher estimated steric factor of the SMA model. 
In conclusion, the intrinsic fluorescence microplate method could be employed as an efficient and 
economical way to investigate buffer effects on protein unfolding for IgG/mAbs, which helped with 
buffer selection for IgG/mAbs during the formulation process and the binding process. The steric factor 
parameter of the SMA model can also be used to probe the effect of buffer on IgG unfolding. Therefore 
acetate buffer is recommended for Bevacizumab binding with Natrix C weak CEX membrane to 
minimize unfolding and obtain high binding capacity as shown in the previous section (4.4.4) where 
the binding capacity of Bevacizumab with Natrix C weak CEX membrane was higher in acetate buffer 
than that in phosphate citrate buffer when the initial concentration was 10 mg/mL. The findings agree 
with that in literature where higher degree of IgG/mAb unfolding was observed for buffers contain 
citrate ions and phosphate ions compare to buffers with acetate ions [140-142, 195]. 
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Chapter 7 Developing design space for mAb capture with weak CEX 
membranes 
7.1 Introduction 
The concept of Quality by Design (QbD) is a systematic approach that aims to ensure product quality 
throughout the manufacturing process. This approach offers flexibility for changes in process 
conditions within the design space [201]. The key elements of QbD include the quality target product 
profile (QTPP), critical quality  attributes (CQAs), critical material parameters (CMPs), critical process 
parameters (CPPs), risk assessments, design space development, control strategy and product life cycle 
management [143]. During the production of pharmaceutical products, variations within and between 
batches are very common and difficult to eliminate, while these variations can be minimized with 
through the design space development. The definition of design space was “the multidimensional 
combination and interaction of input variables that have been demonstrated to provide assurance of 
quality within an acceptable range”, according to the ICH Q8 guidance [145]. The design space 
development is important to quantify the effect of material and process parameters on the performance 
of biopharmaceutical manufacturing process, in terms of productivity and product quality [28, 29].  
The principles of QbD require inspection and regulation of raw materials and process parameters for 
control of the variability and the product quality during the downstream process, which consist of mAb 
capture (binding and elution) and polishing steps. Considering the vast number of parameters involved 
in the capture of mAb compared to small-molecule drugs, it is important to identify critical material 
parameters (CMPs) and critical process parameters (CPPs) by risk assessment. CMPs and CPPs present 
a significant impact on the critical quality attributes (CQAs) of mAb products and productivity, and 
should be monitored and controlled to ensure that the process produces the desired quality. According 
to the ICH Q8 guidance [145], CQAs are “A property or characteristic that when controlled within a 
defined limit, range, or distribution ensures the desired product quality”.  
There is growing work in design space development for downstream processes of mAb 
manufacturing with ion exchange chromatography (IEX) for the polishing step of mAb purification, 
viral clearance or aggregate removal. Strauss et al. [30] defined the design space for viral clearance 
with AEX chromatography, with four process parameters, namely, pH, conductivity, mAb load density 
and flow rate. Connell-Crowley et al. [11] investigated the retrovirus clearance with CEX, and defined 
the design space with two parameters, pH and ionic strength. In terms of design space development for 
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aggregate removal with CEX, Xu et al. [31] defined the design space of the aggregate content with 
mAb load and equilibration buffer. Khalaf et al. [32] developed a model for design space estimation, 
where the elution behavior of the protein with CEX was first predicted with a thermodynamic model 
and then the model was refined with experimentations to help define design space. 
There has been no study on the design space development of the mAb capture step with CEX 
membrane chromatography. Design space development can help explore the potentials of CEX 
membranes for mAb capture through investigating the process performance, namely process 
productivity and product quality in an efficient way. 
The main objective of the work presented in this chapter was to establish a framework for high-
throughput design space development of the binding step of mAb capture with Natrix C weak CEX 
membranes. A different mAb, Rituximab, which is a chimeric mAb, was selected because of its 
different characteristics from Bevacizumab, with size of approximately 144 kDa [61] and the isoelectric 
point is 8.68 [60]. Acetate buffer was selected as the binding buffer because it demonstrated higher 
binding capacity (4.4.4) and lower unfolding (6.3.2) for Bevacizumab with weak CEX membranes. 
Step 1, the critical parameters were identified with risk assessment, based on knowledge acquired from 
the literuature and the work presented in the previous chapters. Step 2, the characterization range was 
studied to help define the range of the critical parameters. Step 3, response surface model (RSM) was 
created to define the design spaces, where the impact of parameters on productivity and product quality 
was assessed from the binding capacity and the degree of protein unfolding. The RSM was established 
by fitting into experimental data generated with a full factorial design of four factors and three levels. 
Protein unfolding was detected with the high-throughput intrinsic fluorescence method developed in 
Chapter 5. Step 4, optimal conditions defined by the design space was applied to Rixtuximab binding 
with Natrix C weak CEX membrane, at static mode and dynamic mode which is the actual operating 
mode. 
 
7.2 Materials and methods 
7.2.1 Buffers  
All buffers and solutions were prepared with ultra-purified water. Sodium acetate buffer was prepared 
by mixing acetic acid (EMD Chemicals Inc., Gibbstown, USA) and sodium acetate (EMD Chemicals 
Inc., Gibbstown, USA). Phosphate citrate buffer was prepared by mixing citric acid (EMD Chemicals 
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Inc., Gibbstown, USA) solution and sodium phosphate dibasic (Fisher Scientific, Fair Lawn, USA) 
solution. Sodium concentration was adjusted with sodium chloride (BDH Inc., Toronto, Canada). See 
Appendix A for details of buffer preparation. 
 
7.2.2 Rituximab 
Chimeric mAb sample, Rituximab, was generously provided by Apotex Inc. (North York, Ontario, 
Canada). All Rituximab samples used in this chapter were dialyzed with the targeting buffer following 
the same procedures as in section 4.2.4. 
 
7.2.3 Membranes 
Weak CEX membrane, Natrix C weak CEX membranes (disc diameter: 47 mm (high-throughput static 
binding, section 7.2.4) and 25 mm (dynamic binding, section 7.2.5)) were kindly provided by Natrix 
Separations Inc. (Burlington, Ontario, Canada). 
 
7.2.4 High-throughput static Rituximab binding and elution with microplate 
The high-throughput static Rituximab binding was performed with 96-well microplates at room 
temperature, with the same procedures as described in section 6.2.5. Circular Natrix C weak CEX 
membrane samples (Diameter: 2.6 mm) were prepared with a cork borer. The membrane volume was 
calculated from total sample mass and membrane density (0.42275g/ml). Rituximab samples with 
initial concentration of 1, 2 and 3 mg/mL were selected. Acetate buffer with different pH, molarity and 
counter-ion concentration Cs (Na+ concentration) was used as the binding buffer. Static binding was 
performed with 96-well non-binding clear microplates (Greiner Bio-One, North Carolina, USA) on the 
shaker at 200 rpm. The equilibration time was 1 h and the binding time was 6 h, as per Bevacizumab. 
Triplicates were performed for each Rituximab concentration. The static binding capacity was 
calculated as described in 4.2.8 from the after-binding solution. 
For Rituximab elution, each membrane was removed from the binding solution and transferred to a 
volume of 250 µL elution buffer of 20 mM phosphate citrate buffer at pH 7.2, with Cs (Na+ 
concentration) 75 mM, contained in 96-well microplates. After incubating for 4 hours on the shaker at 
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200 rpm, the membranes were taken out and the remaining after-elution solution was collected. The 
amount of Rituximab eluted out was estimated from the UV absorbance at 280 nm with the Synergy 4 
multi-detection microplate reader (BioTek Instruments, Winooski VT, US). The recovery was 




 ×  100% 
Equation 7-1 
 
where Proelu is the amount of Rituximab eluted from the membrane and Pro𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 is the amount of 
Rituximab bound to the membrane. Pro𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏  is calculated from the initial concentration and the 
concentration of the after-binding solution. 
 
7.2.5 Dynamic Rituximab binding and elution  
Dynamic Rituximab binding and elution was performed with ÄKTA Avant (GE Healthcare, Uppsala, 
Sweden), and the experimental conditions are listed in  
Table 28. 
Table 28 Experimental conditions of dynamic Rituximab binding with the ÄKTA system. 
Phase Volume (mL) Flow rate (mL/min) 
Equilibration 10 1 
Binding 50 1 
Washing 5 1 
Elution 35 1 
 
A 25 mm Natrix C weak CEX membrane was placed in a membrane holder before the start of 
equilibration phase. A new membrane sample was used for each run. The Rituximab load was adjusted 
to 3 mg/mL during the dialysis the equilibration/binding buffer. Acetate buffer was used as 
equilibration buffer, and buffer conditions was determined by the response surface model, which was 
50 mM acetate buffer at pH 4.8, with Cs (Na+ concentration) 75 mM. Phosphate citrate buffer was used 
as the elution buffer at various buffer conditions, including 20 mM phosphate citrate buffer at pH 7.2 
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and 7.6, and 150 mM phosphate citrate buffer at pH 7.2. Flowrate was 1 mL/min for all experiments. 
The UV detector was set at 280 nm for UV absorbance measurement. Dynamic binding capacity (DBC) 
(Equation 7-2) at 10% breakthrough (DBC10%) was calculated with MATLAB (R2016b). See Appendix 







where Cp is the Rituximab concentration (mg/mL), Vpermeate10%  is the volume of permeate collected 
at 10% breakthrough (mL) and Vmembrane is the calculated volume of the membrane (mL). 
 
7.2.6 High-throughput intrinsic fluorescence measurement 
The intrinsic fluorescence emission spectra of Rituximab was collected as per 6.2.6. 
 
7.2.7 Response surface model (RSM) 
RSM was constructed with the results from the high-throughput static Rituximab binding in acetate 
buffer with Natrix C weak CEX membrane. A full factorial design of experiments (DoE) with four 
factors at three levels for each factor was used to identify their contribution on Rituximab binding 
capacity, and randomization and replication were implemented with a total of 213 runs (Table 29). The 
range of the levels of each factor were identify in 7.3.2. A full second-order RSM was fitted to the 
experimental data with R (version 3.4.0), using the rsm package [202, 203] (See Appendix D). All 
factors were coded to ensure equal contribution to the model. Contour plots and response surfaces were 
plotted with the plotly package. The coefficient of determination R2 and adjusted R2 was used as an 
indication of goodness of fit of the model. The adjusted R2 is a modified version of R2 that is adjusted 
for the number of predictors in the model and it increases only if the new term improves the model. 
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Table 29 Factors and levels of the buffer conditions for high-throughput static Rituximab binding 
DoE (Step 3) 
Factor Level 
 Low Medium High 
pH 4 5 5.5 
Cs (Na+ concentration) (mM) 75 100 150 
buffer molarity (mM) 20 50 80 
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7.2.8 Summary of experimental conditions 
Table 30 lists buffer conditions, model proteins and experimental conditions used in this chapter. 











7.4.2 20, 50, 100 acetate Around 50 mM 
to 100 mM 




Step 2: study 
characterization 
range 
50 acetate Around 50 mM 




50 acetate 50, 100, 200 5 




binding -  for RSM 
analysis 
 
Step 3: RSM 
development 








75 7.2 high-throughput 
static Rituximab 
elution 
50 acetate  75 4.8 Rituximab dynamic Rituximab 
binding 
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7.3 Results and discussion 
7.3.1 Risk assessment 
The risk assessment analysis consists of two steps. The first step of the risk assessment was to identify 
the relevant parameters to mAb binding and elution with CEX and create a cause-and-effect diagram. 
A cause-and-effect diagram for capture by CEX was created based on knowledge from the literature 
(Figure 40). The second step was to select and apply a risk assessment tool for the evaluation of the 
parameters for mAb capture by CEX. Failure mode effects analysis (FMEA) was selected as the most 
commonly used risk assessment tool for protein downstream processing [30, 151, 154]. According to 
FMEA, each parameter is ranked by the risk priority number (RPN). The RPN score is determined by 
the severity (S), occurrence (O), and detection (D) of the given parameter and is calculated as 
RPN=S×O×D. In this work, the FMEA was performed for mAb capture with CEX materials, consist 
of the severity, occurrence, and detection of relevant CEX material and process parameters, which were 
ranked on a ten-point scale [204]. The scale of 1 means the lowest and the scale of 10 means the highest. 
The score was given to each factor based on literature work on IgG/mAb purification (both capture and 
polishing) with CEX, as well as knowledge of buffer effects on IgG/mAb binding with CEX acquired 
in the previous section (Chapter 4). After assigning scores to severity, occurrence, and detection of all 
parameters relating to mAb capture by CEX, the risk priority numbers were calculated accordingly 
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Figure 40 Cause-and-effect diagram defined for identification of the material parameters and the 
process parameters of mAb binding and elution with CEX. 
Table 31 Failure Mode and Effects Analysis (FMEA) for mAb capture with CEX. 
Parameters S O D RPN 
CEX material 5 3 2 30 
Filter 1 3 1 3 
Chemical 1 1 1 1 
pH 9 5 1 45 
Conductivity 9 5 1 45 
Counter-ion 7 1 1 7 
flowrate 5 1 1 5 
Residence time 3 3 1 9 
Load 
concentration 
7 3 1 21 
Load mode 7 1 1 7 
Elution mode 7 1 1 7 
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The classification and identification of the parameters of greatest potential impact on mAb unfolding 
and productivity of CEX capture was done with a Pareto chart(Figure 41) ,and was adapted from the 
work of Xu et al. [31]. A Pareto chart is a graphical representation summarizing the relative importance 
of each parameter and highlight the most important ones. The chart contains bars, representing 
individual values are arranged in decreasing order of the RPN, and a line, representing the cumulative 
value of the RPN. The cumulative percentage was calculated by dividing the RPN value of a given 
parameter by the sum of the RPN value for all parameters. The parameters with high RPN and a 
cumulative impact above 90% were considered as high risk and identified as critical parameters. As 
shown in Figure 41, six of the ten parameters were identified as CMPs and CPPs. These parameters are 
pH, conductivity, CEX material, mAb load concentration, residence time and load mode. The results 
are in good agreement with the literature, where the above parameters are often investigated as critical 
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Figure 41 Pareto chart identifying CMPs and CPPs for CEX capture. Bars represent RPN value of 
each parameters, and the solid line represents the cumulative percentage of RPN. The dash line 
represents the 90% cumulative value, where parameters on the left of the marker contribute to 90% of 
the total impact and are considered critical parameters. 
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The risk assessment analysis developed above for mAb capture with CEX material, will be applied 
to Natrix C weak CEX membranes and the mAb, Rituximab, which will be discussed in the remaining 
sections of this chapter with the following simplifications. Since the Natrix C weak CEX membrane 
was selected as the CEX material for its high binding capacity, thus the CEX material parameter was 
eliminated. The binding of Rituximab with Natrix C weak CEX membrane was performed in static 
mode in the following work, thus residence time and load mode are not relevant. Therefore, three 
critical process parameters, conductivity, pH of equilibration/load buffer, and Rituximab concentration, 
will be examined in the following section. Findings from previous sections showing the significant 
effect of the co-ions on mAb binding (4.4.4) and structural changes (6.3.2) was used to express. the 
conductivity as two parameters, buffer molarity and Cs (Na+ concentration). It is the first time that buffer 
molarity is investigated as the critical process parameter during design space development.  
 
7.3.2 Characterization range  
After identifying the critical parameters, the next step was to define the experimental characterization 
range of the four critical parameters for design space development. Note that the design space is located 
within the characterization range (Figure 42) [28, 205]. In this work one-factor-at-a-time (OFAT) was 
employed as a simple approach to investigate the effect of each of the four critical parameters on the 
Rituximab binding capacity and structural changes during binding with Natrix C weak CEX membrane. 
The range of each factor was based on literature information and will be detailed for each parameter in 
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Figure 42 Comparison of the characterization range and range of the design space. Reprinted from 
Nature Biotechnology, 27/1, A. S Rathore & H. Winkle, Quality by design for biopharmaceuticals, 26, 
Copyright (2009), with permission from Springer Nature [28]. 
 
7.3.2.1 pH of the binding buffer  
The pH of the buffer is the most critical factor among all buffer factors for protein binding with CEX 
materials, especially for weak CEX materials. mAb binding with CEX is based on electrostatic 
interactions. Buffer pH can change the charge distribution on the protein surface and ionization of weak 
CEX materials, which affects the electrostatic interactions between protein molecules and weak CEX 
materials, as well as the electrostatic interactions within protein molecules [114, 135, 136]. For the 
Natrix C weak CEX membrane, pH affect the swelling behavior of the membrane (Section 3.3.1) and 
thus affect the availability of the binding sites on the membrane. 
The effect of the pH of buffer on the binding capacity of Rituximab with Natrix C weak CEX 
membrane was examined by comparing the static binding capacity of Rituximab with Natrix C weak 
CEX membrane in 50 mM acetate buffer according to pH conditions (Figure 43). Acetate buffer was 
selected as the binding buffer because it demonstrated higher binding capacity (4.4.4) and lower 
unfolding (6.3.2) for Bevacizumab with weak CEX membranes. The initial Rituximab concentration 
was set at 3 mg/mL. The binding capacity significantly increased with increasing pH until pH 5.4 
(paired t-test, 95%), and then decreased at pH 6. The results are comparable to the literature, where 
Hou et al. [22] investigated the dynamic binding capacity (DBC) of a mAb with Natrix C weak CEX 
membrane with 50 mM acetate buffer with pH ranging from 4.4 to 5.2, and reported maximum DBC 
at pH 5.2 (conductivity 8 mS/cm).  
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Figure 43 Static binding capacity of Rituximab with Natrix C weak CEX membrane in 50 mM 
acetate buffer according to pH conditions. The initial Rituximab concentration was 3 mg/mL. Error 
bars represent standard deviation (n=3). 
The effect of pH on mAb unfolding was obtained from the intrinsic fluorescence, emission spectra 
of Rituximab samples after binding with Natrix C weak CEX membrane in 50 mM acetate buffer at pH 
4 and 6 and Cs (Na+ concentration) adjusted to 150 mM to avoid interference of the Cs (Na+ 
concentration) effect on mAb structure. The maximum fluorescence intensity of after-binding 
Rituximab samples in acetate buffer at pH 6 was around twice as much as that of after-binding 
Rituximab samples in acetate buffer at pH 4 (Table 32). A red-shift in maximum emission wavelength 
was observed when the buffer pH increased from pH 4 to pH 6, which indicates increased unfolding. 
Based on these results, the range of the pH of the buffer of Rituximab binding with Natrix C weak CEX 
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Table 32 Maximum fluorescence intensity and maximum emission wavelength of emission spectra of 
Rituximab with an initial concentration of 3 mg/mL after binding with 50 mM acetate buffer at pH 4 






4 1672 314 
6 3593 325 
 
7.3.2.2 Molarity of the binding buffer and Rituximab concentration  
The buffer molarity has not been investigated as standalone parameter for design space development 
of mAb capture by CEX. To examine the effect of buffer molarity, static Rituximab binding with Natrix 
C weak CEX membrane was performed in pH 5 acetate buffer with a buffer molarity of 20 mM, 50 
mM, and 100 mM (Figure 44). The molarity of buffer used for mAb binding with CEX materials has 
been reported to range from 20 mM to 50 mM [16, 206, 207]. Guélat et al. [206] used 20 mM sodium 
acetate buffer for the capture of Bevacizumab and Trastuzumab with strong cation exchange resins. Ng 
et al. [16] used 40 mM sodium acetate buffer to purify a humanized mAb with a strong cation resin. 
Tugcu et al. [207] considered 50 mM sodium acetate buffer for the purification of mAb with strong 
cation resins. In order to explore a wider range of buffer molarity, buffer molarity up to 100 mM was 
investigated in this work. The counter-ion concentration Cs (Na+ concentration) of all buffer solutions 
was adjusted to 70 mM to avoid interference of Cs (Na+ concentration) effect.  
Two initial Rituximab concentrations, 0.5 mg/mL and 3 mg/mL were examined. The results indicated 
that the buffer molarity did not affect the binding capacity of Rituximab at low initial Rituximab 
concentration (0.5 mg/mL), while its binding capacity was affected at moderate initial Rituximab 
concentration (3 mg/mL). The effect of buffer molarity was statistically significant (t-test, a confidence 
level of 95%, P = .01). When the buffer molarity was increased from 20 mM to 50 mM, the static 
Rituximab binding capacity increased by 25%. The binding capacity decreased by 12% when the buffer 
molarity was increased to 100 mM. The results indicated that medium buffer molarity (50 mM) is 
preferred for achieving higher binding capacity of Rituximab with Natrix C weak CEX membrane. 
High-throughput fluorescence measurement indicated that no unfolding occurred within the buffer 
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molarity range. The range of buffer molarity for design space development was then set to 20 mM to 
100 mM. 
 
Figure 44 Static binding capacity of Rituximab with Natrix C weak CEX membrane in pH 5 acetate 
buffer, with a molarity of 20 mM, 50 mM and 100 mM. The counter-ion concentration Cs (Na+ 
concentration) of all buffer solutions was adjusted to 70 mM. The initial Rituximab concentration was 
0.5 mg/mL and 3 mg/mL. Error bars represent standard deviation (n=3). 
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7.3.2.3 Counter-ion concentration (Na+ concentration) of the binding buffer 
The effect of the counter-ion concentration Cs (Na+ concentration) on binding capacity has been 
extensively investigated. The lowering of the binding capacity with increasing Cs (Na+ concentration) 
has been reported for polyclonal IgG and monoclonal IgG with CEX resins due to competitive binding 
between the counter-ions and protein molecules for the binding sites of the resins [183, 184]. The 
negative effect of Cs (Na+ concentration) on binding capacity was also confirmed in the previous section 
(6.3.2.3), where static binding capacities of Bevacizumab with Natrix C weak CEX membrane 
decreased with increasing Cs (Na+ concentration) (50 mM, 100 mM and 200 mM) in pH 5 and 50 mM 
acetate buffer.  
In this section, the effect of the Cs (Na+ concentration) on static Rituximab binding with Natrix C 
weak CEX membrane was investigated with 80 mM, pH 5.5 acetate buffer with Cs (Na+ concentration) 
ranging from 75 mM to 225 mM to help locate the range of design space of Cs (Na+ concentration). The 
initial Rituximab concentration was set at 3 mg/mL. The Rituximab binding capacity was summarized 
in Table 33. The decreasing binding capacity of Rituximab with Natrix C weak CEX membrane 
decreased with increasing Cs (Na+ concentration). The effect of Cs (Na+ concentration) on the Rituximab 
structure of after-binding Rituximab samples was obtained from its intrinsic fluorescence emission 
spectra. The maximum fluorescence intensity of after-binding Rituximab samples in acetate buffer with 
Cs (Na+ concentration) of 225 mM was 27% higher than that of after-binding Rituximab samples in 
acetate buffer with Cs (Na+ concentration) of 150 mM (Table 33. A slight red-shift (324nm to 325 nm) 
in maximum emission wavelength was observed when the Cs (Na+ concentration) increased from 150 
mM to 225 mM. Based on these results, the range of Cs (Na+ concentration) for the acetate buffer for 
the design space development of Rituximab binding with Natrix C weak CEX membrane was set to 75 
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Table 33 Maximum fluorescence intensity and maximum emission wavelength of emission spectra of 
Rituximab with an initial concentration of 3 mg/mL after binding with 80 mM, pH 5.5 acetate buffer 









75 88 2074 324 
150 24 2001 324 
225 1 2550 325 
 
7.3.3 Response surface model development 
Response surface models (RSM) are efficient in providing detailed information on the response to 
multiple factors evaluated at multiple levels simultaneously. RSM are useful for the design space 
development where the effect of material and/or process parameters on the performance of mAb 
manufacturing process can be quantified in a systematic approach [28, 29]. For example, the design 
space for the hydrophobic interaction chromatography (HIC) purification step of a Fc fusion protein 
was obtained by investigating five parameters at three level with a half-fraction factorial design [151]. 
A process model was developed and helped in identifying a robust operating window for a high step 
yield and high-molecular weight aggregate clearance. Xu et al. [31] developed the design space for 
robust aggregate removal with CEX through a 25-1 fractional factorial DoE, where five parameters at 
two levels were investigated. Based on the DoE, a model was generated to help define design space for 
high percentage aggregate removal with high yield. 
In this work, RSM was employed in the design space development for Rituximab capture with Natrix 
C weak CEX membrane. The Rituximab quality was expressed as unfolding and the range to ensure 
the quality was established in the previous section (7.3.2), where range indicated no structural change 
was used. In this section, the design space development will focus on the effect of four process 
parameters, pH, molarity, Cs (Na+ concentration) and Rituximab concentration, on binding capacity. 
High-throughput DoE was employed, where a full factorial design containing four critical process 
parameters at three levels was performed with the implementation of randomization and replication for 
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static binding experiment in acetate buffer. The static binding capacity (q) of Rituximab with Natrix C 
weak CEX membrane was collected as the response.  
The full dataset (see Appendix D) was coded and fitted into a first order (FO) linear equation using 
the rsm function, while the R2 of the FO regression was found to be 0.2762, indicating a weak model 
fit to the data. As FO regression is generally suitable when the response surface covers a relatively 
small region of the independent variable space with very little curvature, the full dataset was then fitted 
with a full second order (SO) model (including quadric terms of all parameters) to account for the larger 
curvature. The R2 of the SO linear equation was estimated to be 0.4786, while the adjusted R2 was 
0.4417, which indicated a moderately good fit to the data. Efforts were made to improve the model fit 
by modifying the SO regression equation, while adding in cubic terms, and nonlinear terms 
(log/exponential terms) which did not improve the fit. A residual plot of the SO model (Figure 45) was 
employed to examine the residuals vs. fitted response and the residual points were found to be randomly 
dispersed around the horizontal dotted axis, indicating that a linear regression model is appropriate for 
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Figure 45 Residual plot of the full dataset vs. fitted values for the SO linear equation from the full 
factorial design of static Rituximab binding with Natrix C weak CEX membrane. (Experimental 
conditions: Table 30). 
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The normal distribution of the residuals of the SO regression was then examined by a normal 
quantile-quantile (QQ) plot, using the qqplot function. A normal QQ plot is a scatterplot created by 
plotting the quantiles of the one data set against the quantiles of another data set. Quantiles are the cut 
points dividing data points of a sample, or range of a normal distribution into continuous intervals with 
equal probabilities (Figure 46). A 45-degree reference line is used to evaluate if the two datasets come 
from a population with the same distribution, where the points should fall approximately along this 
reference line. If the two datasets don’t come from populations with the same distributions, the data 
points will deviate from the 45-degree reference line. A normal QQ plot was generated by plotting the 
quantiles of the residuals of the responses, which are the differences between the observed response 
values (binding capacity) and the predicted values by the SO linear equation, against the quantiles from 
a standard normal distribution (Figure 47). 
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Figure 47 Normal QQ plot where the quantiles of the residuals of the responses were plotted against 
the quantiles from a standard normal distribution for the full dataset for the SO linear equation 
developed from the full factorial design experiment of static Rituximab binding with Natrix C weak 
CEX membrane. The solid red line represents the reference line and the dotted red line marked the 
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The QQ plot demonstrated that the points did not fall along the reference line, and exhibited a “heavy 
tail” that deviated from the reference line in the right corner. It meant that the residuals of the responses 
were not from populations with normal distributions, or in another word, meant that the residuals of the 
responses were not normally distributed. The non-normality indicated that the residuals of the responses 
have more extreme values than would be expected if they truly came from a normal distribution. 
Therefore data points related to the residuals that fell into the right corner were further examined. Data 
points that led to residuals over 10 (see Appendix D) were deemed as outliers and eliminated from the 
dataset, which reduced the sample size from 213 data points to 192 data points. The new dataset was 
fitted into the SO model and R2 of the fitted model was found to be 0.7, and the adjusted R2 was 0.67. 
The R2 value was considered satisfactory as it was comparable to the R2 acquired during design space 
development in the literature [31]. Xu et al. [31] achieved a R2 of 0.83 and adjusted R2 of 0.76 while 
modeling a DoE study consisting five parameters at two levels, including the molarity and pH of the 
equilibration buffer, the molarity and pH of the elution buffer and load amount when developing the 
design space of aggregates removal using CEX resin. The normal distribution of the residuals of the 
responses of the new SO model was confirmed by the normal QQ plot (Figure 48), where nearly all 
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Figure 48 Normal QQ plot where the quantiles of the residuals of the responses were plotted against 
the quantiles from a standard normal distribution for modified SO linear equation with the smaller 
dataset. The solid red line represents the reference line and the dotted red line marked the boundaries. 
(Experimental conditions: Table 30; Number of Runs = 192). 
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The R2 value and QQ plot confirmed the goodness of fit of the modified SO model generated from 
the reduced dataset. Therefore the modified SO model was employed as the RSM for describing the 
relationship between the four critical process parameters, pH, Cs, buffer molarity, mAb load, and static 
binding capacity (q). Note that the main purpose of design space development is to understand the 
relationship between the parameters and Rituximab binding capacity, and to assist with the selection of 
the parameters within the range for better binding capacity and acceptable product quality. In this case, 
the established RSM served as a sufficient tool to describe the relationship, but one should not rely on 
the RSM for generating accurate estimations of the binding capacity as the R2 was 0.7. An analysis of 
variance (ANOVA) was performed and confirmed that the four process parameters and their two-way 
interactions are critical to the response, at a 95% confidence level (See Appendix B for details).  
Considering the development in cell culture technology that leads to higher titer [4, 5], it is essential 
to investigate design space for mAb capture at higher mAb load, therefore the mAb load was fixed at 
3 mg/mL in the following analysis. The range of design space for Rituximab capture with Natrix C 
weak CEX membrane was defined through analyzing the characterization range in section 7.3.2, where 
the product quality (low unfolding indicated by low intrinsic fluorescence intensity) was maintained.  
The buffer conditions for the highest static binding capacity based on the RSM, was acetate buffer 
at pH 4.75, 53 mM buffer molarity and Cs (Na+ concentration) 75 mM for 3 mg/mL Rituximab 
concentration. Considering the feasibility of parameter control in industrial processing, the optimal 
buffer condition was rounded off to pH 4.8, 50 mM buffer molarity and Cs (Na+ concentration) 75 mM 
for the following analysis, where the static binding capacity of Rituximab was estimated to be 69 
mg/mL by the RSM. To visualize the design space, 2D contour plots and 3D response surfaces were 
used to demonstrate the relationship between the static binding capacity of Rituximab with Natrix C 
weak CEX membrane, and two process parameters, keeping the third one constant. At constant pH 4.8 
(Figure 49), Rituximab binding capacity (q) decreased with increasing buffer molarity (BM) conditions, 
especially at low Cs (Na+ concentration) conditions. At constant Cs (Na+ concentration), 75 mM (Figure 
50), maximum Rituximab binding capacity appeared around medium pH (~5) and medium buffer 
molarity (~ 50 mM). At constant buffer molarity at 50 mM (Figure 51), the Rituximab binding capacity 
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Figure 49 Contour plot (A) and response surface (B) of static binding capacities of Natrix C weak 
CEX membrane with Rituximab at pH 4.8. 
  
 




Figure 50 Contour plot (A) and response surface (B) of static binding capacities of Natrix C weak 
CEX membrane with Rituximab at Cs (Na+ concentration) 75 mM. 
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Figure 51 Contour plot (A) and response surface (B) of static binding capacities of Natrix C weak 
CEX membrane with Rituximab at buffer molarity 50 mM. 
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7.3.4 RSM application in Rituximab binding and elution 
Static binding capacity is often obtained under overloading conditions therefore it’s the maximum 
amount of protein bound onto the chromatography material at given buffer conditions, while it can be 
predictive of the dynamic binding capacity. Dynamic binding capacity, or the amount of protein that 
bound onto the material under given buffer and flow conditions before a significant breakthrough, is 
obtained under the dynamic mode. Dynamic mode is the actual operating mode employed in mAb 
manufacturing, therefore the optimal buffer conditions obtained from the RSM was then investigated 
in dynamic Rituximab binding and elution. Each method will be discussed separately. 
 
7.3.4.1 RSM application in Rituximab static binding and elution mode 
The RSM established in the previous section will be first examined in the static mode, where Rituximab 
binding was performed with Natrix C weak CEX membrane in an equilibration/load buffer with optimal 
conditions estimated by the RSM and then eluted with an elution buffer with conditions that align with 
the subsequent polishing step. 
The static binding capacity of Rituximab with Natrix C weak CEX membrane obtained was 45 ± 5 
mg/mL, which was 35% lower than the value estimated by the RSM model. The difference can be 
explained by the limitation of the RSM in accurately estimating responses, and the variability in sample 
materials, especially the Natrix C weak CEX membranes that are heterogeneous. 
The bound Rituximab was then eluted with an elution buffer of 20 mM phosphate citrate buffer at 
pH 7.2, with Cs (Na+ concentration) 75 mM. The condition of the elution buffer was selected such that 
it would fall within the design space of a subsequent AEX polishing step, which is the conventional 
subsequent step after capture such as to avoid the need for additional buffer exchange. The Rituximab 
recovery was 78 ±10%. 
To verify the quality of the mAb after the binding and elution step, the after-binding and after-elution 
solution was examined with high-throughput intrinsic fluorescence method and no degree of unfolding 
was detected, which indicated that Rituximab quality was maintained throughout the process. 
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7.3.4.2 RSM application in dynamic Rituximab binding and elution mode 
The DBC10% of Rituximab with Natrix C weak CEX membrane in pH 4.8, 50 mM acetate buffer with 
Cs (Na+ concentration) of 75 mM was 44.3 ± 0.4 mg/mL. The breakthrough curve (Figure 52) showed 
almost a rectangular shape, which indicated little mass transport limitations [209]. The pore size of 
Natrix C weak CEX membrane is around 300 nm, and is significantly larger than that of CEX resins 
(20 to 100 nm for macroporous resins [92]). The mass transport for Natrix C weak CEX membrane is 
dominated by bulk convection, which can improve productivity of mAb capture. The pores of Natrix 
C weak CEX membrane are not clearly defined compared to resins. 
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Figure 52 Breakthrough curve of Rituximab with Natrix C weak CEX membrane in pH 4.8, acetate 
buffer (50 mM) with Cs (Na+ concentration) of 75 mM. Dynamic mode with a flowrate of 1 mL/min. 
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The effect of elution buffer type and pH on Rituximab recovery was investigated. First, Rituximab 
was eluted with phosphate citrate buffer at different pH conditions. The recovery of Rituximab eluted 
with 20 mM phosphate citrate buffer at two different pH conditions, pH 7.2 and 7.6, was 61.4% and 
56.6% respectively (Figure 53). Contrary to the common knowledge that an increase in elution pH will 
enhance the recovery of protein with CEX, the recovery decreased 4.8% in this case. A slightly earlier 
elution was observed at pH 7.6. Second, Rituximab was eluted with phosphate citrate buffer at pH 7.2 
and two different buffer molarity conditions. The recovery of Rituximab eluted with 20 mM and 150 
mM phosphate citrate buffer at pH 7.2 was 61.4% and 53.4%, respectively (Figure 54). Contrary to the 
common knowledge that an increase in elution ionic strength will enhance the recovery of protein, the 
recovery decreased 8% in this case. A much earlier elution was observed with 150 mM phosphate 
citrate buffer. The lower recovery was observed with increasing pH and buffer molarity was suspected 








Figure 53 Chromatogram of Rituximab with Natrix C weak CEX membrane, eluted by 20 mM 
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Figure 54 Chromatogram of Rituximab with Natrix C weak CEX membrane, eluted by 20 mM and 
150 mM phosphate citrate buffer at pH 7.2. Dynamic mode with a flowrate of 1 mL/min. 
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7.4 Conclusion 
In this chapter, a framework for high-throughput design space development for mAb capture with 
Natrix C weak CEX membrane was established.  
Rituximab and Natrix C weak CEX membrane were used for the design space development. The first 
step of defining design space was to identify material/process parameters that have significant impact 
on the product quality and productivity through risk assessment, where pH, counter-ion concentration 
(Cs, Na+ concentration), buffer molarity and mAb load were determined to be critical parameters in this 
work. The buffer molarity was investigated as a critical parameter during design space development for 
mAb capture for the first time. The second step of design space development for mAb capture with 
CEX was to study the characterization range to help define the range of critical parameters for the 
design space. Rituximab binding with Natrix C weak CEX membrane with acetate buffer at different 
levels of pH, buffer molarity and counter-ion concentration (Cs) were investigated. The range of the 
parameters were defined by static Rituximab binding capacity and Rituximab unfolding measured with 
intrinsic fluorescence.  The third step was to establish a response surface model (RSM) for representing 
the design space for Rituximab capture with Natrix C weak CEX membrane. The construction of the 
RSM was based on a DoE study of the four critical parameters at three levels. The RSM was effective 
in describing the relationship of the parameters and Rituximab binding capacity. The fourth step was 
to conduct Rituximab binding with Natrix C weak CEX membrane using the optimal buffer conditions 
estimated with the RSM for two different configurations, static mode and dynamic mode. This 
framework can help significantly improve the efficiency of process development for mAb capture with 
weak CEX membranes. 
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Chapter 8 Conclusions and recommendations 
8.1 Conclusions 
This PhD work focused on investigating the role of buffer effects, especially the buffer co-ions on 
IgG/mAb binding with weak CEX membranes and on IgG/mAb structural change. For strong CEX 
materials, the functional groups are completely ionized over a wide pH range, while for weak CEX 
materials, the ionization of functional groups varies with pH. The variable ionization of weak ion 
exchangers with pH offers better flexibility during elution where pH can be adjusted so that only the 
target proteins are eluted. The effect of co-ions on IgG/mAb binding with strong CEX resins has been 
probed by a few groups [107, 113], however there has not been any work with weak CEX membranes. 
The work focused on Natrix C weak CEX membrane that has the ability to swell according to pH and 
ion conditions. IgG and two different mAbs, Bevacizumab and Rituximab, were investigated with two 
commonly used buffers for mAb binding, phosphate citrate buffer (contain multi-valent co-ions) and 
acetate buffer (contain monovalent co-ions). 
The first specific objective was to investigate the role of buffer pH, counter-ions, and co-ions on 
membrane properties, namely the swelling behavior and surface morphology by ESEM for Natrix C 
weak CEX membrane (Chapter 3). Both the pH and the counter-ions of phosphate citrate buffer and 
acetate buffer had a significant influence on membrane swelling and membrane pore size, while the 
buffer type (co-ion type) did not have significant effect. However, the applicability of ESEM for 
quantitatively characterizing the pore size of Natrix C weak CEX membrane remains limited due to the 
heterogeneity of the material. 
The second specific objective was to examine the effect of the buffer conditions on IgG/mAb binding 
with a weak CEX membrane, with an emphasis on the effect of co-ion type (Chapter 4). This work 
helped expand the knowledge of the effect of co-ions on static IgG binding with the Natrix C weak 
CEX membrane, employing the Langmuir model and the SMA model for assessing binding capacity. 
The estimated model parameters indicated that co-ions may affect IgG binding in two ways. On one 
hand, multi-valent co-ions (phosphate citrate buffer) may promote more protonation of histidine 
residues on IgG surface compared to monovalent co-ions (acetate buffer), as observed by the estimated 
characteristic charge of the SMA model. On the other hand, the co-ion valence may affect the structure 
of IgG molecules thus changing the binding capacity, as observed by the estimated steric factor of the 
SMA model. In the context of static binding of a humanized mAb, Bevacizumab, with Natrix C weak 
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CEX membrane, differences in the binding capacity according to the co-ion type was observed at 
relatively high Bevacizumab concentration.  
The third specific objective was to examine the effect of co-ion type (valence and chemistry) and 
counter-ion concentration (Cs, Na+ concentration) on IgG/mAb structure (Chapter 5/Chapter 6). In order 
to investigate buffer effects on IgG/mAb structure, an intrinsic fluorescence microplate method was 
developed in Chapter 5 for thermally stressed samples and compared to published results. This method 
was used to investigate the effects of co-ion type and Cs (Na+ concentration) on mechanically stressed 
IgG employing a response surface model (Chapter 6). Higher Cs (Na+ concentration) and co-ion type 
induced IgG structural change were observed, and are in good agreement with literature results. In the 
context of Bevacizumab binding with weak CEX membranes, differences in Bevacizumab structure 
were observed with the intrinsic fluorescence microplate method and the SMA model, where a higher 
degree of Bevacizumab unfolding was observed in phosphate citrate buffer compared to acetate buffer 
at a relatively high initial concentration (≥ 7 mg/mL). These observations were supported by the 
estimated SMA parameters which further demonstrated that SMA model can serve as a supplementary 
tool for evaluating protein structural changes, and are in agreement with the results obtained in chapter 
3, where differences in binding capacity was observed at a relatively high initial concentration (≥ 7 
mg/mL).  
The fourth specific objective was to establish a framework for design space development for mAb 
capture with weak CEX membranes (Chapter 7). This framework was developed with the experimental 
observations and tools discussed in Chapter 3 to Chapter 6, using this time a chimeric mAb, Rituximab, 
static and dynamic binding conditions. Four critical process parameters were identified, investigated, 
and used to construct a response surface model (RSM) model. The RSM was effective in describing 
the relationship of the parameters and Rituximab binding capacity.  
Since mAb capture with CEX materials potentially occurs by binding with the variable regions of 
mAb/IgG [25, 26], the framework established in this study could be employed in developing CEX 
capture for other specific mAbs, which could help improve the efficiency of process development and 
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8.2 Recommendations 
8.2.1 Characterization of non-uniform hydrogel membranes 
Pore structure 
The pore structure of hydrogel IEX membranes plays an important role in mAb capture, however it is 
difficult to quantify due to the fragile and heterogeneous properties.  
In this work, the three-dimensional macroporous hydrogel structure of a weak CEX membrane, 
Natrix C weak CEX membrane, was probed by swelling and ESEM. Both methods were satisfactory 
in demonstrating that the hydrogel IEX membrane was sensitive to buffer conditions, while accurate 
quantification of the pore size cannot be achieved with ESEM. There are two limitations, (1) the 
hydrated membrane samples in the chamber suffered from dehydration throughout the visualization 
process, which meant images could only be captured for the first few minutes after positioning the 
sample in the chamber. The dehydration problem was also observed by Wang et al. [178] when imaging 
Sartobind S and C using ESEM; (2) the acquired ESEM images revealed the non-uniform 
characteristics of the pore structure of the membrane investigated, which meant a couple of images 
captured within the first few minutes visualization process cannot be representative of the pore structure 
of the whole sample. To address these problems, it is recommended to apply a combination of 
characterization methods to accurately capture the pore size of the hydrogel IEX membrane treated by 
various buffers, including confocal laser scanning microscopy (CLSM), differential scanning 
calorimetry (DSC), mercury intrusion and nitrogen sorption porosimetry, and permeability 
measurement. [210]. As each technique has its own limitations in detection size, pressure and 
resolution, combining results obtained from all the techniques will generate a more comprehensive 
picture of the pore structure of the hydrogel membrane and help better design the mAb capture process. 
pH within the membrane 
The pH of buffer is one of the most decisive factors in IgG/mAb capture with CEX membranes, 
especially for weak CEX membranes that present variable ionization according to pH. However the pH 
within the CEX membrane, or the pH microenvironment, may differ from the pH of buffer.  
pH microelectrode has been used on various biological systems for monitoring the pH 
microenvironment [211, 212], but the spatial resolution is limited by the tip size and insertion of the 
microelectrode may perturb the local surroundings. Fluorescence microscopic methods, especially 
CLSM, stands out for its accuracy and relative simplicity for monitoring pH microenvironment. 
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Therefore, it is recommended to employ CLSM combining with various pH-sensitive dyes for 
monitoring the pH microenvironment of weak CEX membranes and help optimizing IgG/mAb capture. 
 
8.2.2 Characterization of IgG/mAb aggregates with asymmetric flow field-flow 
fractionation (AF4) 
Characterization of IgG/mAb aggregates is one of the most important elements for quality control 
during IgG/mAb manufacturing. While the high-throughput intrinsic fluorescence method in this work 
is applicable for fast in-line control, the quantitative characterization of IgG/mAb aggregates was 
limited.  
Asymmetric flow field-flow fractionation (AF4) is a promising alternative to SEC for more accurate 
protein structure characterization [213-215], which can also address the limitations of intrinsic 
fluorescence method. AF4 is the most applicable field-flow fractionation technique, where the 
separation field of force is established by a second stream of carrier liquid, pumped in vertical direction 
to the axial flow stream. AF4 technique is superior to size exclusion chromatography (SEC) with 
improved reproducibility [214], higher flexibility for mobile phase selection [213], lower material loss 
and most importantly wider size range, from [216, 217]. The lower limit is determined by the molecular 
weight cut-off of the ultrafiltration membrane, whereas the upper limit is related to the channel height. 
When coupled to a multi-angle light scattering detector and a refractive index or spectrophotometric 
detector, the molar mass and root mean-square radius and their distributions can be determined for the 
components fractionated by AF4 [218]. Therefore, it is recommended to employ AF4 for quantifying 
the number and size of IgG/mAb aggregates. 
 
8.2.3 Design space development with dynamic protein binding and cell culture 
supernatant 
In this work, design space has been developed with static Rituximab binding experiments, while its 
application is limited in terms of helping to reduce residence time. Therefore, it is recommended to 
develop design space for mAb capture with weak CEX membranes employing dynamic protein binding 
experiments that simulate the process conditions. 
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The focus of the design space development in this work was to improve the binding capacity and 
eliminate mAb unfolding, thus purified Rituximab was employed. It is also critical to evaluate the 
separation efficiency of weak cation exchange membranes. Hou et al. investigated the capability of 
Natrix C weak CEX membranes for capturing mAbs from cell culture supernatant, and achieved over 
85% of HCP removal and over 90% yield with selected buffer conditions (Binding: pH 5.2, 
Conductivity 12 mS/cm, 50 mM acetate buffer; Elution: pH 6.5, 100 mM phosphate buffer). Therefore 
it is recommended to develop design space to help improved impurity removal employing cell culture 
supernatant for future work. HCP can be quantified using enzyme-linked immunosorbent assay 
(ELISA) and mAb content can be quantified using Protein-A HPLC.  
 
8.2.4 Multi-modal chromatography for mAb capture 
The potential of weak CEX chromatography for mAb capture explored in this work has shown 
limitations of CEX by its relatively low salt tolerance compared to other chromatographic methods. 
There has been a growing interest in multi-modal chromatography (MMC) for mAb capture, which is 
a chromatographic method combining multiple types of interaction between the stationary phase and 
the mobile phase, where multimodal ligands comprising ion exchange, hydrogen bonding and 
hydrophobic interaction groups are used [80]. MMC may be a superior capture method than CEX in 
that it addresses the problem with salt tolerance through hydrophobic interactions. The complex 
composition of multimodal ligands would offer greater flexibility in designing MMC material with 
high selectivity for protein capture. Therefore it was recommended to explore the potential of MMC 
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Appendices  
Appendix A Buffer preparation and surfactant calculation 
Phosphate citrate buffer 
A stock buffer solution of 150 mM phosphate citrate buffer was first prepared by mixing 100 mM citric 
acid (EMD Chemicals Inc., Gibbstown, USA) solution and 200 mM sodium phosphate dibasic (Fisher 
Scientific, Fair Lawn, USA) solution. 100 mL stock buffer at various pH were made according to Table 
34. Stock buffer was refrigerated after preparation and taken out the night before usage. 
Phosphate citrate buffer with lower buffer molarity was diluted from the stock buffer by mixing it 
with ultra-purified water. Phosphate citrate buffer with higher counter-ion concentration was prepared 
by adding sodium chloride (BDH Inc., Toronto, Canada) to the stock buffer. 
Table 34 Reference table for preparing 100 mL 150 mM phosphate citrate buffer. 
pH 100 mM citric acid (mL) 200 mM sodium phosphate dibasic  (mL) 
4.0 61.45 38.55 
4.2 58.60 41.40 
4.4 55.90 44.10 
4.6 53.25 46.75 
4.8 50.70 49.30 
5.0 48.50 51.50 
5.2 46.40 53.60 
5.4 44.25 55.75 
5.6 42.00 58.00 
5.8 39.55 60.45 
6.0 36.85 63.15 
6.2 33.90 66.10 
6.4 30.75 69.25 
6.6 27.25 72.75 
6.8 22.75 77.25 
7.0 17.65 82.35 
7.2 13.05 86.95 
7.4 9.15 90.85 
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Acetate buffer 
A stock buffer solution of 200 mM sodium acetate buffer was prepared by mixing 200 mM acetic acid 
(EMD Chemicals Inc., Gibbstown, USA) and 200 mM sodium acetate (EMD Chemicals Inc., 
Gibbstown, USA) solution. 100 mL stock buffer at various pH were made according to Table 35. Stock 
buffer was refrigerated after preparation and taken out the night before usage. 
Acetate buffer with lower buffer molarity was diluted from the stock buffer by mixing it with ultra-
purified water. Acetate buffer with higher counter-ion concentration was prepared by adding sodium 
chloride (BDH Inc., Toronto, Canada) to the stock buffer. 
Table 35 Reference table for preparing 100 mL 200 mM acetate buffer. 
pH 200 mM sodium acetate (mL) 200 mM acetic acid (mL) 
4.0 18.0 82.0 
4.2 26.5 73.5 
4.4 37.0 63.0 
4.6 49.0 51.0 
4.8 59.0 41.0 
5.0 70.0 30.0 
5.2 79.0 21.0 
5.4 86.0 14.0 
5.6 91.0 9.0 
6 94.8 5.2 
 
 
Phosphate buffered saline (PBS) 
100 mL 10 mM PBS at pH 7 was prepared by preparing 80 mL of ultra-purified water in a proper 
container, and then add potassium phosphate monobasic (EMD Chemicals Inc., New Jersey, USA), 
sodium phosphate dibasic heptahydrate (VWR International, Ohio, USA), sodium chloride and 
potassium chloride (Fisher Scientific, Fair Lawn, USA) according to Table 36. The solution was 
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Table 36 Reference table for preparing 100 mL 10 mM PBS. 
Chemical Mass Molarity 
NaCl (mw: 58.4 g/mol) 800 mg 0.137 M 
KCl (mw: 74.551 g/mol) 20 mg 0.0027 M 
Na2HPO4 (mw: 141.96 g/mol) 144 mg 0.01 M 
KH2PO4 (mw: 136.086 g/mol) 24 mg 0.0018 M 
Polysorbate 20 calibration curve and concentration calculation 
 
 
Figure 55 Calibration curves of Polysorbate 20 (0.01 mg/mL to 0.08 mg/mL) spiked with Nile Red. 




















Polysorbate 20 Concentration (mg/mL)
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Table 37 Fluorescence intensity for each round of filtrate with corresponding Polysorbate 20 
concentrations. 







1st Filtrate 468 0.041 31% 
2nd Filtrate 476 0.124 41% 
3rd Filtrate 177 0.133 74% 
4th Filtrate 34 0.053 87% 
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Figure 57 Calibration curves of Polysorbate 80 (0.01 mg/mL to 0.08 mg/mL) spiked with Nile Red. 
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Figure 58 Calibration curves of Polysorbate 80 (0.1 mg/mL to 1 mg/mL) spiked with Nile Red. 
 
Table 38 Fluorescence intensity for each round of filtrate with corresponding Polysorbate 80 
concentrations. 
  Average Fluorescence Intensity  Concentration (mg/mL) 
Cumulative Percentage 
Removal 
Filtrate 1 5635 0.232 33% 
Filtrate 2 1238 0.232 66% 
Filtrate 3 134 0.103 81% 
Filtrate 4 14 0.118 98% 
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Appendix B ANOVA tables 
1 ANOVA table for 6.3.1 
For stressed IgG samples in phosphate citrate buffer: 
 SS DF MS F0 Fc 
Cp 19107414960 4 4776853740 1082.215655 
F 0.05, 4, 
50=2.56 
Cs 3168306907 4 792076726.8 179.448206  
interaction 8225439685 16 514089980.3 116.4691772  
error 220697867.2 50 4413957.345   
total 30721859420 74 415160262.4   
 
For stressed IgG samples in acetate buffer: 
 SS DF MS F0 Fc 
Cp 6607085373 4 1651771343 149.3547662 
F 0.05, 4, 50= 
2.56 
Cs 4773356815 4 1193339204 107.9028877  
interaction 5547692213 16 346730763.3 31.35173176  
error 552969076.7 50 11059381.53   
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2 ANOVA table for 6.4.3 
 SS DF F0 Pr(>F)     Significance 
(Intercept)    234993 1 1694.3019 < 2.2e-16 *** 
pH            11865    2    42.7728  3.963e-16  *** 
Cs             4597    2    16.5711  2.256e-07  *** 
Buffer molarity (BM)          2748    2     9.9072  7.983e-05  *** 
PC            12970    2    46.7572  < 2.2e-16  *** 
pH:Cs          8518    4    15.3534  6.211e-11  *** 
pH:BM          6672    4    12.0270  9.340e-09  *** 
Cs:BM 2303   4     4.1503   0.003002  ** 
Residuals     27046  195    
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Appendix C MATLAB code 
1 MATLAB code for SMA analysis 
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2 MATLAB code for RSM of IgG in phosphate citrate buffer 
 
  General model: 
     fitresult(x,y) = A+B.*x.^2+C.*y.^2+D.*x.*y+E.*x+F.*y 
     Coefficients (with 95% confidence bounds): 
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       A =   2.013e+04  (-1.392e+04, 5.418e+04) 
       B =       770.5  (-3324, 4865) 
       C =    -0.09687  (-1.311, 1.117) 
       D =       58.37  (2.29, 114.4) 
       E =      -378.2  (-2.088e+04, 2.013e+04) 
       F =      -29.84  (-419.2, 359.6) 
 
gof (goodness of fit): 
           sse: 2.7959e+09 
       rsquare: 0.7133 
           dfe: 19 
    adjrsquare: 0.6379 
          rmse: 1.2131e+04 
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3 MATLAB code for RSM of IgG in acetate buffer 
 
General model: 
     fitresult(x,y) = A+B.*x.^2+C.*y.^2+D.*x.*y+E.*x+F.*y 
     Coefficients (with 95% confidence bounds): 
       A =      -69.67  (-1.886e+04, 1.872e+04) 
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       B =       -3828  (-6087, -1568) 
       C =     -0.3736  (-1.043, 0.2962) 
       D =       75.55  (44.61, 106.5) 
       E =   1.193e+04  (613.3, 2.324e+04) 
       F =       60.46  (-154.4, 275.3) 
gof (goodness of fit): 
           sse: 8.5127e+08 
       rsquare: 0.8491 
           dfe: 19 
    adjrsquare: 0.8094 
          rmse: 6.6936e+03 
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4 MATLAB code for dynamic binding 
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  198 
Appendix D Dataset and R scripts for response surface model 
1  Full dataset 
pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
4 75 20 1 23.27 
4 75 20 1 30.01 
4 75 20 1 37.87 
4 75 20 2 41.76 
4 75 20 2 42.88 
4 75 20 2 32.78 
4 75 20 3 36.26 
4 75 20 3 39.06 
4 75 20 3 33.45 
4 100 20 2 39.74 
4 100 20 2 38.64 
4 100 20 2 44.69 
4 100 20 3 44.74 
4 100 20 3 39.38 
4 100 20 3 39.38 
4 150 20 1 21.69 
4 150 20 1 26.64 
4 150 20 1 21.40 
4 150 20 2 29.25 
4 150 20 2 42.63 
4 150 20 2 41.47 
4 150 20 3 42.14 
4 150 20 3 33.85 
4 150 20 3 34.72 
4 75 50 1 23.71 
4 75 50 1 25.60 
4 75 50 1 29.38 
4 75 50 2 34.03 
4 75 50 2 49.53 
4 75 50 2 48.02 
4 75 50 3 40.27 
4 75 50 3 35.17 
4 75 50 3 40.84 
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pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
4 100 50 2 35.66 
4 100 50 2 34.87 
4 100 50 2 37.75 
4 100 50 3 57.02 
4 100 50 3 48.78 
4 100 50 3 37.79 
4 150 50 1 33.52 
4 150 50 1 26.63 
4 150 50 1 27.09 
4 150 50 2 30.77 
4 150 50 2 33.98 
4 150 50 2 33.52 
4 150 50 3 0.00 
4 150 50 3 28.24 
4 150 50 3 44.08 
4 75 80 1 23.13 
4 75 80 1 17.50 
4 75 80 1 19.49 
4 75 80 2 42.02 
4 75 80 2 30.44 
4 75 80 2 33.41 
4 75 80 3 30.27 
4 75 80 3 38.21 
4 75 80 3 33.25 
4 100 80 2 34.44 
4 100 80 2 35.92 
4 100 80 2 39.13 
4 100 80 3 33.87 
4 100 80 3 27.20 
4 100 80 3 26.83 
4 150 80 1 23.08 
4 150 80 1 20.72 
4 150 80 1 18.75 
4 150 80 2 48.67 
4 150 80 2 55.74 
4 150 80 2 33.73 
4 150 80 3 80.66 
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pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
4 150 80 3 64.74 
4 150 80 3 70.05 
5 75 20 1 33.40 
5 75 20 1 23.09 
5 75 20 1 31.34 
5 75 20 2 41.38 
5 75 20 2 37.25 
5 75 20 2 47.56 
5 75 20 3 71.34 
5 75 20 3 57.94 
5 75 20 3 67.73 
5 100 20 2 64.30 
5 100 20 2 63.31 
5 100 20 2 68.76 
5 100 20 3 83.06 
5 100 20 3 78.22 
5 100 20 3 78.22 
5 150 20 1 26.50 
5 150 20 1 27.83 
5 150 20 1 20.26 
5 150 20 2 21.95 
5 150 20 2 28.63 
5 150 20 2 31.31 
5 150 20 3 11.56 
5 150 20 3 37.61 
5 150 20 3 18.24 
5 75 50 1 40.89 
5 75 50 1 36.23 
5 75 50 1 34.68 
5 75 50 2 56.00 
5 75 50 2 62.21 
5 75 50 2 52.11 
5 75 50 3 76.42 
5 75 50 3 72.35 
5 75 50 3 65.36 
5 100 50 2 45.13 
5 100 50 2 44.38 
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pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
5 100 50 2 47.12 
5 100 50 3 71.06 
5 100 50 3 63.20 
5 100 50 3 52.72 
5 150 50 1 19.03 
5 150 50 1 22.98 
5 150 50 1 24.63 
5 150 50 2 33.25 
5 150 50 2 31.94 
5 150 50 2 34.57 
5 150 50 3 56.80 
5 150 50 3 59.27 
5 150 50 3 49.88 
5 75 80 1 43.09 
5 75 80 1 33.49 
5 75 80 1 40.29 
5 75 80 2 43.56 
5 75 80 2 42.77 
5 75 80 2 39.57 
5 75 80 3 56.35 
5 75 80 3 34.17 
5 75 80 3 47.96 
5 100 80 2 46.30 
5 100 80 2 47.69 
5 100 80 2 50.70 
5 100 80 3 52.77 
5 100 80 3 46.52 
5 100 80 3 46.17 
5 150 80 1 22.69 
5 150 80 1 22.69 
5 150 80 1 21.10 
5 150 80 2 32.64 
5 150 80 2 41.59 
5 150 80 2 25.60 
5 150 80 3 44.64 
5 150 80 3 41.76 
5 150 80 3 53.27 
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pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
5.5 75 20 1 18.08 
5.5 75 20 1 27.23 
5.5 75 20 1 18.84 
5.5 75 20 2 40.92 
5.5 75 20 2 26.05 
5.5 75 20 2 30.24 
5.5 75 20 3 36.78 
5.5 75 20 3 33.92 
5.5 75 20 3 31.63 
5.5 100 20 2 7.09 
5.5 100 20 2 8.46 
5.5 100 20 2 4.61 
5.5 100 20 3 10.22 
5.5 100 20 3 9.39 
5.5 100 20 3 0.00 
5.5 150 20 1 0.00 
5.5 150 20 1 0.00 
5.5 150 20 1 0.00 
5.5 150 20 2 0.00 
5.5 150 20 2 0.00 
5.5 150 20 2 0.00 
5.5 75 50 1 32.03 
5.5 75 50 1 45.74 
5.5 75 50 1 39.76 
5.5 75 50 2 40.40 
5.5 75 50 2 36.18 
5.5 75 50 2 35.83 
5.5 75 50 3 40.55 
5.5 75 50 3 55.85 
5.5 75 50 3 65.87 
5.5 100 50 2 18.20 
5.5 100 50 2 18.82 
5.5 100 50 2 19.44 
5.5 100 50 3 30.08 
5.5 100 50 3 19.40 
5.5 100 50 3 38.90 
5.5 150 50 1 20.77 
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pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) load (mg/mL) q (mg/mL) 
5.5 150 50 1 35.83 
5.5 150 50 1 21.58 
5.5 150 50 2 41.00 
5.5 150 50 2 41.81 
5.5 150 50 2 34.08 
5.5 150 50 3 86.53 
5.5 150 50 3 86.53 
5.5 150 50 3 59.67 
5.5 75 80 1 22.74 
5.5 75 80 1 17.45 
5.5 75 80 1 16.70 
5.5 75 80 2 34.41 
5.5 75 80 2 38.56 
5.5 75 80 2 23.08 
5.5 75 80 3 96.91 
5.5 75 80 3 90.68 
5.5 75 80 3 75.17 
5.5 100 80 2 19.90 
5.5 100 80 2 28.35 
5.5 100 80 2 23.28 
5.5 100 80 3 42.52 
5.5 100 80 3 40.41 
5.5 100 80 3 44.63 
5.5 150 80 1 9.61 
5.5 150 80 1 11.60 
5.5 150 80 1 11.27 
5.5 150 80 2 18.66 
5.5 150 80 2 14.69 
5.5 150 80 2 16.67 
5.5 150 80 3 20.04 
5.5 150 80 3 22.03 
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2  Data points eliminated from the full dataset 
Data points that led to residuals over 10 
pH Cs  (mM) Buffer molarity (mM) mAb (Rituximab) 
load (mg/mL) 
4.0  150  80  3  
5.0  100  20  2  
5.0  100  20  3  
5.5  150  50  1  
5.5  150  50  2  
5.5  150  50  3  
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4   R script for plotting the response surface and contour plot: 
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Appendix E Calculation example for static protein binding capacity 
Static protein binding capacity of Natrix C weak CEX membrane was calculated according to the 
equation below in this work, 




where qe is the static protein binding capacity at equilibrium (mg/mL); C0 is the initial protein 
concentration (mg/mL); Ce is the equilibrium protein concentration (mg/mL); Vsolution is the total volume 
of binding buffer (mL); and Vmembrane is the volume of the membrane piece (mL).  
For example, for binding of Bevacizumab in 200 mM acetate buffer at pH 5, with an initial 
concentration of 0.5 mg/mL. C0 = 0.5 mg/mL. For high-throughput binding, Vsolution = 0.2 mL, dry 
membrane pieces used for multiple wells were measured together where a total mass was obtained. In 
this example, a total of 48 membrane pieces were consumed for the experiment set, with a total mass 
of 0.0267 g, thus the mass of one membrane piece used for one well is 0.000556g. The density of the 
membrane piece is 0.42275 g/mL, thus the volume of one membrane piece Vmembrane = 0.001316 mL. 
After binding, the equilibrium protein concentration Ce was calculated from the UV absorbance based 
on the calibration curve (Figure 59). The UV absorbance was measured as 0.214, thus Ce = 0.301049 
mg/mL and qe = 30.2405 mg/mL. 
 
 
  209 
 









































  210 
Appendix F Calculation of dead volume for the ÄKTA Avant system 
Dead volume in this case refers to the volume of tubing from the injection valve to the UV absorbance 
detector (Figure 60). It was calculated to be 1.33 mL for the ÄKTA Avant system following the steps 
below, 
• Attach membrane holder (without membrane) 
• Fill a small sample loop (500 μl) with a 5% acetone solution 
• Fill the system with water 
• Run the pump at 1 ml/min and inject the acetone solution as a sample 




Figure 60 Schematic flow diagram of the ÄKTA Avant system. 
 
